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Abstract
Chemotherapy, radiotherapy and surgery, the current treatments for cancer, cure only 
fifty percent of patients. Gene therapy, where therapeutic genes are transferred directly to the 
tumour, offers a new form of cancer treatment. However, gene transfer techniques that are 
currently available can only achieve gene expression in a small proportion of the tumour cells, 
and this may hinder many gene therapy approaches. It may therefore be important to select 
genes for cancer therapy that offer the potential for a significant bystander effect, where cells 
not expressing the therapeutic gene are killed, as well as targeted cells.
At present there appear to be two strategies for cancer gene therapy that achieve 
bystander killing, and hence require targeted expression in only a proportion of the cells. The 
first depends on stimulation of the immune system by, for example, expression of specific 
cytokines that increase proliferation of tumoricidal cells, while the second type of bystander 
effect is associated with enzyme / prodrug systems, which are the focus of the work described 
in this thesis.
The mechanisms and efficacies of the Herpes Simplex virus thymidine kinase / 
ganciclovir (tk / GCV), human thymidine phosphorylase / 5’-deoxy-5-fluorouridine (tp / 
DFUR) and E.coli cytosine deaminase / 5-fluorocytosine (cd / FC) enzyme / prodrug systems 
have been examined. In culture, each enzyme / prodrug combination induced cell death in 
tumour cells expressing the suicide gene and, in mixed cultures of cells that do or do not 
express the gene, death occurred in both cell types, indicative of a bystander effect.
With the tk / GCV system, in human and rodent cell lines, a correlation has been 
demonstrated between the bystander effect and gap junctional intercellular communication 
(GJIC). When cultures lack GJIC, no bystander effect was observed, but only a low level of
XV
communication was required to generate extensive bystander killing. Increased enzyme 
activity, on the other hand, improved the bystander effect, suggesting that high levels of tk 
expression will be important. Additionally, it has been shown that transfer of toxic metabolites 
from tk+ to tk' cells occurs within two hr of GCV application, before degenerative events were 
detected, indicating that apoptosis is the result, not the cause, of the tk / GCV bystander 
effect.
Three of the cell lines used to investigate the tk /  GCV system in culture were also 
used to examine the bystander effect in experimental tumours in nude mice. A correlation 
between the bystander effect in culture and in vivo was demonstrated in two of the cell lines 
but not the third, which suggests that other factors are important in vivo.
In the tp / DFUR and cd / FC systems, bystander killing was due to transfer of toxic 
metabolites through the medium, and did not depend on GJIC or cell-cell contact. Bystander 
killing seen with these systems was weaker than that seen in the tk / GCV system.
Combining the tk /  GCV system with the tp / DFUR or cd / FC systems in culture was 
able to produce more extensive bystander killing than either system separately. The 
improvement was also observed using a cdtk fusion protein.
The results in this thesis suggest that the choice of enzyme / prodrug therapy for 
cancer will be determined by the characteristics of each tumour. In addition they suggest the 
use of fusion proteins, to combine therapeutic proteins, warrants further investigation.
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Chapter 1. Review of the literature
1.1. Current success of cancer treatment
Cancer is a disease associated with morbidity and mortality. In the United States of 
America over one million individuals will develop cancer this year but only fifty percent will 
survive. Cancer is the leading cause of death in females aged 35 to 74, and the second leading 
cause of death in both sexes (22.5% total deaths in USA based on 1987 figures; Blaese, 1997; 
Boring et al, 1991). Frequency of certain cancers is rising, for example, the incidence of lung 
cancer has increased by 5 fold in females during the last 30 years (Boring et al, 1991) and it 
has been suggested that by the year 2000 it is likely that over one percent (in USA, 
approximately 4 million) of individuals will develop cutaneous melanoma (Bonnekoh et al, 
1996).
Worldwide, over 1.6 million individuals develop hepatocellular carcinoma each year 
and 80% die (Willis et al, 1995). In addition, colorectal carcinomas lead to the death of 
175,000 people, annually in USA, UK, Japan, France, Germany, Italy and Spain (Huber et al, 
1995).
In Scotland, mortality rates due to cancer were 2nd and 7th highest (female and male, 
respectively) of 48 countries studied from 1984 to 1986 (Boring et al, 1991).
1.2. Current cancer treatments
Routine treatment for cancer involves surgery, radio- and chemo-therapy. All of these 
treatments can be effective but, as described above, 50% of tumours remain incurable. 
Although surgery removes the cancerous cells, residual cells may repopulate the tumour or
l
lead to metastatic deposits. Tumours that are inoperable must be treated with radio- or chemo­
therapy, which exploit the modest differences between non-neoplastic and neoplastic cells. For 
example, vinca alkaloids, such as vinblastine and vincristine, are cell cycle dependent, 
antimitotic chemotherapeutic agents that bind to the cytoskeletal protein tubulin, inducing 
microtubule depolymerisation. This prevents the formation of the mitotic spindle and rapidly 
dividing cells are most susceptible to killing. 5-fluorouracil (FU) is a chemotherapeutic agent 
that is converted by cellular enzymes to cytotoxic metabolites that interfere with RNA and 
DNA synthesis. Thymidine phosphorylase (tp) is of one of the enzymes involved in the 
conversion and, in certain tumours, such as colorectal carcinoma, the level of tp is increased 
relative to normal tissue (Bimie et al, 1963; Sumizawa et al, 1993), making some of these 
tumours suitable for FU treatment.
A common feature of chemotherapeutic agents is a narrow therapeutic index, therefore 
systemic toxicity is dose limiting. For example, vincristine can result in neurotoxicity, while 
vinblastine can result in leukopenia, and FU often causes leukopenia and gastric ulceration 
(Ratain and Vogelzang et al, 1986; Au et al, 1982). Although systemic toxicity can be reduced 
by regional drug delivery, for example, melanomas or hepatic carcinomas can be isolated by 
limbic perfusion or hepatic vascular perfusion, respectively, these procedures require surgery 
(Anderson et al, 1992). Regional delivery allows higher doses of drug to be administered but 
many solid tumours require a dose that still cannot be achieved (review, Connors and Knox, 
1995). In addition, tumour cells can become resistant to chemotherapeutic agents through 
several mechanisms which include expression of the multiple drug resistance protein (pl70), 
improvement in DNA repair mechanisms and alteration of the composition of the plasma 
membrane lipid composition (review, Vendrik et al, 1992). It is evident that to increase the 
cure rate of cancer, new therapies are required and gene therapy may provide an additional 
treatment which can complement existing regimes.
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1.3. Gene therapy for cancer
Gene therapy was suggested as an additional means of controlling disease in the 1970’s 
by Friedman. Currently there are a number of approaches that are being investigated for cancer 
gene therapy (see figure 1.1).
1.4. Targeting of non cancer cells
I
| 1.4.1. Gene transfer to lymphocytes
t
ft
|
|
| The first studies that investigated transfer of foreign genes to humans, involved[
| introduction of a bacterial gene (neo) to lymphocytes, primarily to assess the safety of gene 
| transfer.
In these studies, tumour infiltrating lymphocytes (TILs) were isolated from metastatic 
| melanoma deposits, then grown in culture (ex vivo) and cell number expanded. Prior to re-
j  infusion of the expanded population of TILs, the neo gene was introduced to these cells by
t
j retroviral transduction. The recombinant genome of the virus integrates into the genome of the
I
| TIL, therefore the persistence of these cells could be monitored (by PCR and Southern blot
f
analysis for the neo gene) both in the circulation and in the tumours of patients. TILs could be 
detected for up to 2 months, in some tumours, and in -30% of cases investigated reinfusion of 
increased numbers TILs led to regression of tumour deposits (Rosenberg et al, 1990; 
Rosenberg, 1992). This approach proved safe and has subsequently been extended to generate 
TILs that secrete interleukin 2 (IL-2) in an attempt to enhance the patients immune response 
to tumours (Rosenberg et al, 1993).
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In another example of ex vivo gene transfer, the Herpes Simplex virus thymidine kinase 
gene (tk; see section 1.10.1.) was transferred, using retroviral transduction, to lymphocytes. 
Patients with haematological malignancies can be cured by high dose chemotherapy, followed 
by allogeneic bone marrow transplantation, but graft versus host disease (GVHD) can occur 
when infused lymphocytes react against host tissue, which can kill the patient. Introduction of 
the tk gene may allow an aberrant reaction to be attenuated since the prodrug, ganciclovir, can 
kill cells expressing this gene (Tiberghien et al, 1994; Munshi et al, 1997).
Gene transfer in culture does enable genes to be transferred to a high percentage of 
cells, but this approach is not always successful (Rosenberg et al, 1990). In some cases it may 
not be possible to establish primary cultures or to expand the cell number sufficiently for 
clinical use. In addition, cells may undergo antigenic changes during the culture period and this 
may lead to cell rejection by the host immune system.
1.4.2. Drug resistance gene therapy
Systemic toxicity associated with chemotherapeutic agents restricts the length and dose 
of treatment, but it may be possible to reduce the extent of toxicity by protecting stem cells 
and early progenitor cells. Tumour cell resistance to chemotherapeutic agents may arise from 
expression of the multiple drug resistance protein, pl70. If the gene (mdrl) encoding this 
protein is introduced to stem cells, then they may acquire resistance to certain 
chemotherapeutic drugs, and it might be possible to increase the dose or the length of drug 
treatment. This hypothesis was tested by Sugimoto et al (1994; 1995) who transfected 
cultured fibroblasts with mdrl and showed resistance to vincristine and adriamycin.
If this approach was used clinically, it is possible that mdrl would also be transferred 
to tumour cells and drug resistant cancers may arise. To avoid this possibility it would be
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desirable to also introduce a conditional suicide gene, such as the tk gene (section 1.10.1), to 
cells. This approach has been investigated, in culture, and cells that were resistant to 
chemotherapeutic agents were also sensitive to GCV (Sugimoto et al, 1995). However, these 
experiments were performed in fibroblasts and whether the approach would also be successful 
in stem cells will need to be evaluated.
1.5. Targeting tumour cells
Most of the work in cancer gene therapy has involved direct targeting of tumour cells 
in culture or in experimental models. An overview of some of the methods used for killing 
tumour cells is provided in figure 1.1. and examples are given below.
1.6. Targeting ribonucleic acid
The mRNA molecules that code for proteins that are over expressed in neoplastic cells 
may provide targets for antisense therapy. This approach introduces complementary sequences 
into tumour cells which may disrupt nuclear transport or mark the targeted mRNA for 
degradation (review, Mercola and Cohen, 1995). For example, the mRNA that codes for the 
proto-oncogenes, such as bcl-2 and ras, or for the immunosuppressive cytokine TGF-p are 
potential targets in some cancers.
The efficacy of the antisense approach has been demonstrated by the killing of low 
grade non Hodgkins lymphoma cells, in culture, by targeting antisense oligodeoxy- 
ribonucleotides to bcl-2 mRNA (Smith et al, 1997a). Killing by this approach is surprising 
because the main mechanism of oligonucleotide uptake is by endocytosis and it might be 
expected that the oligonucleotides would end up, not in the cytoplasm or nucleus, but in the
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lysosomal compartment, hence degraded. Studies in vivo have shown that experimental, 
established pancreatic and lung tumours regress when antisense cDNA or genomic sequence 
to K-ras was introduced by retroviral transduction (Georges et al, 1993; Aoki et al, 1995). 
Again, this result is not necessarily expected since full length antisense sequences may be 
stabilised by secondary structure, which could prevent effective alignment with target mRNA.
Ribozymes represent an alternative way to reduce transcript levels. These naturally 
occurring RNA enzymes can be modified to target, bind and cleave specific mRNA molecules. 
Ribozymes directed to RNA polymerase 1 mRNA (Voeks et al, 1996) or to telomerase 
(Kanazawa et al, 1996) mRNA can kill cells in culture, and established, experimental 
malignant melanomas have been shown to regress when targeted with a ribozyme to H-ras 
(Ohkawa et al, 1997).
These approaches appear effective, at least in some cases, in culture and in 
experimental tumours generated from cell lines. However, tumours in humans develop over 
longer periods of time, and the tumour phenotype arises from several mutations, therefore, 
correcting single genetic defects clinically, may not be as effective as in model systems.
It may also be anticipated that every cell, or a large proportion of the cells within a 
tumour, must be targeted with the therapeutic sequences. However, the available data suggest 
that the level of transduction that can be achieved by retroviruses, in brain tumours, is <0.2% 
(Ram et al, 1995). If gene transfer is this inefficient in other tumours the use of antisense 
therapy in humans may not be beneficial.
1.7. Tumour suppressor gene therapy
Tumour progression is often associated with loss or mutation of tumour suppressor 
genes (anti-oncogenes). The most studied product from this class of genes is p53 which, in
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response to DNA damage, can lead to growth arrest allowing subsequent DNA repair or 
activation of apoptotic pathways (Kastan et al, 1991). In tumours that lack p53 activity, 
introduction of a functional p53 gene may be beneficial.
Small, established tumours, derived from a p53" non small cell lung cancer cell line, 
have been shown to regress, at least in some cases, when transduced with a retrovirus carrying 
the p53 gene (Nguyen et al, 1997; Nielson et al, 1997). Regressions have also been seen in 
breast and bladder cancer models (Qazilbash et al, 1997).
These results are encouraging, but as with the antisense strategy, correction of a single 
genetic defect may be insufficient to be of benefit clinically.
1.8. Enhancement of immunogenicity
To develop, tumours must evade immune detection. This may occur through loss of 
tumour antigens, through loss of antigen presentation machinery or by lack of appropriate 
stimulatory signals. Introducing components involved in immune stimulation can, in some 
cases, lead to tumour regression. Furthermore, activation of the immune system can lead to a 
bystander effect, where cells not expressing the therapeutic gene are killed as well as the 
targeted cells. Some of the investigations to determine which components of the immune 
system are important are described below.
1.8.1. Enhancement of tumour antigen presentation
Evasion of immune detection by tumour cells often correlates with reduced levels of 
antigen presenting molecules (e.g. histocompatability complex; MHC) or co-stimulatory 
molecules (e.g. B7) which are required for efficient activation of CD8+ cytotoxic lymphocytes
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(Rubin et al, 1997; Wendtner et al, 1997). Ma et al (1996) have shown transduction of B16 
melanomas in culture with MHC II or B7 abrogates the tumorigenicity of these cells in 
syngeneic mice. Furthermore, when animals were immunised with these transduced cells, a 
subsequent rechallenge of B16 parental cells was rejected in some cases, indicative of a 
bystander effect, in the form of immune memory in this instance.
Loss of tumorigenicity does not occur in all cell lines transduced with MHC II or B7 
and it is likely that this can be explained by the correlation between antitumour effect and 
inherent immunogenicity of the tumour (Chen et al, 1994). However some lines of evidence 
suggest that enhancing tumour immunogenicity with cytokines, such as interleukin 2 or 
interleukin 12, may increase the effectiveness of MHC and B7 expression (Ma et al, 1996; 
Lotze et al, 1997).
Enhancing the immune response with cytokines has been the focus of many reports and 
details of some of the findings are given in the next section.
1.8.2. Cytokine gene therapy
Early attempts to enhance the immune response to tumours involved intratumoural 
injection with non specific adjuvants such as Corynebacterium parvum. The basis of this 
approach was that the inflammatory reaction to a foreign protein would increase antigen 
presentation and cause an infiltration of T-lymphocytes to the vicinity of the tumour. Current 
efforts to express cytokine genes in tumour cells are an extension of this concept (review, 
Miller etal, 1994).
Cytokines are small secreted glycoproteins that are required for activation and 
proliferation of cells of the immune system, such as T-cells, granulocytes and macrophages. 
Interest has arisen in these proteins because systemic delivery of some (e.g. tumour necrosis
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factor-a, TNF-a; interleukin-2, IL-2) has been shown to induce tumour regression of 
experimental animal tumours. However, the systemic doses that can be achieved in humans are 
up to 50-fold lower than those in mice, and clinical use of TNF-a or IL-2 has led to systemic 
toxicity, or even death of patients (Rosenberg, 1992).
Expression of cytokine genes within tumour cells may produce high local 
concentrations of cytokine that could have an antitumour effect, without systemic toxicity. 
However, determining the mechanism of action of individual cytokines is often hindered by 
redundancy, or the events that occur following expression. For example, IL-2 activates B- 
cells, T-cells, natural killer (NK) cells and macrophages, but these cells can release other 
cytokines, including TNF-a, interferon-y (IFNy) and granulocyte-macrophage colony 
stimulating factor (GMCSF). In turn, these cytokines may lead to secretion of others. This 
cascade means that studying the action of a single cytokine is difficult (review, Miller et al, 
1994).
Some reports have described the effects of several cytokines in one tumour model 
(Dranoff et al, 1993; Allione et al, 1994) but as the intrinsic properties of each model varies, 
so does the action of the cytokine. For example, the tumorigenicity of mammary 
adenocarcinoma engineered to express IFNy was reduced in syngeneic mice while expression 
of IL-6 had no significant antitumour effect (Allione et al, 1994), but in B16 melanoma, the 
reverse was true (Dranoff et al, 1993). In a separate report, immunisation of syngeneic mice 
with melanoma cells expressing IL-2 was shown to induce specific, systemic immunity to a 
subsequent challenge of B16 cells (Ma et al, 1996), but this effect had not been seen 
previously (Dranoff et al, 1993). These differences may be explained by the observation that in 
some tumours IL-2 has a dose dependent window, and higher or lower concentrations of the 
cytokine reduce protection (Cavallo et al, 1992).
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The effects of particular cytokines are consistent, between reports, in some animal 
models. For example, the tumorigenicity of B16 melanoma cells expressing IL-2 is reduced 
(Dranoff et al, 1993; Allione et al, 1994; Ma et al, 1996) and y-irradiated B16 cells expressing 
GMCSF, or live B16 cells expressing IL-2 and GMCSF, generate specific, systemic immunity 
to parental cell rechallenge, in some cases (Dranoff et al, 1993; Yu et al, 1997).
Producing a systemic response is of particular interest because even when only a
fraction of the tumour is transduced with these cytokines, it may lead to complete destruction 
of local and distant tumour deposits. This bystander effect is absent from animals depleted of 
CD4+ and CD8+ lymphocytes, suggesting that these cells are essential in the response (Fearon 
et al, 1990; Dranoff et al, 1993; Lotze et al, 1997; Yu et al, 1997).
The published data concerning the use of cytokines in cancer gene therapy have shown
tumour regression can occur. However, the models used are usually far removed from a 
clinical setting. Experimental models that evaluate the antitumour effects of cytokines are 
often gauged on the ability of cell lines, engineered to express a cytokine, to form tumours in 
animals, rather than investigating the effect of cytokine gene transfer to established tumours. If 
tumours are transduced with cytokine genes, then the level of cytokine production can be 
expected to be lower than in experimental models, since the efficiency of gene transfer to solid 
tumours is lower than that achieved in culture. More clinically applicable data might be 
generated if spontaneously arising tumours, such as those in the transgenic mouse expressing 
the neu oncogene (Sacco et al, 1996), are treated.
Selection of the most suitable cytokine for therapy may be difficult because it appears, 
at least from the reports in this section, that the effectiveness of cytokines may vary between 
studies using the same model. In addition, many cytokines may not possess antitumour 
properties, for example, studies in a B16 tumour model have shown that of 10 cytokines 
investigated, only IL-2 led to a significant reduction in tumorigenicity (Dranoff et al, 1993).
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1.9. Suicide gene therapy
When expressed in cells, suicide genes can lead to direct cytotoxicity (toxin gene 
therapy) or to conditional cytotoxicity (enzyme / prodrug systems). Enzyme / prodrug systems 
have been studied more extensively since they can induce bystander killing on neighbouring 
cells without the suicide gene. Both systems are described below, and the mechanism of 
bystander killing is considered further in section 1.11.
1.9.1. Toxin gene therapy
Diphtheria toxin (DT; from Corynebacterium diphtheriae) is a dimeric toxin consisting 
of a  and (3 subunits. The a  subunit is an ADP-ribosyltransferase which ADP-ribosylates 
elongation factor 2, preventing protein synthesis. Transgenic mice expressing the a  subunit 
cDNA specifically in pancreatic acinar cells have an abnormal pancreas at birth due to cell 
ablation (Palmiter et al, 1987).
Ricin and abrin are plant lectin toxins which, like DT, also have a  and (3 subunits. The 
(3 subunit is required for binding and entry while the a  subunit mediates toxicity by 
depurination of ribosomal RNA, preventing protein synthesis. Killing of mammalian cells, in 
culture, following exposure to these proteins has been demonstrated (Hughes et al, 1996).
It is therefore likely that the cDNA encoding the a  subunit of these toxins could be 
used for cancer gene therapy. However, cytotoxicity arises immediately after translation, 
making the system difficult to control and it is likely that only the cells expressing the toxin 
would be killed, hence there would be no bystander effect.
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1.10. Enzyme / prodrug systems
In this form of suicide gene therapy, the cDNA for an enzyme which can convert a 
prodrug to a toxic metabolite (s) is introduced and expressed in cells. Separately, the enzyme 
and prodrug are relatively non toxic but in combination the metabolites produced induce cell 
death. Enzyme / prodrug systems allow conditional toxicity and these two stage strategies are 
popular in cancer gene therapy. Many combinations exist and details for three are given below.
1.10.1. Herpes Simplex virus thymidine kinase / ganciclovir (tk / GCV) system
Mammalian thymidine kinase (EC:2.7.1.21) is part of a salvage pathway that enables 
cells to phosphorylate and reclaim thymidine that would otherwise be degraded (Elion, 1980). 
Herpes Simplex virus thymidine kinase (tk; deoxynucleoside kinase; EC:2.7.1.75) is a 
comparable enzyme but also phosphorylates purine deoxynucleoside analogues that are poor 
substrates for the cellular kinases (Elion, 1980). This difference in substrate specificity has 
been exploited for the treatment of HSV infections (Elion, 1980; Cheng et al, 1983) using 
ganciclovir (GCV; 9-[(l,3-dihydroxy-2-propoxy)methyl]guanine; Cymovene) or acyclovir 
(ACV; 9-(2-hydroxy ethoxymethyl) guanine), although GCV is more effective (Golumbek et 
al, 1992).
The tk / GCV system is the most extensively studied of such two stage therapies, tk 
activates GCV, by phosphorylation of an acyclic, pentose like moiety, yielding GCV 
monophosphate (Cheng et al, 1983; Field et al, 1983). This reaction is rate limiting in the 
production of the toxic form of the drug. Further conversion to di- and tri-phosphate forms is 
catalysed by endogenous cellular kinases (figure 1.2.). GCV triphosphate (GCV-TP) is a toxic 
metabolite and competes with deoxyguanosine triphosphate (dGTP) for incorporation into
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nascent chains of DNA in proliferating cells. aDNA polymerase may bind irreversibly to this 
site, causing chain termination and hence cell death (Cheng et al, 1983).
Clinically GCV is a relatively non toxic prodrug at therapeutic concentrations and this 
has attracted attention to tk for use in cancer gene therapy. Moolten et al (1986) demonstrated 
neoplastic murine cell lines transfected with the tk gene were highly sensitive to ganciclovir 
and subsequently others have made similar observations in a variety of cell lines (Golumbek et 
al, 1992; Abe et al, 1993; Barba et al, 1993; Kato et al, 1994; Smythe et al, 1994). In each 
report there was up to 1000-fold difference in sensitivity between tk transfected cells and 
parental cells. Extension of these studies to animal models has demonstrated that tumours 
derived from cell lines expressing the tk gene, including melanoma (Vile et al, 1993), glioma 
(Barba et al, 1993; Kruse et al, 1997), myeloma (Dilber et al, 1996), lung cancer (Osaki et al, 
1994), hepatocellular carcinoma (Kuriyama et al, 1997) and large (>4cm) adenocarcinoma 
(Plautz et al, 1991) can regress with GCV treatment.
Established tumours, derived from cell lines, have been targeted with the tk gene and 
subsequent treatment with GCV resulted in tumour regression (Culver et al, 1992; Perez- 
Cruet et al, 1994; Chen et al, 1995b). This was an important observation since only a fraction 
of the tumour expressed tk and indicated that bystander killing had occurred. A review of the 
mechanisms of bystander effects is provided in section 1.11. The tk / GCV system is the 
subject of several clinical trials (Oldfield, 1993; Culver et al, 1994; Raffel, 1994; Freeman et al, 
1996) and preliminary data suggest that this enzyme / prodrug combination can, in some cases, 
lead to therapeutic benefit (Culver et al, 1996).
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1.10.2. Thymidine Phosphorylase / 5 ’-deoxy-5-fluorouridine (tp / DFUR) system
Thymidine phosphorylase (tp; platelet derived endothelial cell growth factor; 
pyrimidine phosphorylase; thymidine orthophosphate deoxyribosyl-transferase; EC: 2.4.2.4) is 
a human enzyme involved in the reversible formation of thymidine and orthophosphate from 
thymine and deoxyribose-1-phosphate (Wadler et al, 1990). Leukocytes and platelets express 
tp, where the primary function appears to be the regulation of plasma thymidine levels (Chu et 
al, 1990).
tp also plays a role in angiogenesis (Sumizawa et al, 1993) and since rapidly growing 
tumours require formation of new capillaries, elevated levels of tp activity are seen in several 
different cancers, including colon, stomach, bladder and ovarian carcinomas (O’Brien et al, 
1996). This association provides an opportunity for targeted chemotherapy using 5’-deoxy-5- 
fluorouridine (DFUR; Furtulon; Doxifluridine) which is converted, by tp, to 5-fluorouracil 
(FU).
FU is a base analogue which has been used as a chemotherapeutic agent for many 
years (Bimie et al, 1963). FU is converted, by cellular enzymes, to toxic metabolites which 
lead to cell death by interfering with RNA and DNA synthesis (see figure 1.2.). FUTP affects 
maturation and processing of messenger and ribosomal RNA hence inhibits protein synthesis. 
FdUTP is a nucleotide analogue which becomes incorporated into DNA and interferes with 
DNA synthesis. FdUMP (5-fluoro-2’-deoxyuridine-5’-monophosphate) inhibits thymidylate 
synthetase by covalently binding to N5N10 methylene tetrahydrofolate to form a ternary 
enzyme-inhibitor-cofactor complex. This irreversible inhibition prevents DNA biosynthesis 
(review, Springer and Niculescu, 1996). Therefore, FU can lead to apoptotic cell death by 
mechanisms both dependent and independent of the cell cycle (Schipotin et al, 1994; Crystal et 
al, 1997).
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FU has been successfully used to treat some tumours, however, systemic toxicity is 
seen in humans and mice at a dose of 15mg / kg, which can limit the therapeutic effect. Toxic 
symptoms include gastrointestinal tract ulceration and bleeding, and occasionally 
cardiovascular complications (Connolly et al, 1983; Crystal et al, 1997). In addition, cancer 
cells often become resistant to FU and this has been attributed to reduced levels of tp enzyme 
(tp converts FU to FUR and FUdR, see figure 1.2.) in the surviving tumour cell population 
(Peters et al, 1987). Ideally a less toxic alternative that can be applied at a high dose would be 
preferred.
DFUR is a relatively non toxic nucleoside analogue which is converted, by endogenous 
tp, to FU (figure 1.2.). In humans and mice doses of up to 1200mg / body and 200mg / kg 
respectively, have been administered without toxicity (Yamamoto et al, 1996; Connolly et al,
1983). This should result in an increased level of toxic metabolites within the tumour. DFUR 
treatment of Ehrlich Ascites tumour in mice (Connolly et al, 1983) and breast tumours in 
humans (Yamamoto et al, 1996) suggests that DFUR is more effective and less toxic than FU. 
However, DFUR is not always effective against tumours, and this has been attributed to the 
variation in levels of endogenous tp activity (Fujimoto et al, 1985).
The cDNA for tp was cloned in 1993 (Sumizawa et al, 1993) which has allowed 
introduction and expression of the tp gene in cells in culture. Human epidermal carcinoma 
(KB) cells (Haraguchi et al, 1993), human breast cancer (MCF-7) cells (Patterson et al, 1995) 
and lung cancer (PC9) cells (Kato et al, 1997) have been transfected with tp cDNA and in 
each case there was an increased sensitivity to DFUR.
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1.10.3. Cytosine deaminase / 5 fluorocytosine (cd / FC) system
Cytosine deaminase (cd; EC: 3.5.4.1) is a prokaryotic enzyme that deaminates cytosine 
and the base analogue fluorocytosine (FC) to uracil and fluorouracil, respectively (Austin and 
Huber, 1993). No similar enzymic activity is found in mammalian cells and clinically FC has 
been used extensively to control bacterial and fungal infections, including Cryptococcus and 
Candida (Hirschowitz et al, 1995).
Bacterial conversion of a relatively non toxic prodrug to a toxic metabolite has 
attracted attention to cd for use in gene therapy. While FU has a narrow therapeutic window 
and is systemically toxic at doses of >15 mg / kg in humans, no toxicity is seen with FC at 
doses of 200mg / kg / day for 8 weeks (Huber et al, 1995). Higher doses of FC do cause 
toxicity, but this is mainly due to uptake of FU produced by bacteria in the intestine (review, 
Mullen, 1994). This difference in toxicity between prodrug and drug allows high local 
concentrations of FU to be produced by treating tumours expressing the cd gene with FC, (FU 
is also produced by the tp / DFUR system and its further metabolism has been described in 
section 1.10.2 and figure 1.2.).
The cd / FC strategy has been successfully used to kill mammalian cells, for example, 
Huber et al (1993) demonstrated WiDr (colorectal carcinoma) cells expressing the cd gene 
required 27 pM FC to reduce survival by 50%, approximately 1000-fold less than parental 
cells. This is well below the peak plasma concentration that can be achieved in humans 
(approx. 700pM FC; Huber et al, 1995).
Tumours derived from cell lines expressing the cd gene, including mouse mammary 
adenocarinoma (Consalvo et al, 1995), human colorectal carcinoma (Huber et al, 1993; Huber 
et al, 1995; Trinh et al, 1995) and colon carcinoma (Hirschowitz et al, 1995), have been 
shown to regress with FC treatment. In some instances local FU concentrations in the tumour
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exceeded 400pM (Huber et al, 1994). Since FC is less toxic than FU, treatment can be given 
for longer periods of time leading to greater tumour regressions and an increased number of 
tumour cures (Consalvo et al, 1995). Longer treatment may also enhance the immune 
response towards tumour cells (section 1.11.5.; Consalvo et al, 1995).
More recently adenoviral delivery (section 1.15.2.) of the cd gene to liver metastases 
derived from colorectal carcinoma cell lines, in combination with FC treatment, has been 
shown to result in significant tumour regressions (Ohwada et al, 1996). Observations such as 
these have led to a clinical trial using the cd / FC enzyme / prodrug system for the treatment of 
metastatic colon cancer of the liver (Crystal et al, 1997).
1.11. Bystander effects associated with enzyme / prodrug systems
Enzyme / prodrug systems can lead to bystander killing of cells with and without the 
therapeutic gene, an effect that has also been described previously in association with 
enhancement of the immune system (section 1.8.). However, the mechanism of bystander 
effects associated with enzyme / prodrug systems appears to be mediated by toxic metabolites 
as well as components of the immune system. Since only a low level of transduction can be 
achieved with current delivery systems (Caruso et al, 1993; O’Malley et al, 1995; Calvez et al, 
1996), it will be important to understand the mechanism by which bystander killing occurs. 
The suggested mechanisms of bystander effects of enzyme / prodrug systems is considered 
below.
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1.11.1. Possible mechanisms for culture and in vivo bystander effects
A physical property of all prodrugs used for suicide gene therapy is that they should be 
able to cross the cell membrane. For example, FC crosses the membrane by diffusion 
(Haberkom et al, 1996b), while GCV is carried by a nucleoside transporter (Haberkom et al, 
1996a). For a bystander effect involving transfer of toxic metabolites to occur, metabolites 
produced by the suicide enzyme must pass to neighbouring cells. If these metabolites can leave 
the transfected cell and enter the untransfected cells by crossing the plasma membrane, which 
might be expected in the case of FU (see section 1.10.2.), then no specialised mechanism is 
required. However, if the metabolites produced by the transfected cells are unable to cross the 
membrane, then transfer must occur by a different pathway.
It is possible that in the tk / GCV system, phosphorylation of GCV (figure 1.2.) 
prevents the toxic metabolites from crossing the membrane. The suggested mechanisms for 
spread of toxic metabolites to tk' cells include phagocytosis of apoptotic vesicles liberated 
from dying GCV treated tk+ cells (Freeman et al, 1993) and transfer of GCV phosphates 
through gap junctions, by a process known as metabolic co-operation (Bi et al, 1993). This is 
a controversial issue and evidence for each mechanism is considered below.
1.11.2. Transfer via apoptotic vesicles
Freeman et al (1993) have demonstrated that in mixed cultures of 10% tk+ and 90% tk' 
cells, almost all cells are killed with GCV treatment. In a subsequent experiment, the lipophilic 
membrane dye, pKH26 (red fluorescence with 488nm excitation), was used to label tk+ human 
colorectal carcinoma cells, while tk' murine tumour cells could be identified by a mouse 
specific FITC labelled antibody. When mixed cultures of these cells were treated with GCV,
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apoptotic vesicles were released from tk+ cells and their presence was detected in neighbouring 
tk' cells. From these experiments it was concluded that toxicity could be transferred via 
phagocytosis of apoptotic vesicles (Freeman et al, 1993).
Apoptosis and necrosis are two methods through which cell death can occur. Necrosis 
is a relatively uncontrolled progressive degradation that occurs after death and is normally 
associated with severe changes in environmental conditions, for example, hypothermia, 
hypoxia, ischemia or complement attack. Membrane integrity is reduced, causing swelling and 
rupture of the membranes surrounding the cell and the organelles. Release of lysosomal 
enzymes results in degradation of cellular components (review, Walker et al, 1988).
Apoptosis, however, is a well controlled process and occurs in two distinct phases. In 
the latent phase, chromatin compacts to dense masses that associate with the nuclear envelope. 
The cytoplasm of the cell condenses and DNA undergoes double stranded cleavage at linker 
regions between nucleosomes to produce fragments which are multiples of 185 bp. Cleavage is 
specific and associated with a Ca++/ Mg++ dependent endonuclease (Kerr et al, 1972; Arends et 
al, 1990). This phase is variable in length lasting from hours to days (Lazebnik et al, 1993).
The active phase occurs rapidly, in as little as an hour, and is characterised by 
extrusion of vesicles from the main body of the cell. These apoptotic vesicles vary in size, 
contain intact organelles and may or may not contain fragments of chromatin. Vesicles are 
rapidly engulfed by neighbouring cells which prevents the release of macromolecules, such as 
lysosomal enzymes, that could lead to toxic consequences (Savill et al, 1993).
In support of the role of apoptotic vesicles in transfer of toxicity, the presence of 
apoptotic bodies in neoplastic cells has been observed (Kerr et al, 1972) and treatment of cells 
with cytotoxic agents, such as cisplatin or ricin, has been shown to induce shedding of 
apoptotic vesicles within 24 hr (Cece et al, 1995; Hughes et al, 1996). However, if apoptotic 
bodies were involved, it is likely that vesicle transfer would occur by phagocytosis, rather than
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fusion. This would result in vesicular contents ending up, not in the cytoplasm, but in the 
lysosomal compartment. Even if toxic metabolites were not degraded, there would still be a 
membrane (s) to cross to reach the cytoplasm. The role of vesicles in transfer is investigated 
further in chapter 3.
1.11.3. Transfer via gap junctions
Mixed cultures of human fibrosarcoma cells with and without the tk gene only show a 
bystander effect when cells are in contact (Bi et al 1993). In sparse cultures only tk+ cells were 
killed and subsequent experiments showed that incorporation of 3H GCV to tk' cells only 
occurred when they were in contact with tk+ cells. These results suggested that the mechanism 
of transfer of toxicity involved metabolic co-operation requiring the presence of functional gap 
junctions (Bi et al 1993).
Metabolic co-operation between coupled cells has been readily demonstrated in other 
culture systems. Fibroblasts taken from patients with Lesch-Nyhan disease are deficient in 
hypoxanthine phosphoribosyl transferase (HPRT). This enzyme is involved in the salvage 
pathway of purine nucleotide synthesis from hypoxanthine. If the normal pathway of 
nucleotide biosynthesis is inhibited by aminopterin, then these mutants are unable to grow in 
full medium supplemented with hypoxanthine, but can be rescued when cultured in contact 
with HPRT4- cells. Mutant cells undergo prompt phenotypic reversion when separated, even 
though the enzyme has a long half life and this suggests that transfer of nucleotides, rather 
than enzyme, had occurred (Cox et al, 1970).
Moreover, HPRT cells are resistant to the purine analogue thioguanine (TG) when 
cultured alone but in mixed cultures with wild type cells, become sensitive to the toxic effects 
of TG (Fujimoto et al, 1971). This effect has been termed the kiss of death and is directly
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analogous to the bystander effect seen with the tk / GCV system, supporting metabolic co­
operation as a mechanism of transfer of toxicity.
If gap junctions are involved in the tk / GCV bystander effect then the use of this 
enzyme / prodrug system may be limited to tumours that have high levels of gap junctional 
communication. With this in mind, a brief review of the structure, function and role of gap 
junctions is provided in section 1.12.
1.11.4. Possible mechanisms for in vivo bystander effects
Cell killing in vivo is more effective than killing in culture, in some models. For 
example, Barba et al (1993) demonstrated that all C6 tk+ glioma cells could not be killed by 
continuous GCV in culture, but brain tumours formed from these cells could be cured. In this 
study tk+ cells were seeded (in culture) at relatively low density and it is possible that some 
cells acquired resistance to GCV (by disruption or methylation of the tk gene or promoter 
sequences), but due to the lack of cell-cell contact, were not killed by neighbouring tk+ cells 
that retained the functional gene. If resistant cells did arise in vivo then additional factors must 
have led to bystander killing. Experiments have shown a functional immune system and 
damage to tumour vasculature are important for effective tumour clearance.
1.11.5. Role of the immune system
There is an increasing amount of evidence to suggest that a functional immune system 
is required for tumour eradication. For example, lung metastases, derived from a B16 
melanoma cell line, have been shown to regress in syngeneic but not nude mice (Vile et al, 
1994b). In a separate study, rats with established 9L tk+ brain tumours were cured with GCV
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and, while all naive animals succumbed to a subsequent rechallenge of parental cells in the 
contra-lateral flank of the body and the brain, pre-treated (9L tk+ / GCV) animals did not 
develop tumours, in some cases. Immunity was also shown to be specific since protection 
against 9L cells and not other tumorigenic cell lines was observed (Barba et al, 1994) 
suggesting that the response was T-cell mediated. The role of the immune system has been 
implied by others who have shown extensive infiltration of the residual tumour by CD8+ 
lymphocytes, to a lesser extent CD4+ and CD3+ cells, granulocytes and macrophages (Caruso
i
| et al, 1993; Consalvo et al, 1995; Gagandeep et al, 1996; Yamamoto et al, 1997).
If
| The particular role of some of these immune cells has been demonstrated by the use of
[
l antibody blocking experiments. In colon carcinoma and adenocarcinoma models granulocytes
I
! are required for initial tumour inhibition, CD4+ helper cells are required for rejection of tumour
cell rechallenge and CD8+ cytotoxic cells function in both roles (Chen et al, 1995b; Consalvo
j et al, 1995). This suggests that CD4+ and CD8+ cells are required for efficient generation of
| immune memory.
|
j  Release of cytokines from GCV treated tumours, derived from cell lines engineered to
i
j
| express the tk gene has been documented, but appears to depend on the particular tumour cell
[
i
| line. For example, tk+ tumours derived from fibrous histocytoma cell lines release interleukin
| (IL) l a  / p, IL-6, IL-8 and the chemokine RANTES after GCV treatment, but tk+ ovarian
carcinomas released IL-la, / [3 and IL-8 (Abboud et al, 1996). TNFa has been associated with 
GCV treatment of experimental tk+ human colon carcinoma (Freeman et al, 1995), while IFNy 
and GMCSF are released from tk+ murine fibrosarcoma (Ramesh et al, 1996). In separate 
studies, these cytokines have been shown to exhibit antitumour activities in experimental 
models (see section 1.8.2.).
Due to the apparent importance of the immune system, some reports have documented 
combination of suicide and cytokine genes, for example tk and IL-2 (Chen et al, 1995b) or cd
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and IL-6 (Mullen et al, 1996), for treatment of experimental tumours. This approach has led to 
an increased number of tumour cures compared to either system alone and it has been 
suggested that cell death caused by the enzyme / prodrug combination may increase antigen 
presentation, while the cytokine activates local T-cells (Mullen et al, 1996). Consistent with 
this hypothesis, GCV mediated killing of experimental renal carcinomas, expressing the tk 
gene, leads to increased expression of MHC-I antigen (Barba et al, 1994).
1.11.6. Damage to tumour vasculature
Fast growing tumours require a good blood supply and damage to vasculature may 
lead to tumour ischemia. It has been demonstrated that retroviral vectors transduce endothelial 
cells of tumour capillaries in the brains of rats (Ram et al, 1993) and endothelial cells may be 
coupled, by gap junctions, to surrounding cells (Kam et al, 1986). After tk transduction and 
GCV treatment, tumour haemorrhaging has been observed (Perez-Cruet et al, 1994) and 
Doppler imaging has shown a five fold decrease in the number of tumour blood vessels in a 
subcutaneous glioma model (Ram et al, 1994).
1.12. Gap junctional intercellular communication (GJIC)
It has been suggested that metabolic co-operation is required in the tk / GCV 
bystander effect (see section 1.11.3.). Therefore a basic understanding of the structure and 
function of gap junctions may be necessary to complete an investigation of transfer of toxic 
metabolites from tk+ to tk' cells (Chapter 3).
GJIC is necessary in complex, differentiated organisms to co-ordinate the activities, 
differentiation and growth of component cells. Gap junctions allow ions and small molecules
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(Mr of <1000) to pass between coupled cells by diffusion, but macromolecules such as 
proteins and nucleic acid cannot pass to neighbouring cells. Exchange of low molecular weight 
solutes is, however, restricted to distinct communication compartments, where cells within a 
compartment are coupled to each other, but not to cells within neighbouring compartments 
(review, Pitts and Finbow, 1986). The role of junctional communication within excitable 
tissues and during tumorigenesis is considered in section 1.12.2., but to understand gap 
junctions better, some basic structural information is provided below.
1.12.1. Gap junction structure
The gap junctional channel is composed of two hemi-channels termed connexons. Each 
hemi-channel joins end to end with another, provided by the apposing membrane of an 
adjacent cell. Each connexon is composed of six subunits, arranged symmetrically around an 
axial water filled channel with a diameter of 1-2 nm (figure 1.3.). However, there has been a 
controversy as to what protein is the principal channel component of the connexon (review, 
Finbow and Pitts, 1993). The debate revolves around two proteins, ductin and connexin.
Ductin is a 16 kDa protein which is found in cells of diverse origin, for example, in 
plants, fungi, vertebrates and invertebrates (Finbow et al, 1984; Finbow et al, 1993). Isolated 
gap junctions or gap junction regions in tissue sections are bound by antibodies to invertebrate 
ductin (Buultjens et al, 1988; Leitch and Finbow, 1990). GJIC is inhibited when anti-ductin 
antibodies are injected into mammalian or invertebrate cells (Finbow et al, 1993). However, 
ductin also forms a major component of the vacuolar ATPase proton channel (Mandel et al, 
1988) and it is not possible to produce ductin knockouts that are not lethal Evidence 
therefore remains circumstantial.
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Figure 1.3. Schematic representation of the proposed gap junction connexon
Hemi-channel subunit: 
ductin or connexin Cell 1 plasma membrane
Channel pore
Hemi-
channel
Cell 2 plasma membrane
Based on diagram by Makowaki et al. 1977.
Several studies have demonstrated that junctional communication of poorly coupled 
cells can be increased by introducing connexin genes (Mesnil et al, 1996; Elshami et al, 1996; 
Shinora et al, 1996) and reports such as these lend support to the requirement for connexins in 
gap junction formation. However, introduction of connexin genes into MCF-7 mammary 
carcinoma cells that lack a functional endogenous gene and are not coupled, fails to introduce 
communication (Pitts, unpublished data) and no connexins have been identified in 
invertebrates, despite successful isolation of gap junctions from such organisms (Finbow et al,
1984).
It is therefore possible that ductin forms the major protein of the gap junction, while 
connexins play a largely regulatory role.
1.12.2. Communication compartments
Organisation of tissues into communication compartments allows cells within a 
coupled population to share the same low molecular weight signals, while cells in different 
compartments can share different signals. Sharing such signals may cause cells to act in 
synergy or may place homeostatic pressure on aberrant cells.
Gap junctions, acting as electrical synapses, allow action potentials to spread quickly 
and uniformly within excitable tissues such as the heart and smooth muscle. In other excitable 
tissues however, such as skeletal muscle and the CNS, gap junctions are lost during the 
terminal stages of differentiation (review, Pitts and Finbow, 1986) as electrical coupling would 
produce unacceptable all or nothing responses.
The homeostatic pressure which arises due to communication within a coupled cell 
population can suppress the expression of individual cell phenotypes. For example, in culture, 
normal cells can suppress the aberrant growth of certain transformed cells, providing gap
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junctions are formed between the two cell types (Mehta et al, 1986). The mechanism of this 
suppression may involve the uniform distribution (hence dilution) of second messengers 
associated with the transformed phenotype between cells of the coupled population. It has 
therefore been suggested that for a tumour to form, cells must lose junctional communication 
(review, Yamasaki, 1990). However, it has become apparent that it is rare for tumour cells to 
actually lose the capacity to communicate, but in most cases communication is markedly 
reduced. For example, reduction of junctional communication has been observed during the 
progression of mouse squamous cell carcinomas to spindle carcinomas (Holden et al, 1997). In 
this model, B9 squamous cells represent an intermediate stage of progression and have high 
levels of GJIC, but further progression to CarB spindle cells results in the loss of the adhesion 
protein, E-cadherin, and a >5-fold reduction injunction communication. Other studies suggest 
that an important factor in tumour formation appears to involve reduction or loss of 
communication between the tumour cells and the surrounding normal cells, rather than 
between tumour cells (review, Yamasaki, 1990).
Therefore, before considering the application of the tk / GCV enzyme / prodrug 
system, it will be important to establish the mechanism of transfer of toxic metabolites from tk+ 
to tk' cells. If high levels of GJIC are required for the spread of toxic metabolites then it is 
possible that the tk / GCV system will not be suitable for treatment of many tumour types.
1.13. Vectors
In culture, vectors such as retroviruses can achieve a high efficiency of gene transfer to 
cells because most cells are readily accessible and are cycling, a requirement for retroviral 
infection. This contrasts to the dense 3 dimensional structure of solid tumours, where access 
to the majority of the cells is restricted, cell division is slow and the level of gene transfer is low.
2 6
Ideally cells would be explanted from tumours and therapeutic genes introduced to the cells 
while in culture. This ex vivo approach has been adopted for transfer of IL-2 and TNF-a 
cytokine genes to TILs (Rosenberg et al, 1993), with treatment being beneficial in some cases.
Explanting cells to culture is not always successful, since primary cultures cannot 
always be established and cell numbers cannot always be increased sufficiently to be of clinical 
value. Another consideration is that the antigenic profile of the cells may change during the 
period of culture and when reintroduced to the patient, the expanded cell population may be 
rejected. The ex vivo approach is also labour intensive and time consuming, since expansion 
of, for example, TILs, requires up to 10 weeks (Rosenberg et al, 1990). For cancer gene 
therapy to be successful, it is likely that gene transfer will have to be accomplished in vivo. 
Some of the current delivery methods being investigated are considered below, and the 
problems of gene delivery are discussed further in section 1.17.
1.14. Non viral delivery
1.14.1. Naked DNA
Introduction of naked DNA by direct intratumoural injection has been suggested as a 
method of gene transfer (Vile et al, 1993) because DNA is of low immunogenicity and, unlike 
some viral vectors (section 1.15.), allows tissue / tumour specificity of promoters (section
1.16.) to be retained. However, transfer efficiency is low and only in some instances has a 
therapeutic effect been observed (Vile et al, 1993; Vile et al, 1994b).
To try to improve the efficiency of gene transfer, Nishi et al (1996) used ‘electrogene ’ 
therapy in which intra-arterial plasmid DNA coding for (3-galactosidase was injected and short 
piulses of electricity were used to increase efficiency of uptake. However, this approach
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succeeded in only doubling the level of (3-gal activity in the tumours compared to when 
control plasmid was introduced by this approach.
1.14.2. Liposomal delivery
Cationic liposomes are positively charged lipid based complexes that can condense 
DNA spontaneously to form complexes with high affinity to cell membranes. Endocytosis of 
complexes, followed by disruption of the endosomal membrane appears to be the major 
mechanism of gene delivery (Gao and Huang, 1995). Liposomes are non immunogenic, safe 
and may preferentially target tumours since it has been suggested that they are able to leak 
from newly forming capillaries which are found in developing tumours (review, Boulikas, 
1996).
Liposomes have been used to deliver therapeutic genes, such as the tk gene, to 
cultured cells and experimental tumours, including pancreatic cancer (Aoki et al, 1997) and 
B16 melanoma (Calvez et al, 1996). Although gene transfer to 10% of B16 tumour cells was 
achieved in culture, therapeutic doses of prodrug (=20 [uM GCV) killed only 20% of cells 
(Calvez et al, 1996). A bystander effect using the tk /  GCV system has previously been 
demonstrated in these cells in culture, therefore it is possible that the level of tk expression 
was low or not sustained. The use of viral delivery may achieve higher levels of expression and
f
this method is considered below.
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1.15. Viral delivery
1.15.1. Retroviruses
Retroviruses represent a very efficient method of gene transfer to cells in culture, with 
transduction rates of 90% in some fibroblastic cell lines, but since tumours have long 
replication cycles and these vectors persist for a short time, transduction efficiency in vivo may 
be <0.1% in some cases (Short et al, 1990). However vector producer cells (vpcs) have been 
shown to be able to achieve gene transfer to 10% of cells in experimental tumours (Short et al, 
1990). Vpcs can allow the production of recombinant retroviral particles for up to 14 days in 
vivo, but after this time they are removed by an immune response (Moorman et al, 1994).
Vpcs are constructed from a cell line, often fibroblastic, which is engineered to express 
the viral genes, gag, env and pol, in trans while a helper virus expresses the viral genes 
required to generate an empty retroviral particle. This cell line is also stably transfected with a 
plasmid carrying the remaining retroviral genes, in the 5’ and 3’ LTRs. Expression of the 
foreign nucleic acid is often driven by the promoter regions in one of the viral LTRs. 
Therefore the vpcs derived, produce replication defective viral particles that can transduce 
dividing cells and express the therapeutic gene. Injection of vpcs carrying the tk gene to 
experimental tumours in animals, combined with GCV treatment, has led to a significant 
tumour regressions, without apparent toxicity to surrounding normal tissue (Culver et al, 
1992; Caruso et al, 1993; Ram et al, 1993a; Izquierdo et al, 1995; Ram et al, 1993b). Several 
clinical trials are on-going using this method of gene transfer (Oldfield et al, 1993; Culver et 
al, 1994; Izquierdo et al, 1996).
There are, however, several problems with retroviruses, for example, they only infect 
dividing cells. Although this has made them a popular choice for treatment of brain tumours
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where the surrounding tissue is mainly quiescent (Izquierdo et al, 1995), tumour cells are often 
not dividing and surviving untransduced cells may repopulate the tumour (Maron et al, 1996; 
Cool et al, 1996). Furthermore, in some cell lines expression of the tk gene has been 
demonstrated after retroviral transduction in culture, but not when delivery was attempted in 
tumours derived from these cell lines (Zhang and Russell, 1997). It is possible that the tk gene 
in the vpcs used was unstable, or the cells within the tumour were not cycling at a sufficient 
level to permit infection by these retroviruses.
To achieve expression of the therapeutic gene, viral sequences must integrate into the 
host genome. This event is non specific and although the risk of oncogene activation, through 
insertional mutagenesis is remote (Moolten et al, 1992), integration into silenced regions of 
the genome may reduce therapeutic gene expression. Blaese et al (1993) reported 100-fold 
variation in levels of expression of therapeutic genes and attributed the differences to position 
of gene insertion.
A concern for the future use of retroviruses are the observations that viral titre has 
been reduced when tissue specific promoter elements are introduced to the vector, and that 
tissue specific expression (section 1.16.) is not always retained (Kuriyama et al, 1991; Vile et 
al, 1994a).
1.15.2. Adenoviruses
Adenoviruses have been investigated as a method of gene delivery because, unlike 
retroviruses, they infect a wide range of cells, independent of cell cycle (review, Vile et al, 
1994c). Adenovirus can be prepared to a high titre and can superinfect a cell which may lead 
to high levels of gene expression (Kaneko et al, 1995). Currently most adenoviruses used in 
gene therapy have the El and E3 regions of the genome deleted and replaced with foreign
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genetic sequences. E l, but not E3, is essential and must be supplied in trans by a producer cell 
line. The particles released from this cell line are replication defective.
Intratumoural injection of recombinant adenovirus has been used to deliver the tk gene 
to experimental tumours, and combined with GCV treatment, can lead to long term animal 
survival (Perez-Cruet et al, 1994; Chen et al, 1994; Colak et al, 1995). More recently clinical 
trials have been initiated (Crystal et al, 1997; Alvarez et al, 1997).
Despite these promising reports there are still several issues that require attention. 
Adenoviruses can infect many cell types and as such can cause non specific cytotoxicity which 
appears to vary depending on the cell line or the animal model For example, toxicity in 
cultured astrocytes has been shown to occur at a multiplicity of infection (MOI) of 10 (Maron 
et al, 1995), while survival of C6 glioma cells was unaffected at an MOI of 125 (Chen et al, 
1994). In baboons intracranial injection of >107 pfu resulted in severe toxicity (Goodman et al, 
1996) whereas in rhesus monkeys injected with up to 1011 pfu, to the same site, showed no 
significant toxicity (Smith et al, 1997b). The variation in cytotoxicity observed may be due to 
differences in binding and entry of adenovirus that have been suggested from culture studies 
(Bonnekoh et al, 1996; Smythe et al, 1995; Chen et al, 1996b).
Adenoviruses elicit an immune response which may inhibit further vector
administration. However, recent findings show antibodies to one serotype do not always cross 
react with another and it may be possible to circumvent the immune response by sequential 
delivery of a different recombinant adenovirus serotypes (Kass-Eisler et al, 1996). 
Alternatively deletion of further adenoviral genes may reduce the immune reactivity of the 
virus (Chen et al, 1996b) and this approach may also prevent disruption of tissue specific
therapeutic gene expression that has been reported (Ring et al, 1996).
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I 1.15.3. Adeno-associated virus (AAV)[
Ii
AAVs are single stranded parvoviruses that can be prepared to high titre. Infection is 
not dependent on cell division and due to their small size (*20nm compared to adenovirus of 
=70nm), they may penetrate into tumours more readily. AAVs are non pathogenic in humans
i
| and have been used to achieve tissue specific expression of the tk gene in hepatoma cell lines
i
| in culture (Su et al, 1997).
I
| However, as AAVs have a small genome, only 4kb can be replaced by foreign genetic
t
| sequences and, while wild type viruses have been shown to integrate site specifically to 
chromosome 19, recombinant AAVs appear to lack this specificity (Ponnzhagan et al, 1997).
i
| Therefore there is a theoretical risk of insertional mutagenesis, similar to that when using
I retroviral gene transfer. Also similar to retroviruses, recombinant AAVs may integrate into
' silenced regions of the host genome, and expression of the therapeutic gene may be reduced.
f
|
1.16. Tumour specific gene expression
f
| In order to achieve expression of a therapeutic gene exclusively in tumour cells, gene
i
| transfer must be accomplished to a selected population of cells in culture, or as a targeted
j approach in vivo. Ex vivo transduction of cells isolated from a tumour has been described
t
previously in section 1.4.1. In this approach, primary cultures often fail and antigenic changes 
can occur during adaptation of cells to culture conditions (Rosenberg, 1992). Therefore, it is 
likely that gene transfer protocols will need to be accomplished in vivo.
The requirement for restricted gene expression, if gene transfer is accomplished in 
' vivo, has been demonstrated using adenoviral delivery of the tk gene intrahepatically to mice,
or intracranially to baboons, where combined treatment with GCV led to death of animals
(Brand et al, 1997; Goodman et al, 1996). In these studies, injection of GCV or adenovirus 
alone did not lead to animal fatalities. Therefore it is possible that the tk / GCV combination 
killed dividing endothelial cells causing haemorrhage and death. It has also been suggested that 
the fatalities were due to killing of non dividing cells (Brand et al, 1997) but further studies are 
required to investigate this suggestion.
The method of tumour targeting that has been used most frequently is regional delivery 
of murine retroviruses, because these vectors preferentially infect dividing cells. Studies 
involving implantation of vector producer cells into experimental liver and brain tumours have 
demonstrated that transduction was restricted to tumour cells and some endothelial cells (of 
tumour capillaries) since surrounding normal cells were mostly quiescent (Curaso et al, 1993; 
Barba et al, 1994). The disadvantage of this method of tumour targeting is that in many human 
tumours only a relatively small proportion of the cells are dividing at any one time and studies 
in patients with glioblastoma multiforme have demonstrated that the number of tumour cells 
transduced was <0.2% (Ram et al, 1995).
To accomplish gene expression in tumour cells following systemic delivery of a vector, 
further means of targeting are required. However, attempts to engineer retroviral envelope 
proteins so that they recognise specific cell surface receptors have been hampered by incorrect 
ligand folding in the viral membrane, resulting in poor entry to tumour cells (review, Chong 
and Vile, 1996). At the present time the most realistic approach appears to be the use of 
transcriptional control.
Ideally transcriptional control of therapeutic genes would be accomplished using a 
promoter that is only active in tumour cells and produces a high level of gene expression. 
However, most promoter activity is only increased, relative to normal tissue, during 
carcinogenesis or restricted to specific tissues. For example, carcinoembryonic antigen (CEA) 
is highly expressed in several cancers of epithelial origin, such as those in the lung, breast and
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pancreas, but this protein is also found in normal colonic mucosa (Osaki et al, 1994; Lan et al, 
1996). The CEA promoter has been shown to drive expression of the tk gene in CEA positive, 
but not CEA negative cell lines (Dimaio et al, 1994). Tissue specific expression can be 
achieved from the tyrosinase (tyr) promoter and a tyr-lacZ construct was shown to express |3- 
gal in 12 of 14 melanomas but not in 12 cell lines from different origins (Vile et al, 1993) The 
tyr promoter has also been used to direct expression of suicide genes (Vile et al, 1993; Vile et 
al, 1994a; Hughes et al, 1995).
Several other promoter elements with a level of tissue or tumour specificity have been 
used for therapeutic gene expression in cell lines. These include the promoters of a- 
foetoprotein (AFP) for liver cancer (Ido et al, 1995), myelin basic protein (MBP) for gliomas 
(Miyao et al, 1993), ErbB2 for breast cancer (Harris et al, 1995) and osteocalcin for 
fibroblastic osteosarcoma (Ko et al, 1996).
There are some reports that suggest the tissue specificity of promoter elements may be 
reduced, in some cases, when constructs are delivered using retro- and adeno-viral vectors 
(Vile et al, 1994a; Ring et al, 1996). Furthermore, some promoters, such as AFP, may achieve 
less than 1% of the expression seen with CMV promoter, which is often used in experimental 
systems (Kaneko et al, 1995; Kanai et al, 1997).
Another consideration is that targeting expression of suicide genes to tumour cells may 
reduce the effectiveness of the therapy. For example, damage to tumour capillaries may result 
in tumour ischemia (Ram et al, 1993a; Ram et al, 1994) but tissue specific targeting may 
reduce suicide gene expression in the endothelial cells of the capillaries, thereby reducing this 
part of the bystander effect. Targeting using specific promoters may also reduce the level of 
gene expression due to the heterogeneity seen in human tumours since some cells may not 
possess the appropriate transcription factors.
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1.17. Problems facing gene therapy
l
The reports described in this chapter demonstrate that introduction of therapeutic 
l genes to cells in culture, or tumours derived from these cells, can lead to tumour cell death
I after treatment with prodrug. In addition, most of the approaches described here are currently
i
being investigated as phase I clinical trials. However preliminary clinical data suggest that 
killing of human tumours is not nearly as successful as that achieved in experimental animals.
! A summary, which includes some possible problems facing gene therapy, is provided below.
[
I Perhaps the foremost problem is one of gene transfer to tumour cells. It has been
I
demonstrated that the level of retroviral transduction achieved in tumours derived from a C6 
glioma cell line is <0.1%, but this can be improved 100-fold by the use of vector producer 
cells (vpcs). However these studies were performed under favourable conditions, such ast[
targeting small tumours that have been freshly produced and hence are rapidly growing and
! susceptible to retroviral infection. Furthermore, the number of vpcs in these models are often
[
j greater than the number of tumours cells (Short et al, 1990). It is perhaps not surprising that
i
[
| <0.2% of cells expressed the tk gene following implantation of vpcs into large, slowly dividing
i
i
| tumours such as human glioblastomas (Ram et al, 1995) and that subsequent treatment had
| little effect in most cases. Cure of small experimental tumours has been observed only when
>4% of tumour cell expressed the cd gene (Huber et al, 1994).
It is possible that gene transfer will be more successful when vectors that do not 
require cells to be in cycle, such as adenovirus, are used. However, to achieve a high level of 
gene transfer, even in culture, may require a high multiplicity of infection (MOI) which could 
prove to be toxic. For example, at an MOI of 1, adenoviral mediated delivery of the tk gene 
was detected in 2% of 9L cells in culture, but cytotoxicity was seen at an MOI of 50. In
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humans it is unlikely that even an MOI of 1 can be achieved, since tumours are large and often 
contain >10u cells, but the maximum dose in current clinical trials is <1010 adenoviral particles 
(Crystal et al, 1997; Alcarez et al, 1997). It is therefore apparent that delivery systems need to 
be improved, both in terms of gene transfer efficiency and reduced toxicity.
One potential method for reducing toxicity is to target expression specifically to 
tumour cells, and the most likely way this can be accomplished at present is by the use of 
transcriptional control (section 1.16.). However this may mean using a weaker promoter and 
achieving expression in fewer tumour cells, which might be expected to reduce the therapeutic 
effect.
Due to the problems of therapeutic gene transfer and expression, it may be important 
to select systems where the therapeutic effect can be amplified. This may be the case in 
enzyme / prodrug systems but not in antisense strategies. For example, it might be expected 
that antisense treatment will lack a bystander effect and that gene transfer to every cell within 
the tumour will be required, which is unlikely to be possible. In addition, the number of 
effector molecules is low since the only amplification step, in this strategy, is from DNA to 
RNA. This contrasts to enzyme / prodrug systems that often show a bystander effect and the 
level of toxicity is relatively high since the processes of transcription, translation and enzymic 
conversion of prodrug to toxic metabolites amplifies the number of effector molecules.
The immune system has also been shown to be important for tumour clearance and is 
likely to be an essential feature of any cancer gene therapy protocol. However, further work is 
required to determine which cytokine(s) is most effective for treatment of tumours since the 
antitumour effect appears to vary between different experimental models. For example, 
tumorigenicity of mammary adenocarcinoma cells engineered to express IFNy was reduced, 
while EL-6 had no significant antitumour effect (Allione et al, 1994), but in B16 melanoma, the 
reverse was true (Dranoff et al, 1993).
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The current problems that face gene therapy reflect the infancy of this area of research. 
Each aspect of cell targeting and killing needs to be improved, in particular, gene transfer and 
bystander effects. If this can be achieved then it is possible that gene therapy may provide a 
supplementary treatment for cancer. The aim of this project was to investigate the mechanism 
of bystander effects associated with enzyme / prodrug systems, and these aims are summarised 
below.
1.18. Aims
The first clinical trials using the tk / GCV system were initiated in 1993. The 
mechanism of the bystander effect associated with this strategy was not fully understood, 
although various suggestions had been made. These included spread of toxic metabolites to 
neighbouring cells without the tk gene, a role of the immune system and damage to tumour 
capillaries leading to tumour ischemia. The mechanism of transfer of toxic metabolites from 
tk+ to tk' cells was a controversial issue and it was suggested that it may depend on gap 
junctions (Bi et al, 1993) or phagocytosis of apoptotic vesicles released from dying tk+ cells 
(Freeman et al, 1993). During the course of this thesis, it was also suggested that transfer may 
occur via the medium (Kuriyama et al, 1995).
Spread of toxic metabolites may be an essential feature of enzyme / prodrug systems. 
Therefore the aim of this project was to determine the mechanism of transfer of toxic 
metabolites in tk / GCV system. The project was also aimed at investigating the mechanism 
and efficacy of the tp /  DFUR and cd / FC enzyme / prodrug systems, in comparison to the tk / 
GCV strategy. In addition, as it seems likely that bystander effects will need to be enhanced 
for successful application of these systems, methods by which they can be optimised were 
investigated.
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Chapter 2. Materials and Methods.
2.1.1. Chemicals
Chemicals used throughout this thesis were of “AnalR” grade and obtained from BDH 
Chemicals Ltd., Poole, Dorset, England or Sigma Chemical Co. Ltd., Poole, Dorset, England, 
except those obtained from the suppliers listed below.
Supplier Chemical
Amersham International Pic., Aylesbury, 
Bucks, UK.
a[32P]-dCTP (3000Ci/mmol)
Hybond-ECL
Hybond N*
BRL (UK), Gibco Ltd., Paisley, Scotland. All restriction enzymes and buffers 
T4 DNA ligase and buffer
Boehringer Mannheim UK Ltd., Lewes, 
East Sussex, England.
DNA molecular weight marker (VI)
J. Burrough (FAD) LTD., Witham, Essex, 
England.
Ethanol
Central Services, Beatson Institute. Sterile distilled water, PBS, L-Broth, PE 
buffer (PBS.EDTA buffer)
Difco Labs., Detroit, Michigan, USA. Bacto-agar and Bacto-tryptone
Gateway Pic., Glasgow, Scotland. Marvel dried non-fat milk powder
Moravek Biochemicals, USA 6-[3H] cytosine. 0.14mCi/mmol
NEN DuPont, Stevenage, Hertfordshire, 
England.
5-[125I] Iodo-2’-deoxycytidine. 2200 
Ci/mmol.
Oxoid Ltd., Basingstoke, England. PBS tablets
Pharmacia Biotech Ltd., Milton Keynes, 
England.
Micro spin columns s-400 HR
Syntex Pharmaceuticals, Maidenhead, Ganciclovir, Sodium Salt
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Berkshire, England.
2.1.2. Kits
Supplier Kit
Amersham International Pic., Aylesbury, 
Bucks, England.
ECL Western Blotting analysis system
Boehringer Mannheim UK Ltd., Lewes, 
East Sussex, England.
Cell death detection kit
frivitrogen, De Schelp 12, Netherlands. TA cloning kit
Nucleon, Coatbridge, Scotland, UK. Mini plasmid preparation kit
Pharmacia Ltd., Milton Keynes, England. Oligo-labelling kit
Promega, Southampton, England. Non Radioactive Cell Proliferation kit
Qiagen, Crawley, West Sussex, England. Maxi plasmid preparation kit 
Qia-quick Gel Purification kit 
PCR Purification kit
Stratagene, Cambridge, England. pCR-Script kit
[
2.1.3. Waterf
j  Distilled water for solutions was obtained from a Millipore MilliRO 15 system, and for
l
i
I nucleic acid procedures it was further purified on a Millipore MilliQ system.
[ 2.1.4. Equipment and Plasticware
| Main pieces of equipment are referred to in the appropriate sections. The suppliers of
the most commonly used items are listed below.
Supplier Equipment
Becton Dickinson Labware, Plymouth, 
Devon, England.
Tissue culture plates (60 and 90mm)
Bibby Sterilin Ltd., Stoney, Staffs., Bacteriological dishes (90mm)
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England.
Chance Propper Ltd., Warley, England. 22 x 50mm coverslips
Clarke Electromedical Instruments, 
Reading, England.
Kwik-fill thin wall glass capillaries
Costar, Cambridge, Massachusetts, USA. 6 and 96 well plates. 
Disposable cell scrapers 
Multichannel pipette
Eastman Kodak Co., Rochester, New York, 
USA.
X-ray film (XAR-5)
Gibco Europe, Life technologies, Paisley, 
Scotland.
Nunc 1 ml cryotubes.
Nunc 0.02pm tissue culture filter inserts 
2 well glass chamber slides
Griener Labortechnik Ltd., Dursley, 
England.
Eppendorf tubes
Pipette tips (200 and 1000 pi)
Varian Ltd., California, USA Bond elute SCX 1ml columns
Whatman International Ltd., Maidstone, 
England.
DE81 ion exchange paper
i  2.1.5. Plasmids and bacterial host.
! Competent E.coli DH5a cells were obtained from BRL Gibco Ltd., Paisley, Scotland.
|
I Below are details of the plasmids used in this thesis and where they were obtained from.
Plasmid Resistance
marker
Origin
pCDNA 3.1+ Neomycin Purchased from Invitrogen, De Schelp 12, 
Netherlands.
pCDNA 3.1' Neomycin Purchased from Invitrogen.
pCEP4 Hygromycin Purchased from Invitrogen.
pCDNA 1-TP (Thymidine 
Phosphorylase)
Neomycin A gift from Dr. Adam Patterson, MRC 
radiation unit, Oxford, England.
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pL8 -TP (Thymidine 
Phosphorylase)
A gift from Dr. Carl Heldin, Sweden.
pGK-TK (Thymidine 
Kinase)
Neomycin A gift from Prof. Alan Balmain, Beatson 
Institute.
pCD2 (Cytosine 
Deaminase)
Neomycin A gift from Dr. Craig Mullen, Houston, 
Texas, USA.
pSVL-p gal (p- 
galactosidase marker)
A gift from Iain Foulkes, Beatson Institute 
(cotransfected with pBAG - Neo resistance)
pRc/CMV Cx43 Antisense Neomycin A gift from Dr. Alan Lau, Hawaii, USA.
2.1.6. Antiserum
For detection of Connexin 43 in Western Blot analysis the following antibodies were
used.
Primary antibody: mouse monoclonal anti-connexin 43 (Zymega Research, San
Francisco, CA 94080, USA.)
Secondary antibody: Sheep anti-mouse hp-linked whole antibody (Amersham 
International Pic., Bucks., England.)
2.1.7. Cell Culture Materials.
Supplier Material
Gibco Europe, Life technologies, Paisley, 
Scotland.
2.5% (w/v) trypsin 
Gentamycin 
Amphotericin B 
200mM Glutamine 
7.5% Sodium Bicarbonate 
lOOmM Sodium Pyruvate 
Hepes Buffer 
10 x DMEM 
1 x SLM
Northumbria Biologicals. Foetal Calf Serum
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Sigma Chemical Co., St Louis, USA. 4% (w/v) Trypan Blue
2.1.8. Cell Lines.
Cell Line Origin and Description
BHK21 Syrian Baby Hamster Kidney fibroblast line (Macpherson and Stroker, 
1962).
CarB Mouse spindle cell carcinoma. Established by Prof. Alan Balmain at the 
Beatson Institute.
CarB-E Mouse spindle cell carcinoma stably transfected with E-Cadherin by 
Brenda McGuire at the Beatson Institute.
B9 Mouse epithelial line. Established by Prof. Alan Balmain at the Beatson 
Institute.
L 929 Mouse fibroblast line (Sanford et al, 1948).
MCF-7 Human mammary epithelial tumour line (Rose and McGrath, 1975).
B95 p53 negative fibroblast line established by Prof. Alan Balmain at the 
Beatson Institute (From p53 knockout mouse).
2.1.9. Tissue Culture Media.
Media Components
DMEM Dulbecco’s Modified Eagles Media supplemented with 10% FCS and 
2mM L-glutamine
SLM Special Liquid Media supplemented with 10% FCS and 2mM 
L-glutamine
RPMI RPMI Media supplemented with 10% FCS and 2 mM L-glutamine
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2.2. Methods.
2.2.1. Cell Maintenance
The medium requirements of the cell lines (and clones) used throughout this are listed 
in section 2.2.3. Antibiotics and antifungal agents were not used unless otherwise stated in the 
text or figure legends.
All cell lines were grown in 90mm tissue culture plates in a 5% CO2 atmosphere at 
37°C. Cells were routinely subcultured every 2 to 4 days, unless otherwise stated. All cell 
culture was carried out in a category LI laminar-flow-hood. All cell lines were tested for 
mycoplasma on a routine basis, and were always negative.
2.2.2. Determination of viable cell numbers
Viability of cultured cells was determined by the trypan blue dye exclusion assay. 
Following trypsinisation, 50pi of cell suspension was mixed with an equal volume of 0.05% 
(w/v) trypan blue. Viable cells can be counted using a Neubauer haemocytometer on the basis 
that non viable cells lose membrane integrity and the blue dye enters them. Cell number per ml 
of suspension was determined by multiplying number of live cells from 2 x 16 square grids, by
104.
2.2.3. Transfection of cell lines
The most commonly used technique for introducing foreign DNA into cells in this 
thesis was by the calcium phosphate method, and is described below. It should be noted that 
for transfection by chemical means DNA was prepared using Qiagen Maxi plasmid preparation 
kit, section 2.5.3.
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Cells were plated at a density of 1 x 105 to 1 x 107 cells in a 90mm petri dish, 
depending on cell growth rate, and allowed to grow for 16 hr at 37°C in an atmosphere of 5% 
CO2 . Following this time, fresh full media was added to the plates.
To prepare the DNA precipitate, 20pg of appropriate plasmid DNA was mixed with 
62.5pl of 2M calcium chloride solution and sterile water added to a total volume of 500pl in 
an eppendorf tube. To a second eppendorf 500|ul of 2 x HBS (38mM Hepes, 274mM NaCl, 
74mM KC1, 1.6mM Na2HP0 4 -H2 0 , llmM glucose, pH 7.05; filter sterilised) was added. The 
DNA containing solution was then added dropwise to the 2 x HBS, whilst bubbling air 
through the HBS. This enhances the formation of a fine precipitate. The precipitate was then 
allowed to form for 30 min. at room temperature.
The precipitate was resuspended and added directly to the medium of the monolayer. 
Cells were incubated for 5 hr at 37°C in an atmosphere of 5% CO2 .
After this time cells were washed with PBS, and then a solution of 15% glycerol in 
HBS was added and cells were left at room temperature for exactly 2 min. This enhances the 
uptake of the calcium phosphate-DNA precipitate. The cells were washed twice more with 
PBS, then full medium added and the cells left to grow for 24 to 48 hr.
For selection of stably transfected cells, the cultures were trypsinised and 5 to 10% of 
the cell suspension transferred to each of 10 petri dishes containing 10ml of appropriate 
selection media, as described in table 2.1.
Colonies were allowed to form over a period of 1 to 4 weeks, depending on cell 
growth rate, and selection media replaced every 3 to 4 days. After this time resistant colonies 
were ring cloned (see below).
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Cell Line Medium for 
w.t. cells
Transfected gene (plasmid) and drug selection.
CarB SLM tk (pGK-tk) or E-Cadherin* or Cx43 antisense (pRc/CMV- 
Cx43 AS) or (3-gal (pSVL-gal). Selection, 400pg/ml G418. 
E-Cadherin*, then tk (pCEP4-tk), separate transfections. 
Dual selection, 400pg/ml G418 and 300pg/ml hygromycin, 
respectively.
tk (pGK-tk), then tp*, separate transfections. Dual 
selection, 400pg/ml G418 and 1.5pg/ml puromycin, 
respectively.
L929 SLM tk (pGK-tk) or cd (pcDNA3.1'-cd) or tp (pcDNA 1-tp) or 
(3-gal (pSVL-gal). Selection, 800pg/ml G418.
BHK DMEM tk (pGK-tk) or cd (pcDNA3.1'-cd) or cdtk fusion 
(pcDNA3.1’-cdtk). Selection, 800pg/ml G418.
Cx43 antisense (pRc/CMV-Cx43 AS) or (3-gal (pSVL-gal). 
Selection, 800pg/ml G418.
tk (pGK-tk), thentp (pCEP4-tp) separate transfections. 
Dual selection, 800pg/ml G418 and 150pg/ml hygromycin, 
respectively.
B9 SLM tk (pGK-tk). Selection, 400pg/ml G418.
MCF-7 RPMI tk (pGK-tk). Selection, 300pg/ml G418.
B95 (p53‘) SLM tk (pCEP4-tk). Selection, 50pg/ml Hygromycin.
Table 2.1. Transfecion of cell lines. E-cadherin was transfected prior to this thesis (Holden et 
al, 1997). tp was introduced to CarB tk+ transfected cells by retroviral transduction, by Adam 
Patterson, MRC radiation unit, Oxford.
2.2.4. Ring cloning of resistant colonies
The position of colonies resistant to drug selection was marked on the bottom of tissue 
culture plates. Media was aspirated and the cells washed with PBS. Autoclaved metal cloning 
rings (Gibco BRL) were dipped into sterile vacuum grease and placed over the marked 
colonies. Approximately lOOpl of trypsin was added to each ring until cells had detached and 
the cells were transferred to 1 ml of selection media in a 24 well plate.
Once cells were at least 20% confluent they were washed in PBS and released with 
trypsin. Equal numbers of cells were transferred to two wells of a 24 well plate. Cells in one 
well were allowed to grow in normal media while cells in the second well were tested for 
expression of the transfected gene. To test for expression of the suicide gene (tk+, tp+ or cd+) 
cells were incubated for 5 days with the corresponding prodrugs, GCV (5pM), DFUR (2pM) 
or 5FC (lOOOpM), respectively.
To test for expression of the (3-gal lineage marker, cells were examined for the ability 
to convert the chromagenic substrate x-gal to a blue product, section 2.2.13.
Clones expressing Cx43 AS were analysed by Western Blot analysis, section 2.4.2.
2.2.5. Population doubling time
105-107 cells were plated in 35 mm dishes and allowed to settle for 8 hr. After this 
time, and every 24 hr for 2 days, number of live cells was determined as described above. 
From growth curves, population doubling times were determined.
2.2.6. Frozen cell stocks
Aliquots of wild type and transfected cell lines were maintained in liquid nitrogen for 
long term storage. To freeze cells, 106-107 cells were washed in PBS, trypsinised and 10 ml of
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media added (to inhibit the trypsin). Cells were pelleted by centrifugation at 1000 rpm for 5 
min.. The pellet was resupended in 1 ml appropriate media supplemented with 10% 
Dimethylsulphoxide (DMSO). The suspension was transferred to a 1ml Nunc cryotube, 
wrapped in cotton wool and stored at -70°C overnight, to facilitate a slow cooling process. 
The following day vials were transferred to liquid nitrogen vats. .i
|
[
2.2.7. Determination of cell survival
|
| Transfer of toxicity in enzyme prodrug systems may require cell to cell contact.
| Therefore, cells were seeded to achieve approximately 25% confluence at the time of prodrug
t
■ treatment. At a later time in the assay, when cells were confluent, transfer to 96 well plates 
was performed to enable further cell growth and then cell survival to be assessed.
|
Monolayers of tissue culture cells were trypsinised and viable cells counted using the 
1 trypan blue dye exclusion method (section 2.2.2.). Mixed cultures of cells, (0.5 to 2.5 x 105
i
i
viable cells) with and without suicide gene, were seeded, in triplicate, in 1 ml total volume and
[
| allowed to settle overnight (see text and figure legends for details). After this time most cells
[
I were in contact with the surrounding cells.
i
1 Prodrug was dissolved in PBS to provide a stock solution. At time of use, this was\
\
i
j diluted so that 12.5pl could be added to each well to provide the correct concentration (see
j
i figures). Controls were treated with PBS. Cells were then allowed to grow for a further 48 hr.I
I Transfer of cells to 96 well plates was used to prevent over growth of cells which
| would lead to cell death in controls and distort results. This cell transfer was termed ‘standard
;
protocol’ and is described below. It is important to stress that in all assays prodrug
i
I concentration was the same before and after cell transfer. The exceptions were medium 
transfer and filter separation experiments (section 2.2.9.) where the medium in 96 well plates 
did not contain prodrug.
Using a multichannel pipette (costar, 8 channel) 120 pi of media were placed in each 
well of a 96 well plate and diluted prodrug added at the required concentrations (where 
required). Cultures from the 24 well plates were washed in PBS and trypsinised with 5% 
trypsin in P.E. and lOpl of the cell suspension was transferred from each well of the 24 well 
plate to four corresponding wells of a 96 well plate, so that prodrug concentration throughout 
each individual experiment was constant. Cells were allowed to grow for a further 72 hr.
At this time cell survival was quantitated using the cell proliferation assay (see below).
2.2.7.I. Cell proliferation assay
Cell proliferation was measured by using the Promega Cell Titre 96™ Non-Radioactive 
Cell Proliferation Assay. This is an indirect method for determining cell number achieving 
comparable results to 3H thymidine incorporation. The assay is based on cellular conversion of 
a tetrazolium salt (MTT) into a coloured formazan product which can be detected 
spectrophometrically by an ELISA plate reader. The protocol below is based on that described 
by Promega.
To assay cell survival 14pl of the dye solution (MTT based) was added to each well of 
a 96 well plate and colour developed by incubating plates at 37°C for 1 to 4 hr. Time of 
incubation depended on cell density and the metabolic activity of a particular cell line to 
convert MTT to formazan product.
The reaction was terminated by the addition of lOOpl of stop solution per well and 
formazan crystals were solubilised by incubation at 37°C overnight.
Absorbance was determined spectrophotometrically at dual wavelengths of 590nm and 
630nm using an ELISA plate reader (Dynatech) with shaking facility. By using dual
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wavelengths greater accuracy is achieved as interference through plate damage, such as 
scratching, is reduced.
Survival was calculated by comparing absorbance of treated versus untreated cultures.
2.2.8. GJIC in tp / DFUR bystander effects
\ Cultures were seeded at high or low density were used to assess whether the presence
of gap junctions enhances the bystander effects in the tp system.
| Mixed cultures of tp+ with tp' cells were seeded at 5-15 x 104 cells / ml for high density
E
| and 1-3 x 103 cells / ml for low density experiments. Cells were allowed to settle overnight.
I
| Application of prodrug, transfer to 96 well plates and determination of cell survival were
i
! performed as described previously (standard protocol, section 2.2.7.).
i
ts
i
[
I 2.2.9. Role of medium mediated toxicity in bystander effects
[
The mechanism of transfer of toxic metabolites from cells transfected with suicideI
|
! genes (gene+) to those with out the gene (gene') was investigated by medium transfer and filter
F
f
I separation experiments.
|
| For medium transfer, gene+ cells were seeded at 5-10 x 104/ml and gene' cells were
ii
3seeded at 5-10 x 10 /ml in 24 well plates. Cells were allowed to settle for 24 hr.
[ The appropriate concentration of prodrug (see text and figure legends for details) was
I added to gene+ cells and incubated at 37°C for 48 hr.
iF
| After this time, media from the gene' cells was replaced with the drug treated media
j from the gene+ cells. Cells lacking the gene were then incubated for a further 48 hr.
[
! Cells were then transferred to 96 well plates (section 2.2.7.) and survival assayed
(section 2.2.7.1.).
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Two negative controls were also included. Media with prodrug only (no gene+ cells) 
was incubated for 48 hr prior to transfer to gene' cells. In the second control, gene+ cells were 
incubated with media (no prodrug) before transfer.
For filter experiments, 5-15 x 104 gene' cells were seeded in 24 well plates in 0.5ml 
(see text and figure legends for details). Using sterile forceps, 0,02pm filter inserts were then 
placed into the wells containing the gene' cells and 5-15 x 104 gene+ cells (in 0.5 ml) were 
seeded in the insert. The appropriate concentration of prodrug was added immediately and 
cells were incubated at 37°C for 3 days. After this time, gene' cells were transferred to 96 well 
plates (section 2.2.7.) and survival assayed (section 2.2.7.1.).
2.2.10. Time course of the tk / GCV bystander effect
The effect of short periods of GCV application on colony formation was used to 
determine the earliest time at which toxicity is transferred from tk+ to tk' cells.
5-20 x 105 tk+ cells alone or a mixture of tk+ and tk' cells (1:1) were seeded in 35 mm 
dishes and allowed to settle for 4 hr.
20 pM GCV was applied to the media of the cultures and incubated at 37°C for various 
periods of time.
Cells were washed with PBS, trypsinised and an aliquot of the cell suspension was 
transferred to a 100mm dish containing full media without prodrug. Cells were incubated until 
visible colonies had formed and at this time colonies were stained with Giemsa stain, as 
described in section 2.2.14. Survival of the drug treated cultures was compared to untreated 
cultures.
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2.2.11. Effective range of the tk / GCV bystander effect
A colony based assay was used to determine the approximate number of tk' cell
diameters the tk / GCV bystander effect can pass through. In this experiment tk' colonies were
identified using the p-galactosidase lineage marker.
\\
1 25 tk* p-gal+ cells were plated in each of four 35 mm dishes. Three sets of four plates
were seeded for each size of tk' p-gal+ colony that was investigated.
Once desired colony size was attained, 1-3 x 105 tk+ p-gal* cells were added to two
plates of each set and allowed to settle for 24 hr (see table below).
At this time 1 set of plates was fixed and stained with x-gal (section 2.2.13.) to keep a
| record of initial colony size.
20pM GCV was applied to two wells in each set, one well containing only tk' p~gal+
i and the other containing tk' p-gal+ and tk+ P-gal' (see table below). Cells were incubated for 2
! days at 37°C. A second set of plates were fixed and stained with x-gal for final colony size.
| The cells in the final set of plates were trypsinised and aliquots from each plate in the
I
| set used to assess the ability of the cells to form colonies.
Ii
ii
Plate
Number
Purpose Cell types in dish 2 days 20p,M GCV 
treatment (sets 2 & 3)
1 Control tk' p-gal+ No
2 Control tk' P-gal+ Yes
3 Control tk' p-gal+ and tk+ P-gal' No
4 Test tk' p-gal+ and tk+ P-gal* Yes
50
2.2.12. Measurement of gap junctional intercellular communication by dye transfer
The level of homologous communication was measured in wild type and transfected
cells so that the effect of increasing levels of GJIC on the tk / GCV bystander effect could be
determined, and to ensure that transfection of suicide genes did not affect communication.
Measurement of GJIC involved micro-injecting cells with Lucifer Yellow CH tracer dye, based
on the method described by Pitts and Kam (1985).
To prepare for the assay, cells were grown until 80% confluent in 60 mm Falcon tissue
culture plates. In addition, micro electrodes were made from 1.0mm OD “Kwik-filT thin-wall
| glass capillaries and back-filled with a 4% aqueous solution of Lucifer Yellow CH.
Ii
| Immediately before dye injection, media was replaced with fresh media buffered with
j 25mM Hepes (in place of sodium bicarbonate). Cells were transferred to the heated (37°C)
I stage of a Leitz Diavert inverted microscope and an individual cell, with apparently normal
morphology, was selected and iontophoretically injected with dye using the micro electrodes
prepared previously. Injections were performed for 2 min. using a current of lOnA in 0.5
second pulses at 1 Hz and the process monitored with UV (epi-illumination) or visible (phase
contrast) light sources. The extent of dye spread to neighbouring cells was recorded
| immediately and every fifth inj ection photographed.
i
|
iI
1
I 2.2.13. p-galactosidase staining
Cells expressing the p-galactosidase lineage marker can be identified through a
i colorimetric assay utilising 5-Bromo-4-Chloro-3-Indyol p-D-Galactopyranoside (x-gal).
Monolayers of cells were washed once in PBS and fixing solution added (2%
formaldehyde, 0.2% glutaraldehyde in PBS) for 30 min.. Following this time, the cultures were
washed again with PBS and incubated with staining solution for 8 hr. Staining solution was
prepared by combining the following volumes of stock solutions:-
250pl of x-gal (40mg / ml) in DMSO 
lOOpl of 0.5M Potassium Ferricyanide (KsFetCNg]) 
lOOp.1 of 0.5M Potassium Ferrocyanide (K4Fe [CN6]-H20  
20p,l of 1M MgCl2.H20.
After this time the cultures were washed three times in water, inverted and allowed to air dry.
2.2.14. Glemsa staining
Giemsa is a purple stain that binds to cytosolic proteins and can be used for the 
visualisation of cultured cells.
Cells were washed once with PBS and fixed in methanol for 30 min. at room 
temperature. Plates were washed with water and 10 ml of Giemsa stain (1 in 10 dilution with 
water) was added and incubated at room temperature for 10-20 min.. Stained cells were 
washed three times in water, inverted and allowed to air dry.
2.3. In vivo analysis of enzyme / prodrug systems
To further investigate bystander effects, a nude mouse model was used. Tumours were 
induced using tumorigenic cell lines that had previously been investigated in culture systems.
Pilot studies using small numbers of animals were set up initially to determine rate of 
tumour formation in animals, and to ensure that unnecessary distress was not caused to the 
animals by tumour burden and prodrug treatment. These studies enabled the following regime 
to be employed.
Monolayers of gene+ and gene' cells were trypsinised and cell viability determined by 
trypan blue dye exclusion. The required number of cells were pelleted, in full medium, by 
centrifugation at 1000 rpm for 5 min., and the pellet resuspended in serum free medium to give
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a cell suspension containing 106 cells / ml gene + and gene' cell suspensions were mixed at 
specific ratios (see figures legends and text).
Tumours were generated by injecting lOOpl of cell suspension, subcutaneously, into 
each flank of nude mice with a 1ml syringe.
Tumours were allowed to form for approximately 4 (CarB) or 10 (BHK and L929)
j
| days at which time intraperitoneal administration of prodrug was initiated and continued for 7 
or 14 days (see text and figure legends). Solutions of prodrug were prepared and injected as 
follows:-
f
i - GCV : Stock solution llm g / ml PBS. 4p,l / gram body weight injected (=45mg / kg).
|
| - FC : Stock solution 12.5mg / ml PBS. 20pl / gram body weight injected (=250mg / kg).
i\\
! During the period of treatment, weight of the animals monitored to calculate
I appropriate drug administration and to ensure the animals remained healthy. Tumours were
I
i  measured in two dimensions during and after treatment.
Animals were removed from the study when the tumour burden exceeded 500mm3 or if
1
| animals became sick or if the experiment continued for greater than 6 months.
t
[ Animals were terminated by placing them in an environment containing high levels of
I CO2 , (schedule 1 procedure) and tumours removed. Samples were initially prepared for
I
j histological or enzymic analysis by snap freezing. Alternatively, tissue was digested (10% 
trypsin, in P.E. for 1 hr, agitating) and released cells grown under tissue culture conditions for 
subsequent analysis. Growth medium contained the fungicide, amphotericin B, and antibiotic,
! gentamycin, for 7 days following tumour removal from mice.
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2.4.1. Protein calibration
For Western blot and tk enzyme activity analysis quantitation of protein levels was 
required. This was performed using the Pierce Micro BCA Protein Assay Reagent kit. The 
protocol is outlined below:-
For lOmls of working solution 4.8ml and 0.2ml of solutions MB and MC are mixed, 
then 5mls of solution MA is added and mixed.
2 pi of sample was diluted into 1ml water, before adding 1ml of working solution. In 
the same way, standards containing 0, 5, 10, 15 or 20pg/ml BSA were prepared. Tubes were 
mixed prior to incubation for 60 min. at 60°C.
After this time, samples were then cooled to room temperature and absorbance of 
standards and samples analysed spectrophotometrically at 562nm.
A curve of the standards was plotted and protein concentration of the samples 
determined.
2.4.2. Western Blot analysis
Western Blot analysis was used to examine alterations in the level of connexin 43 
(Cx43) expression in wild type and transfected (stable transfection expressing Cx43 AS) cell 
lines. Clones that were down regulated in gap junctional intercellular communication could be 
used to further investigate the tk / GCV bystander effect.
Cell lysates were prepared from 80% confluent monolayers in 35mm tissue culture 
plates. Monolayers were washed with PBS and 300pl of cell lysis buffer added (150mM NaCl, 
20mM tris, 20mM sodium pyrophosphate, lOpM NaV04, 2mM PMSF, 0.001% aprotinin, 1% 
NP40; pH 6.8). Samples were collected with a cell scraper and transferred to an eppendorf
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tube, prior to sonication for 30 seconds. Protein levels were calibrated, using the Pierce BCA 
kit, (as described in section 2.4.1.) and stored on ice until use.
! Proteins were resolved, according to their molecular weight, using sodium dodecyl
iI
| sulphate polyacrilamide gel electrophoresis (SDS-PAGE). The components required are
| described im Table 2.2.
[
I To prepare the gel, two 16 x 16 cm glass plates were clamped together and sealed with
!
| a 0.75 mm rubber gasket. The resolving gel mix was carefully poured between the plates, in an
i
I effort to minimise air bubble formation. The mixture was overlaid with water-saturated
i
[ isopropanol and allowed to polymerise at room temperature (exposure to air inhibits the
| reaction). Once the gel had set, isopropanol was removed by capillary action using Whatman
|
3MM paper and replaced with stacking gel mix. A gel comb was added and the solution
I
I allowed to polymerise at room temperature. At this time the gel apparatus was transferred to
| an electrophoresis tank and the reservoirs filled with 1 x electrophoresis buffer (50mM Tris,
50mM glycine, 0.5% SDS). The comb was removed and the wells washed out with buffer to 
| remove unpolymerised stacking gel.
If
I 40pg of protein lysate was added to an equal volume of 2 x loading buffer (5% SDS,
i
i
I 10% glycerol, 80mM Tris, 4% 2-mercaptoethanol, 0.2% bromophenol blue; pH 6.8). Samples
II
| were boiled for 1 min., prior to loading and then resolved at a constant current of 30mA / gel
i
i
\ for 2 hr.i|
j In preparation for semi-dry blotting of proteins to nitrocellulose, six sheets of
i
[
Whatman 3MM filter paper and one sheet of nitrocellulose ECL-hybond membrane were cut 
| to match the dimensions of the gel, and prewet in transfer buffer (0.5M tris, 40mM glycine,
0.04% SDS, 20% methanol).
Once electrophoresis was completed, the gel apparatus was dismantled, the gel 
trimmed and transferred onto the nitrocellulose filter, cutting one comer for orientation.
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10% Resolving gel 30% Acrylamide / 0.8% Bisacrylamide 
10% sodium dodecyl sulphate 
1.5 M Tris-HCl pH 8.8 
water
10% Ammonium persulphate (freshly made) 
TEMED
8 ml 
0.23 ml 
5.8 ml 
10 ml 
0.2 ml 
10 pi
5% Stacking gel 30% Acrylamide / 0.8% Bisacrylamide 
10% sodium dodecyl sulphate 
1M Tris-HCl pH 6.8 
water
10% Ammonium persulphate (APS) 
TEMED
1 ml 
0.11ml
1.4 ml
3.5 ml 
50 pi
2.5 pi
Table 2.2. Separation of proteins using SDS-page
Three sheets of prewet 3MM paper were placed on the lower graphite plate of a semi­
dry electroblotter. The gel and membrane were positioned, with gel upper most, on the filters, 
and three more sheets of prewet 3MM filter paper were added. The upper graphite plate was 
I replaced and electroblotting performed at a current of 200mA for 1 hr.
| On completion of transfer, the nitrocellulose membrane was shaken in blocking
| solution (4% Marvel in PBS) for 3 hr at room temperature.
i
| Primary antibody to connexin 43 (Zymega laboratories) was diluted 1:1000 in blocking
Ii
I solution and applied to the membrane and shaken gently for 3 hr at room temperature.
f
| The membrane was washed 4 times (1,15,10 and 5 min. / wash) in blocking solution.
s
| Secondary antibody was diluted 1:1000 in blocking solution and placed on the
|
membrane for 1 hr at room temperature. This was followed by 3 washes in blocking solution 
I ( l x l  min. and 2 x 45 min.), one 5 min. wash in TBS-Tween (25mM tris, 150mM NaCl,
| 0.05% Tween-20; pH 7.5), and by two twenty min. washes in blocking solution.
To determine the position of antibody binding and hence connexin 43, an Amersham 
Enhanced chemilluminescence (ECL) kit was used, in accordance with the manufacturers 
instructions. Equal volumes of solutions 1 and 2 were mixed in a universal container and
I
I applied to the nitrocellulose membrane, with gentle agitation, for 1 min. After this time the
| excess solution was discarded and the membrane wrapped in saran-wrap, before exposure to
f
i
| Kodak XAR-5 autoradiographic film for 60 min.
|
Ii
2.4.3. tk enzyme assayi!\
| To prepare lysates for the enzyme assay, a subconfluent plate of cells were trypsinised
| and pelleted by centrifugation (lOOOrpm / 5min). The cells were washed by resuspending in
PBS, then collected by centrifugation as before. This was repeated once. The assay is based on 
that described by Brinster et al, (1981). The pellet was then resuspended in 400pl
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homogenisation buffer (lOmM KC1, 2mM MgCl2, lOmM Tris-HCl, ImM ATP, lOmM NaF,
50mM e-amino caproic acid, pH 7.4) and subjected to 3 rounds of freeze / thaw (liquid 
nitrogen / 37°C) treatment. Cell debris was removed by centrifugation (14000 rpm / 15 min. / 
4°C) and protein levels of lysates determined (section 2.4.1.). 2pg protein was added to 28pl 
reaction buffer (lOmM MgCl2, 25mM NaF, lOmM p-mercaptoethanol, 56pM
tetrahydrouridine, 150mM Tris-HCl, lOmM ATP, 2pl (lpCi) of Iododeoxycytidine, pH 
7.5) and reactions were incubated for 90 min. at 37°C.
At this time, samples were spotted to DE81 Whatman ion exchange filters and air
dried.
To remove unincorporated 125j Iododeoxycytidine the filters were washed (20 min.
per wash) as follows:-
4 times in 3mM ammonium formate 
Once in water 
Once in methanol.
Filters were air dried, placed in scintillation fluid and radioactivity was measured in a Beckman 
LS5000CE scintillation counter. Picomoles of iododeoxycytidine phosphorylated per hr was 
calculated, and specific activity per mg protein determined.
2.4.4. cd enzyme assay
Cells were trypsinised and washed by the same process as described in section 2.4.3. 
The assay was based on that described by Kanai et al, (1997). The pellet was resuspended in 
400pi of reaction buffer (lOOmM Tris-HCl, ImM EDTA, pH7.8) and cells were lysed by 3 
rounds of freeze / thaw (liquid nitrogen / 37°C) treatment. Cell debris was removed by 
centrifugation (14000 rpm / 15 min. / 4°C) and protein levels of lysates determined (section
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2.4.1.). 10(j,g protein was diluted in a total of 15pl reaction buffer (containing 2\i\ of 
0.14mCi/mmol) and reactions were incubated for 5 min. at 37°C. At this time the reaction was 
terminated by the addition of 345^il 1M acetic acid.
lml SCX bond elute columns were pre-equilibrated with 500pl 1M acetic acid by 
centrifugation (2000rpm / 2min). Reaction samples were loaded to column and centrifuged 
(2000rpm / 2min). The 3H uracil produced was eluted with 1 ml lm acetic acid and 
radioactivity was measured in a Beckman LS5000CE scintillation counter. Picomoles of 
cytosine converted to uracil per min. was calculated, and specific activity per mg protein 
determined.
2.5. Nucleic Acid Techniques
2.5.1. Bacterial Transformation
The competent bacterial strain DH5a was purchased from Gibco BRL in 200pl 
volumes. Cells were allowed to thaw on ice, aliquoted in 30 p,l volumes and frozen rapidly on 
dry ice until further use.
For transformation 30pl of competent cells were thawed on ice and between 1 and 
50ng of DNA added and cells incubated on ice for 30 min.
The cells were then heat shocked for exactly 45 seconds and incubated on ice for 2 
min. 170|a1 of SOC medium (2% bacto-tryptone, 0.5% bacto-yeast extract, 9mM NaCl, 
2,5mM KC1, lOmM MgCk, 20mM glucose) was added and cells shaken at 225rpm at 37°C for 
1 hr to promote expression of the ampicillin resistance marker.
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[After this time transformed cells were spread onto agar plates (1.5% in L-Broth) 
supplemented with ampicillin (50mg/ml) and incubated up-side-down at 37°C overnight to 
allow colony formation.
Sterile yellow pipette tips were used to transfer colonies into plastic universals 
containing 4ml L-Broth supplemented with 50mg/ml ampicillin and the culture expanded by 
shaking (225 rpm) for 6 hr at 37°C. After this time mini or maxi plasmid preps protocols were 
followed.
j
| 2.5.2. Mini plasmid preparations
; Depending on the quality and quantity of mini prep DNA required, one of two
i
I procedures was followed. The first yields crude plasmid DNA which can be used for
I
i  restriction mapping only and is based on the Qiagen maxi prep kit, while the second produces
i
| a larger quantity of high quality plasmid DNA, requiring the Nucleon mini prep kit.!
: For both preparations, 1.5ml of bacterial culture was pelleted by centrifugation at
ii
| 14000rpm for 30 seconds. The supernatant was discarded and samples were vortexed after the
i
addition of each of the buffers 1, 2 and 3 (supplied with kits) from corresponding Qiagen 
(300pl of each buffer) or Nucleon kits (150pl each buffer). Cell debris was pellet by 
centrifugation at 14000rpm for 5 min. The remainder of each protocol is described below.
i
i  For crude plasmid DNA (Qiagen):
I
I
| Supernatant was transferred to a fresh tube containing 700pl propan-2-ol and DNA
was precipitated by vortexing, then pelleted by centrifugation at 14000rpm for 10 min. The 
pellet was washed and dried as described in section 2.5.8.
Nucleon Mini-prep:
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Supernatant was transferred to spin column containing 200pl of DNA binding resin 
and centrifuged for 30 secs at 14000 rpm. The effluent was discarded and 500pl of lx  wash 
buffer added to the sample, before centrifugation for 2 min. at 14000rpm. The resin was 
allowed to dry for 5 min. at room temperature before eluting the plasmid DNA in 50p,l of 
elution buffer, by centrifugation for 1 min. at 14000rpm.
2.5.3. Maxi plasmid preparations (Qiagen kit)
The bacterial suspension prepared in section 2.5.1. was transferred to a flask 
containing 250 ml of L-Broth supplemented with 50pg / ml ampicillin and the culture 
expanded by shaking (225 rpm) over night at 37°C.
The bacteria were pelleted by centrifugation at 5000rpm for 10 min. in a Sorval 
centrifuge (JLA 10500 rotor) and the supernatant discarded.
The bacterial pellet was resuspended in 4 ml buffer PI (50mM tris, lOmM EDTA, 
100pg/ml RNAse, pH 8.0) and bacteria were lysed by the addition of 4 ml buffer P2 (0.2M 
NaOH, 1% SDS (w/v)). 4 ml buffer P3 (2.55M potassium acetate, pH 8.4) was added and the 
sample incubated at room temperature for 10 min. to precipitate protein. The sample was 
transferred to a Qiagen filter tip, and incubated at room temperature until precipitated matter 
had formed the upper layer of the sample. The soluble fraction was collected, in a beaker, by 
plunging the sample through the filter.
A Qiagen-500 tip was equilibrated with 5 ml of buffer QBT (750mM NaCl, 50mM 
MOPS, 15% ethanol, pH 7.0) and the soluble material from above applied to the tip. The 
sample was then washed twice with buffer QC (1M NaCl, 50mM MOPS, 15% ethanol, pH 
7.0) and eluted with 5 ml buffer QF (1.25 M NaCl, 50mM MOPS, 15% ethanol, pH 8.2).
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DNA was precipitated, by mixing vigorously with 0.7 volumes (3.5 ml) isopropanol, 
and pelleted by centrifugation at 10000 rpm at 4°C for 30 min. in a Beckman centrifuge (JA 
25.50). The pellet was washed with 70% ethanol, resuspended in 300pi water and the 
concentration of nucleic acid determined.
iI
i
2.5.4. Determination of nucleic acid concentration
The concentration of nucleic acids was determined spectrophotometrically. The 
spectrophotometer (Beckman) was calibrated using a water blank, then the absorbance of
ij
! samples diluted in water was measured at wavelengths of 260 and 280 nm in a quartz cuvette
f
I with a path length of 1 cm. For plasmid and genomic DNA an A260 of 1 was taken to
i|
I correspond to 50mg/ml and for primers an A260 of 1 was taken to correspond to 33mg/ml.
I 2.5.5. Polymerase Chain Reaction (PCR)
I
| PCR amplification of the cd and tk cDNAs was used for two purposes:-
i
1) Subcloning of the suicide genes into alternative expression vectors when appropriate 
restriction sites were not available.[
|
| 2) The addition of genetic material to the ends of the cDNAs. This included addition of Kozak
j
j  sequence (to enhance translation) and restriction sites (for the generation of cd-tk chimeras).
Amplification of the tk gene was performed using the proof reading DNA polymerase,
|
| pfu, while amplification of the cd gene was accomplished with a Boehringer Mannheim PCR
| kit comprising a Taq / Pwo DNA polymerase mix. Components of each reaction are described
in table 2.3.A., primer pairs in table 2.3.B., primer sequence table 2.3.D., and cycling 
conditions detailed in table 2.3.C. PCR amplification was performed using a Perkin Elmer 
(Cetus 480).
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Table 2.3.A. - PCR reaction components Volumes of components
Components of reaction tk / pfu reaction cd / Taq-Pwo 
reaction
Water 49 pi 30.25 pi
10 x Buffer 10 pi (pfu buffer)* 5 pi (Buffer 1) *
DMSO 10 pi -
50% Glycerol 10 pi -
2.5mM dNTPs (dCTP, dGTP, dTTP, dATP) 8 pi 7 pi
5’ Primer (20 pM) 5 pi 2.5 pi
3’ Primer (20 pM) 5 pi 2.5 pi
Template (lng / pi) 2 pi 1 pi
DNA Polymerase 1 pi 0.75 pi
Total Volume 100 pi 50 pi
* Buffer supplied with enzyme
Table 2.3.B. - Primer pairs
cDNA Primer pairs a Purpose PCR program5
tk tkl and tk2 Amplifies the tk gene 2
cd cdl and cd2 Adds Kozak sequence to cd gene 1
tk tk3 and tkcdl Adds Kozak sequence and Xbal site for tkcd 
chimera
3
cd tkcd2 and cd2 Adds Xbal site for tkcd chimera 1
cd cdl and cdtkl Adds Kozak sequence and Xbal site for cdtk 
chimera
1
tk cdtk2 and tk4 Adds Xbal site for cdtk chimera 2
a See Table 2.3.B. for details of primer sequences 
b See table 2.3.C. for details
Table 2.3.C. - Primers for PCR amplification
Primer Name Primer Sequence 5’-» 3*
tk 1 ATG GCT TCG TAC CCC GGC
tk 2 TCA GTT AGC CTC CCC CAT
tk 3 GAG GAG TCT AGA GCC ACC ATG GCT TCG TAC CCC
tk 4 GTG GTG TCT AGA TCA GTT AGC CTC CCC CAT
cd 1 GCC GCC ACC ATG TCG AAT AAC GCT TTA CAA
cd 2 TCA ACG TTT GTA ATC GAT GGC
tkcd 1 GTG GTG TCT AGA GTT AGC CTC CCC CAT
tkcd 2 GAG GAG TCT AGA ATG TCG AAT AAC GCT
cdtk 1 GTG GTG TCT AGA ACG TTT GTA ATC GAT GGC TTC
cdtk 2 GAG GAG TCT AGA ATG GCT TCG TAC CCC
!
Table 2.3.D. - Cycling conditions for PCR amplification
Program 1 Program 2 Program 3
94°C for 2min -1 cycle 94°C for 2min -1 cycle 94°C for 2min -1 cycle
94 °C for lOsec) 94 °C for 30sec) 94 °C for 30sec)
54 °C for 30sec) 10 cycles 37 °C for 30sec) 5 cycles 42 °C for lmin ) 2 cycles
68 °C for 45sec) 72 °C for 30sec) 72°Cfor45sec)
94 °C for lOsec) 94 °C for 30sec) 94 °C for 30sec)
54 °C for 30sec) 25 cycles 54 °C for 30sec) 30 cycles 54 °C for 45sec) 30 cycles
68 °C for 2min ) 72 °C for 30sec) 72°Cfor45sec)
68 °C for 7min -1 cycle 72 °C for 7min -1 cycle 72 °C for 7min - 1 cycle
Table 2.3.E. PCR ligation reactions
Components Stratagene cloning kit 
(pfu)
Invitrogen cloning kit 
(Taq / Pwo mix)
Water
10 x Ligation Buffer 
Cloning vector 
Fresh PCR product 
lOmM rATP 
Srf I enzyme (5 U/pl)
T4 DNA Ligase (4 U/pl)
3.5pl
lpl
pCR-Script lp l (lOng)
2pl
0.5(ti
lpl
lpl
4pl
lp l
pCR™ H vector 2pl (50ng) 
2pl
lp l
Ligation Time 1 hr at room temperature 4 hr at room temperature
Following amplification, an aliquot of the PCR product was visualised by gel 
electrophoresis (section 2.5.7.). tk PCR products (generated using pfu enzyme) were cloned 
with a Stratagene pCR-Script cloning kit, while cd PCR products (amplified with Taq / Pwo 
enzyme mix) were cloned using an Invitrogen TA cloning kit, in accordance with 
manufacturers instructions which are summarised below
• Following the ligation reaction, the plasmids were transformed into bacteria, asI
I described previously (section 2.5.1.).
2.5.6. Restriction Digest Analysis
i
| For the purposes of gene cloning and Southern blot analysis DNA was digested with
i
restriction enzymes.
iI
| Reactions were performed at 37°C for 1 hr using restriction enzyme diluted in
I
| appropriate 1 x React buffer (Gibco).
i
j 2.5.7. Agarose gel electrophoresis
ii
! For general DNA analysis a 1% agarose gel was used. To prepare the gel, lg  of
I
agarose was dissolved in 100ml 1 x TBE buffer (5 x TBE is 0.45M Tris, 0.45M boric acid,
I
j  10mM EDTA, pH8.0) by microwave heating until boiling. The mixture was allowed to cool to
i
t
j  approximately 50°C before pouring into the gel cast. The gel was allowed to set at 4°C, after
![
i  which the combs were removed and the gel was placed in a gel tank containing 1 x TBE with|
ethidium bromide to a concentration 0.25pg/ml.
DNA samples and molecular weight standards (marker VII: 350bp to 8500bp, 
Boehringer Mannheim) were mixed with loading buffer (V6 volume), loaded and resolved by 
electrophoresis at 100 volts for approximately 1 hr.
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Following this time the gel was illuminated on a 312nm transilluminator and the sizes 
of DNA fragments compared to the molecular weight standards. A photographic record of the 
gel was taken on an Appligene imager.
2.5.8. Ethanol Precipitation
In order concentrate or purify aqueous DNA samples, ethanol precipitation was used. 
The method is a modification of that described by Maniatis et al (1989).
Vio volume of 3M sodium acetate (pH5) and 2.5 volumes of absolute ethanol were 
added to the DNA solution. This was mixed well and stored on dry ice for 15 min. 
Precipitated DNA was pelleted by centrifugation at 15000rpm for 15 min.
At this time supernatant was removed and the pellet was washed in 70% ethanol. The 
pellet was collected by centrifugation (15000rpm for 5 min.), dried and resuspended in an 
appropriate volume of water.
2.5.9. DNA Sequencing
DNA sequencing was performed using the dye terminator method on the ABI373
automatic sequencer. 1 pg of plasmid DNA was mixed with 3.2 pmoles of appropriate primer
in a total volume of 12 pi in ABI PCR tubes. 8 pi of reaction premix (supplied) was added.
PCR was performed on samples as follows:-
Preheat to 96°C
96 °C x 15 seconds )
50 °C x 1 second ) 25 cycles
60 °C x 4 min. )
Soak4°C
On completion of the reaction, the DNA was ethanol precipitated (section 2.5.8.). Samples 
then processed by R. McFalane, using Long Ranger gel mix (ABI).
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2.5.10. Genomic DNA Isolation
Puregene genomic DNA isolation kit was used to isolate DNA. This protocol uses high 
salt concentration to precipitate DNA. Prior to DNA isolation, cultured cells were washed in 
PBS, trypsinised (10% in PE) and transferred to an eppendorf tube for centrifugation (3000 
rpm, 1 min.). Alternatively, tumour samples were ground to a powder, in liquid nitrogen, using 
a pestle and mortar.
To isolate genomic DNA 1ml of lysis solution was added and mixed by pipetting. 
Samples were incubated at r.t. for 60 min.
After this time, 4pl of RNAseA solution was added and samples incubated for 6 hr at
37 °C.
Samples were placed on ice for 10 min., before adding 200pl of ice cold protein 
precipitation solution. Precipitation was aided by vigorous vortexing (approx. 40 seconds) and 
then samples were chilled on ice for a further 15 min., prior to centrifugation (14000 rpm, 5 
min.).
Supernatant was transferred to a fresh tube containing 600pi of propan-2-ol and DNA 
precipitated by inversion. DNA was collected by centrifugation, (14000rpm, 30 seconds) 
washed in 70% ethanol and then repelleted (14000rpm, 10 min.).
After removing supernatant, samples were air dried, resuspended in 50-100pl DNA 
hydration solution (overnight at r.t.) and stored at 4°C until further use.
2.5.11. Southern Blot Analysis
Detection of the tk gene from tumours containing various proportions of tk transfected 
cells was performed by Southern blot analysis.
64
Genomic DNA was isolated by the Puregene DNA extraction method (section 2.5.10.) 
and DNA concentration determined spectrophotometrically (section 2.5.4.);
15p,g of genomic DNA was digested with Sstl and Smal restriction enzymes in a total 
volume of 30p,l, as described in section 2.5.6.
DNA was separated using 1% agarose gel electrophoresis at 100 volts for 3 hr in 1 x TBE 
buffer.
Following this time the gel was placed in depurination solution (25ml concentrated
HC1 in 975 dH20) and shaken gently for 15 min. at r.t. The gel was then transferred to alkali
transfer solution (0.4M NaOH) and shaken for a further 15 min. at r.t.
DNA was then transferred to a nylon membrane (Hybond N+) by overnight capillary 
blotting (described by Sambrook et al, 1989) using 0.4M NaOH.
DNA was UV cross linked to the filter using a UV Statalinker 1800 and the positions
of the molecular weight standards marked. Hybridisation was carried out as described in
section 2.5.11.2.
2.5.11.1. Radiolabelling of cDNA probes
For Southern blot analysis radiolabelled cDNA was produced using the random 
priming technique described in the Pharmacia Oligo-labelling kit, and is summarised below: -
To generate labelled tk probe, 25-50ng tk cDNA in a volume of 34pl of cfflfeO was 
denatured by boiling and then cooled rapidly on ice.
lOpl of reaction buffer (supplied) was added along with 5pl of a[32P]-dCTP (3000Ci 
/mmol) and lp l Klenow fragment. The reaction was incubated at 37°C for 30-60 min.
Following this time, unincorporated nucleotides were separated from probe by 
centrifugation at 3000rpm for 2 min. through a Sephadex resin column (Pharmacia). Due to
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the size of the unincorporated nucleotides, these remain in the column, while the larger 
labelled probe is collected in a clean eppendorf tube and used for hybridisation.
The probe was denatured by boiling for 2-3 min. and then cooled rapidly on ice until 
further use.
2.5.11.2. Southern Blots
Prehybridisation of the Hybond N+ membranes was carried out in Hybaid bottles at 
65°C for 4 hr in hybridisation buffer (20mM dextran sulphate, 4x SETS, lOx Denhardts, 0.1% 
SDS, lmg/ml type vi RNA from yeast).
Prehybridisation solution was replaced with hybridisation buffer (pre-hyb buffer with 
probe) containing the appropriate 32P-labelled cDNA probe, and hybridisation allowed at 65°C 
for 16 hr. After this time, non-specifically bound probe was removed from the filter by 
washing as follows
2 x SSC / 0.1% SDS 2 x 20 min. washes at 65°C
0.2 x SSC / 0.1% SDS 2 x 30 min. washes at 65°C
The filter was then wrapped in Saran wrap and exposed to Kodak XAR-5 film for 24 
hr at -70°C, with two intensifying screens. The film was processed through a Kodak processor.
2.6. Apoptosis Assays
For assays investigating the time course of apoptosis and changes in the cell cycle in 
GCV treated cultures, cells were seeded at density of 5-15 x 104 cells / ml. After settling 
overnight, cells were treated, at the appropriate time, with 20pM GCV for the specified period 
(see text and figure legends). In each assay, treated cells and controls were analysed at the 
same time.
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2.6.1. In situ cell death assay
An in situ cell death detection kit (supplied by Boehringer Mannheim, section 2.1.2.) 
was used to analyse the time course of cell death in tk transfected tissue culture cells treated 
with ganciclovir. The DNA of cells entering apoptosis or necrosis undergo strand cleavage. 
This kit utilises immunochemical detection of DNA strand breaks, allowing single cells 
undergoing cell death to be detected.
The procedure was based on the protocol supplied with the kit, and is described below.
Cells were seeded and treated with GCV as described above. Cell fixation was carried 
out in freshly prepared 4% paraformaldehyde in PBS (pH 7.4) for 30 min. at room 
temperature.
Following this time, cells were permeabilised in 0.2% Triton X-100 (in PBS) for 5 min. 
at room temperature, then rinsed twice in PBS. Fresh TUNEL reaction was made by mixing 
50pl enzyme solution and 450pl Label solution (supplied) and 50pl of this solution was 
applied to the cells. Samples were covered with coverslips, to prevent excessive evaporation, 
and incubated for 60 min. at 37°C in a humidified chamber.
After this time the fixed cells were washed 3 times in PBS, mounted in 50% glycerol/ 
PBS and viewed under UV or visible light sources using an Orthoplan fluorescent microscope 
(Leitz).
Positive and negative controls were also included in each experiment. For these, the 
above protocol was followed, with the following alterations. For the negative control, cells 
were incubated with Label solution rather than TUNEL reaction. The positive control was 
treated with 25 pi DNAse I (supplied) for 10 min. at room temperature before washing and 
applying the TUNEL solution.
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2.6.2. DNA Laddering
To determine if apoptosis was occurring in ganciclovir treated cultures, genomic DNA 
was isolated as described in section 2.5.10. DNA fragmentation was analysed using a modified 
version of the end labelling technique described by Quarrie et al (1996).
4pg of genomic DNA was incubated with 10pl MgC12, lp l Klenow fragment, and 
0.1 pi a [32P]dCTP for 10 min. at room temperature.
30pl of 17mM EDTA were added to stop the reaction and 1 pi of glycogen was added 
to enhance DNA precipitation. Ethanol precipitation was carried out as in section 2.5.8., 
however 1 volume of 7.5M ammonium acetate was used instead of sodium acetate.
Samples were resuspended in lOpl TE and incorporation of radioactivity into DNA 
was measured in a scintillation counter (Beckman).
Fragmented DNA was separated by agarose gel electrophoresis, using a 1.8% agarose 
gel (section 2.5.7.).
DNA was fixed in the gel by placing the gel in 7% TCA for 40minutes. After this time 
the bromophenol blue in the loading buffer turns yellow in colour.
The gel was then dried by capillary action, for 4 to 6 hr, by gentle compression 
between 3MM filters.
Once dry, the gel was then sealed in plastic and exposed to Kodak XAR5 
autoradiographic film for 2 to 24 hr.
2.6.3. Propidium iodide staining for flow cytometry
Flow cytometry was used to examine the DNA content of wild type cells and tk 
transfectants after varying periods of GCV treatment. Propidium iodide intercalates with DNA
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and fluoresces when excited by 488 nm light. By quantitating the level of fluorescence, DNA 
content of a cell population can be determined.
After GCV treatment, monolayers were harvested with trypsin. An equal volume of 
10% FCS (in PBS) was added and the suspension transferred to a 15ml falcon tube. Cells 
were pelleted using a bench top centrifuge (1000 rpm for 5 min.), washed with 10ml ice cold 
PBS and repelleted. Cells were resuspended in 1ml ice cold PBS and fixation achieved by 
adding 9ml of cold 70% ethanol, then incubating on ice for lhr.
Fixed cells were pelleted and then resuspended in 2ml staining solution (250pg / ml 
DNAse free RNAse A, lOpg / ml propidium iodide, 0.2% (v/v) Tween 20 in PBS). Samples 
were incubated at room temperature for 30 min.
Samples were filtered through 71pm nylon gauze, collected in 6ml falcon tube and 
stored on ice. DNA content was examined by exciting samples using a 488nm argon laser and 
emissions collected through a 630 / 22 band pass filter, (FACScan, Becton Dickinson). 
Duplicate readings from 10000 cells per sample were analysed.
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Chapter 3. Results - Analysis of the tk / GCV system in culture
3.1. Introduction
It is well established that the tk / GCV enzyme / prodrug system can cause cell death in 
a variety of cell lines in culture and in vivo (Moolten et al, 1986; Culver et al, 1992; Vile et al, 
1993). A bystander effect associated with this strategy, where cells with and without the tk 
gene are killed, has also been reported (Culver et al, 1992). There are several mechanisms that 
could lead to the additional, unexpected, cell death. In vivo an immune component appears to 
be involved in the bystander effect. Regression of experimental tumours is seen more 
frequently in immune competent, compared to immune deficient, animals (Vile et al, 1994). A 
role of the immune system is also suggested by experiments based on antibody blocking of T- 
cells, which reduces the antitumour effect (Consalvo et al, 1995). Damage to the tumour 
vasculature may also contribute to the bystander effect, causing tumour ischemia as retroviral 
transduction of tumours, with the tk gene, has been shown to reduce the number of capillaries 
(Ram et al, 1994).
Another explanation for the bystander effect seen in culture and in vivo is transfer of 
toxicity from tk+ to tk' cells. The phenomenon is well documented but the mechanism of 
transfer of toxicity has been a controversial issue. The suggested pathways include transfer of 
toxic metabolites via gap junctions (Bi et al, 1993) or transfer of the metabolites, tk enzyme or 
genetic material coding for the enzyme, by some less well defined mechanism that could 
involve phagocytosis of apoptotic vesicles released from dying tk+ cells (Freeman et al, 1993). 
A soluble cytotoxic factor has also been suggested as a minor contributor to bystander killing 
in this system (Kuriyama et al, 1995).
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A bystander effect is likely to be an essential feature of successful enzyme / prodrug 
systems for cancer therapy and it is important to understand the mechanism of transfer of 
toxicity for correct clinical application* For example, if gap junctions are involved, then the tk / 
GCV system may be restricted to tumours with high levels of gap junctional communication, 
while the other suggested mechanisms would not necessarily limit the use of this strategy. This 
chapter describes the experiments which have been performed in culture to determine the 
mechanism(s) involved.
3.2.1. Selection of cell lines
If GJIC is involved in transfer of toxicity in the tk / GCV system, it is anticipated that 
cells that do not form gap junctions will show no bystander effect and that increasing 
communication will produce a stronger bystander killing. Ideally a study of this enzyme / 
prodrug combination would involve selective modulation of communication within chosen cell 
lines. This would enable gap junctional communication to be the only variable. However, 
currently available inhibitors lack specificity and do not completely inhibit communication (see 
section 3.3.5.). Conversely, expression of genes involved in gap junction formation has not 
introduced communication into cells that show no detectable coupling (see section 3.3.5). It is 
however, possible to increase the level of GJIC in lines that are poorly coupled and this 
approach has been adopted (see below). Due to these limitations in modulating 
communication, a variety of cell lines with differing in levels of coupling were selected to 
study the tk / GCV bystander effect These are described below.
Previous work within the group has demonstrated a reduction of GJIC during mouse 
skin carcinogenesis (see section 1.12.2.; Holden et al, 1997). From this model B9 squamous 
carcinoma cells (well coupled) and CarB spindle carcinoma cells (poorly coupled) were
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selected. These cell lines represent intermediate and late stages of carcinogenesis, respectively. 
Loss of E-cadherin, an adhesion protein that can facilitate the formation of gap junctions, is 
one of the changes that occurs during this progression. Transfection of CarB cells with a 
functional E-cadherin gene increases coupling by >5 fold, but the morphology of the 
transfectants (termed CarB-E) appears unaffected. If gap junctional communication is a factor 
in the tk /  GCV bystander effect, then the role of increased coupling can be studied with these 
cells.
These lines have high or low levels of junctional communication. BHK cells (hamster 
origin) were selected since GJIC is intermediate to CarB cells and B9 or CarB-E cells. This 
cell line has been used previously to study metabolic co-operation (Sheridan et al, 1979). Cell 
lines with no communication were also required in this strategy. L929 mouse fibroblast line 
and MCF-7 human breast cancer line were selected because the clones we have show no 
detectable communication.
To summarise, cell lines which lack communication or that are poorly, moderately and 
well coupled have been selected to study the tk / GCV bystander effect (figures 3.1a. and 
3.1b.). If gap junctions do play a role in the bystander effect, then the level of communication 
required and the effect of increasing GJIC can be established. Since these cell lines vary in 
origin (human, mouse and hamster) results seen will also determine whether species dependent 
differences effect bystander killing in the tk / GCV system.
3.2.2. Characterisation of cell lines transfected with the tk gene
The cell lines described above were transfected with the tk gene (section 2.2.3.; figures
3.1.a. and b.). Selection with the appropriate drug (G418 or hygromycin B) resulted in 
formation of colonies. Clones similar in morphology to parental cells were picked and those
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Cell line Population doubling Gap Junctional Intercellular communication
time (hi) Dye spread Immunofluorescence Phase
(2 min)
L929 19.1 +/ 1.2 0 .0 +/ 0
L929 tk+ 19.6 +/ 1.5 0 .0 +/ 0
MCF-7 48.9 +/ 6.6 0.0 +/ 0
MCF-7 tk+ 43.3+/ 4.2 0 .0+/ 0
CarB 22.5+/ 0.1 3.2+/ 0.4
CarB tk+ 20.0 +/ 1.5 4.1+/ 0.7
Figure 3.1a. Transfection and expression of the tk gene does not significantly alter population doubling 
time. GJIC or morphology of the cell lines investigated. For determination of population doubling time 
parental or tk transfected cells were seeded (L929. 1 x 105: MCF-7. 2.5 x 105: CarB. 1.5 x 105 cells / ml), 
in duplicate, in 35 mm plates and allowed to settle for 24 hr. At this time and then once every 24 hr for 
2 days, viable cell numbers were determined using trypan blue dye exclusion. From these data doubling 
times were calculated. Data represent mean +/- SE of two experiments. GJIC was determined by Lucifer 
Yellow dye injections as described in section 2.2.12. Data represent a minimum of 10 separate. 2 minute, 
injections +/- SE. Representative immunofluorescence (L.Y. dye spread ) and phase contrast photomicro­
graphs are shown. L929 and MCF-7 cells lack GJIC. whereas CarB cells communicate at a low level.
Cell line Population doubling Gap Junctional Intercellular Communication
time (hr) Dye spread 
(2 min)
Immunofluorescence Phase
BHK 10.3 V 0.4 9.1V 0.7
BHK tk+ 10.4 V. 0.1 9.8 V 0.9
CarB-E 16.8 V 0.2 25.5 V 1.6
CarB-E tk+ 16.4 V 0.2 20.2 V 1.7
B9 23.8 V. 0.9 24.6 V 1.5
B9 tk+ 20.4 V 0.3 24.1 V 2.0
Figure 3.1b. Transfection and expression of the tk gene does not significantly alter population doubling 
time. GJIC or morphology of the cell lines investigated. Cells were seeded (BHK. 5 x 104: CarB-E.
1.5 x 105: B9. 2.5 x 105 cells / ml) in 35 mm plates. Population doubling times and GJIC were determined 
as described in figure 3.1a.
sensitive to 5pM GCV were expanded. It is possible that GJIC of clones could be different to 
parental cells. If communication is involved in the tk / GCV bystander effect, such a change 
may effect results. Changes may occur through clonal variation, or integration and / or 
expression of the tk gene may interfere with gap junction formation, although there are no 
reports to substantiate the latter suggestion. Therefore the level of coupling of the selected 
clones was measured by microinjection, for 2 minutes, of the fluorescent dye Lucifer Yellow 
(section 2.2.12.). This method gives an indication to the extent of communication by counting 
the number of cells into which dye spreads in a fixed time under standard conditions. 
Comparison of the results from the tk+ clones and the parental cells showed that 
communication is similar (figures 3.1a. and b.). In L929 and MCF-7 cells the dye was 
restricted to the injected cell, confirming that these cells do not form gap junctions, whereas 
CarB, BHK, CarB-E and B9 cells showed a progressively increased levels of coupling.
Growth rates may also be important in the effectiveness of killing in the tk /  GCV 
system. GCV kills tk+ cells that are in S-phase of the cell cycle (Cheng et al, 1983) and cells 
with a faster growth rate are more susceptible. The population doubling times of clones were 
measured over 48 hr and were not significantly different (t-test, p >0.05) to those of the 
parental cells (figures 3.1a. and b.).
This panel of cell lines has been successfully transfected with a functional tk gene and 
significant differences in morphology, mitotic index or GJIC were not seen between parental 
cells and the selected clones. This suggests no obvious changes have occurred during the 
transfection or selection process that might influence the results obtained.
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3.3.1. Analysis of the tk / GCV bystander effect in culture
Initial screening showed that clones selected were sensitive to 5pM GCV, a 
concentration that has no significant effect on survival of parental cells. The following 
experiments were performed to determine the therapeutic index (the difference in sensitivity 
between tk+ and tk' cells) and to establish whether any of the cell lines selected show a 
bystander effect. The protocol chosen is summarised below.
Previous reports using the tk system have described the requirement for cell to cell 
contact and a 5 day treatment regime with GCV to achieve an effective spread of toxicity (Bi 
et al, 1993; Freeman et al, 1993). For sufficient contact to occur, cell cultures must be at least 
10% confluent at the time of GCV treatment. The short doubling times of these cell lines (with 
the exception of MCF-7) meant that after two days cultures became confluent, and stopped 
growing, which may not be long enough for maximum cell death to occur at low prodrug 
concentrations. Growth inhibition could reduce the toxic effect of GCV. To ensure cells 
remain in cycle during treatment, cells were released with trypsin and aliquots transferred to 
96 well plates containing medium (and GCV at the appropriate concentration) so that 
subconfluence was achieved in untreated controls after a further 3 days. At this time survival 
was assessed, using the MTT assay (section 2.2.7.I.), and treated cultures compared to 
untreated (part A, figures 3.2.a. and b.). The use of this protocol enabled treatment of all cell 
lines, with long or short doubling times, to be performed in the same way. The inclusion of a 
subculture step means the assay did not just measure survival, but also measured the ability of 
cells to reattach and grow. It is therefore likely to be more sensitive to toxicity.
In all cell lines studied, there was a reduction in survival when cultures containing 
100% tk+ cells were treated with >0.05pM GCV, whereas parental cells (0% tk+) were largely 
unaffected by concentrations below 10pM. A reduction (*15%) in survival of wild type L929
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and MCF-7 cells was seen with l-10|xM GCV. Variations in sensitivity between cell lines are
I
i common in the literature, for example, Chen et al, (1995a) have shown 9L cells are resistant to
i
50pM GCV, while lpM leads to approximately 15% inhibition of NIH3T3 cells.
Examining the survival of mixed cultures revealed that cells lacking GJIC did not show
i
[ a bystander effect, for example, in cultures containing 50% L929 tk+ or 50% MCF-7 tk+ cells,
I
! lOpM GCV killed 47% and 55% of cells respectively, close to the predicted value of 50%. In
i
| contrast, 2.5% tk+ cells killed between 42% and 65% of the communicating cultures (CarB,
BHK, CarB-E and B9) when treated with 10pM GCV (part A, figure 3.2.a. and b.). This
i
| represents a 17- to 26-fold increase compared to the predicted level of cell death.
ii
An alternative way to present these data is to plot the concentration of GCV required
II
| to reduce cell survival by 50% (IC50) against the percentage of tk+ cells in the culture (part B
I figures 3.2.a. and b.). Each data point in B has been calculated from a survival curve shown in
I
! A. This method of presentation enables the presence or absence of a bystander effect to be
; readily determined, even when the effect is weak, which is important in later sections (see
[
1 5.2.2.). Bystander killing produces a concave curve. In addition, these data enable the effect to
l
I be quantitated by calculating the ratios of IC50 for untransfected cultures and those containing
10% tk+ or 100% tk+ cells (figures 3.2a. and b.; Table 3.1.). This allows direct comparison of 
the bystander effects seen in different cell lines.
The parental cell lines showed a small variation in IC50 (<3 fold variation; table 3.1.). 
The IC50 in L929 and MCF-7 cultures remains high until >50% of cells are tk+. This is logical 
because in a population where less than half the cells are tk+ and there is no significant 
bystander effect, only tk+ cells will be killed by low prodrug concentrations. In contrast,
| IC50’s in communicating cultures were reduced by at least 10 fold by the presence of only
2.5% tk+ cells. Increasing the percentage of transfectants reduced the IC50 further. All the tk+
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cell lines, with or without communication, cultured alone had low IC50’s, (part B, figures
3.2.a. and b.). A summary of these results is provided in Table 3.1. For comparative purposes
the bystander effect (IC5° m  /  icso 1 0% tk+) and therapeutic index (IC5° m  &+ /  icso 1 0 0 % tk+) 
are given. Calculation of bystander effect from cultures containing 10% tk+ cells was 
arbitrarily chosen, although it does represent the upper level of transfection that might be 
achieved in vivo. These values have been calculated from figures 3.2.a. and b., part B. The 
results show there was no significant bystander effect when GJIC was undetectable, but in 
cultures that were coupled by gap junctions, even at a low level, there was extensive bystander 
killing. This difference was not due to relative insensitivity to toxic metabolites because L929 
cells had the largest therapeutic index. However for cell lines that did form gap junctions, 
there was no correlation between level of GJIC and the observed bystander effect. For 
example, the bystander effect was greater in CarB cultures than in CarB-E cultures, where 
transfection of CarB cells with E-cadherin has increased the level of communication >5 fold 
(Table 3.1; figure 3.1.).
If the tk / GCV bystander effect does involve of GJIC then an increase in killing might 
be expected in response to increased coupling (Table 3.1.). This was clearly not the case and 
other factor(s) must have influenced the effect. For example, high levels of tk activity would 
produce high concentrations of GCV-phosphates, and gap junctions when present, may not be 
the limiting factor in transfer of toxicity. Under these conditions, local concentrations of GCV 
in tk+ cells may be restrictive. Other possibilities are that the conversion of GCV- 
monophosphate (GCV-MP) to triphoshphate (GCV-TP) in the tk+ and tk' cells, or the 
subsequent incorporation into DNA is rate limiting. If tk activity was low in some of the tk+ 
cell lines, then this may account for a reduced bystander effect. Production of limited GCV-TP 
may successfully kill tk+ cells, since it is possible that only one, or a very few molecules, could
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cause cell death. However, higher concentrations of toxic metabolites would be required to kill 
tk+ and tk' cells.
Absence of GJIC may account for lack of bystander effect in some cell lines, but in 
view of the lack of correlation between increased coupling and increased bystander killing, 
attention must be given to other possible explanations. Transfer of toxicity could occur via the 
medium since it has been reported that a cyclic form of GCV-MP can pass through the cell 
membrane (Prisbe et al, 1986). Kuriyama et al (1995) have suggested the cellular enzyme 
responsible for conversion of guanosine monophosphate to guanosine 3’,5’-cyclic phosphate 
may also produce a cyclic form of GCV-MP so the lack of such an enzyme may prevent a 
bystander effect. Another suggestion for the differences in bystander effect that are seen is the 
secretion of a cytotoxic cytokine from some, but not other, dying tk+ cell lines. TNFa appears
|
| to be released from only some tumour cell lines and can have inhibitory effects in culture (see
i
i
| section 1.11.5.; Sugarman et al, 1985; Freeman et al, 1995).
I
I
! Phagocytosis of apoptotic vesicles released from dying cells has also been suggested as
\
I a mechanism of transfer of toxicity (Freeman et al, 1993). The arguments for a role of such
I
I vesicles in the bystander effect has been provided in section 1.11.2. If apoptosis is not a
I mechanism of cell death in GCV treated tk+ cells or occurs only to a limited extent, there may
i
| not be sufficient production of vesicles to transfer toxicity. This may explain the absence of a
| bystander effect in some cell lines.
These possibilities must be investigated in order to conduct a comprehensive study of
| the tk / GCV bystander effect. The methods and results from these analyses are described 
below.
77
3.3.2. Bystander effect in relation to level of tk activity
An HSV-tk specific assay (section 2.4.3.) was used to establish the level of enzyme 
activity in each of the cell lines (Table 3.1.). All parental cells had a specific activity of <0.2 
units (pmoles 125I-iododeoxycytidine converted / hr / mg protein), whereas that of the 
i transfectants ranged from 11.7 (L929 tk+) to 25.0 (MCF-7 tk+) units. From these data it is 
I apparent that a lack of bystander effect was not due to low tk activity, since MCF-7 tk+ cells
i
; had the highest activity of the six cell lines, but in the communicating cell lines an increase in
j
I tk activity appeared to be associated with a stronger bystander effect. For example, CarB tk+
[
| cells had the highest activity and strongest bystander effect, while a lower activity in B9 tk+
sI
[ cells corresponded to a weaker bystander effect (Table 3.1.).
! In order to investigate the relationship between tk activity and bystander effect in this
|
i  system, BHK cells, which are susceptible to bystander killing (Table 3.1.), were transfected
|
j with constructs expressing the tk gene and clones with differing tk activities expanded. Clone 
I 1 has an activity of 1.1 units while clones 2, 3, 4, 5, and 6 have activities of 3.4-, 3.8-, 9.5-,
i
| 13.8-, and 18.7-fold higher, respectively. Production of clones 4 (BHK cd+-tk+) and 5 (BHK
j
I cdtk+) is described in section 6.3. The remaining clones express only the tk gene. The clones
I
[ were morphologically indistinguishable, but there were variations in GJIC (dye spreads 9.1 to 
13.6) and doubling times (9.2 to 12.2 hr) that were significant (t-test: p <0.05; figure 3.3.a.; 
see below).
Survival of mixed (10% tk+ ; 90% tk') and separate cultures of tk+ and tk' cells was 
determined after 5 days of GCV treatment, as described previously (section 3.3.1; Section
2.2.7.). From the IC50s, bystander effect and therapeutic index were calculated for each clone 
I and plotted against relative tk activity (figure 3.3.).
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A Clone GJIC Doubling
Time
Rel. tk 
activity
Bystander
Effect
Therapeutic
Index
1 10.8 V. 0.7 9.8 V. 0.7 1 5 V 1 1040 V 196
2 12.4 V. 0.8 9.2 V. 0 3.4 32 V 5 3643 V. 440
3 9.1 V. 0.6 11.5 V 1.0 3.8 158 V 39 3069 V 271
4 13.2 V. 2.5 10.5 V 0.5 9.4 118 V 27 1895 V 228
5 13.6 V 1.0 12.2 V 0.2 13.1 314 V 31 2441 V 60
6 9.8 V. 0.9 10.4 V 0.1 18.7 292 V 53 3530 V 258
B
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Figure 3.3. Effect of increasing tk expression on bystander effect and therapeutic index 
in BHK cells. BHK cells were transfected with the pGK-tk plasmid which carries neo and tk genes. 
Clones showing resistance to 800pg/ml G418 and sensitivity to 10pM GCV were further assayed for 
tk activity (section 2.4.3.). GJIC was determined by Lucifer Yellow dye injections (section 2.2.12.).
Data are from 10 separate, 2 minute, injections and represent mean +/- SE. Doubling time of cells, after 
initial seeding at 5 x 104 / ml was measured (section 2.2.5.). Data are mean +/- SE of 2 experiments. (A) 
Survival of separate and mixed (10% tk+) cultures of BHK tk+ and BHK tk' was analysed as described in 
section 2.2.7. By calculation from each survival curve, the IC50 for wild type cells, (0% tk+) transfected 
cells (100% tk+) and mixed cultures (10% tk+) was determined. From these values (B) bystander effect 
(tcsoott lk+/IC5010% tk+) and (C) therapeutic index (IC500% lk+/IC50100% tk+) were calculated and plotted versus 
tk activity (relative to tk clone with lowest expression, see section 3.3.2.). Each data point represents 
mean +/- SEM (bars) of two independent experiments, each performed in triplicate and relative tk 
activity represents the mean of two independent experiments, each performed in duplicate.
There was a strong correlation (0.855) between bystander effect and relative tk activity 
(figure 3.3.A. and B.). This did not appear to be influenced by the variations in mitotic index 
and GJIC that occur. For example, a faster cell cycle may be expected to enhance GCV 
toxicity, and hence the bystander effect, as toxicity from GCV-triphosphate arises from 
incorporation into nascent DNA strands and inhibition of aDNA polymerase during S phase. 
Increased gap junctional communication would, if anything, be expected to enhance the 
| bystander effect. However, this was not the case since clone 2 had a shorter doubling time and 
was better coupled than clone 6 (figure 3.3.A.) but higher tk activity was associated with a
! stronger bystander effect.
[
[ In contrast to the changes in bystander effect, progressive increases in tk activity didI
i
| not produce a larger therapeutic index (figure 3.3.A. and C.). For example, the bystander
rt
j effect (figure 3.3.A) varied by approximately 60-fold between clones 1 (bystander effect of 5)
I'
| and 5 (bystander effect of 314), whereas the therapeutic index (figure 3.3.A) varied <3-fold
i
between the same clones (therapeutic index of clone 1 was 1040 and clone 5 was 2441). The
| variation in therapeutic index seen here was similar to that seen earlier between the different
[f
I cell lines (Table 3.1.). To kill a tk+ cell it is possible that only one, or a very few molecules of
I[
| GCV-TP need to be incorporated into DNA so even low levels of tk expression could lead to
cell death. Increasing expression might be expected to have little effect since the cells are
j
| already being effectively killed. The maximum therapeutic index is reached with low tk
!
expression (figure 3.3.C.). However, in the bystander effect, under the conditions described 
here (10% tk+ cells), one tk+ cell must kill 4 tk' cells to reduce survival of the culture by 50%. 
Sufficient toxic metabolites must be transferred to the tk' cells in the culture and this will be 
achieved more effectively when levels of tk are high. Other factors may ultimately become 
limiting, such as uptake of GCV, and a plateau of maximal effect will be reached. It has also 
been suggested that low levels of toxic metabolites can be tolerated in some cell lines and
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buffering of toxicity by competition with dGTP may reduce the bystander effect (Wygoda et 
al, 1997). This will be considered further in the discussion of this chapter (section 3.4.)
If this model is true then the bystander effect or the therapeutic index might be 
expected to increase initially and then plateau in response to increasing tk expression. While 
the data may be consistent with this expectation, there is too much variation to support any 
such conclusion. Variations are to be expected as the bystander effect and therapeutic index 
are calculated as ratios of IC50s (096tk+ /  10%tk+ and 0%tk+ /  ioo%tk+ > respectively) and any 
differences due to biological variation, or experimental error, will be amplified.
From these data it is possible to conclude that low levels of tk activity result in little or 
no bystander effect, but increasing activity leads to stronger bystander killing.
3.3.3. Can toxicity be transferred via the medium?
Previous reports have demonstrated cell contact is required for a tk / GCV bystander 
effect with fibrosarcoma or Kirsten ras transformed cells in culture (Bi et al, 1993; Freeman et 
al, 1993). For this reason, the survival experiments described in section 3.3.1. were designed 
to optimise contact. The results in previous sections indicate that gap junctions may be 
required for the effect. If this is correct then toxicity would not be expected to be transferred 
via the medium. If it is not correct and toxicity is transferred via the medium, bystander killing 
would be expected in L929 or MCF-7 mixed cultures. There is some evidence in support of 
medium transfer as Kuriyama et al (1995) showed that medium from tk+ cells treated with 
GCV could kill a proportion of the tk' culture. They hypothesised that cyclic GCV-MP or a 
cytotoxic cytokine were involved (section 3.3.1.). If these toxic products are not produced by
80
(A) Medium transfer experiments (B) Filter separation experiments
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rigure 3.4. Transfer of toxicity in the tk / GCV bystander effect does not involve soluble metabolites.
A) tk+ cells were seeded (L929 and CarB, 1 x 105; BHK, 5 x 104) cells / ml in 24 well plates and treated 
vith lOfiM GCV for 48 hr. The medium from drug treated cells was transferred to untransfected tk'
ells and incubated for 2 days. Survival was assayed using standard protocol (see section 2.2.7.) and 
ompared to survival of controls. Treatments in each experiment are summarised below the graphs.
B) untransfected tk' cells were seeded (L929, 5 x 104; CarB, 7 x 104; BHK, 2 x 104) in 0.5 ml in 24 
veil plates. 0.02pm filter inserts were placed in each well and an equal number of tk+ cells added to 
he insert. lOpM GCV was added to the media and cells were incubated for 3 days. Survival was 
issayed using standard protocol (section 2.2.7.) and compared to untreated controls. Each data point 
epresents mean +/- SEM (bars) of two independent experiments, each performed in triplicate.
I L929 tk+ and MCF-7 tk+ cells, this may account for the lack of bystander effect in these cells.
I
Therefore, transfer of toxicity via the medium was investigated.
In medium transfer experiments, cultures of tk+ cells were treated with lOpM GCV for 
2 days, a concentration known to produce a bystander effect (section 3.3.1.; figure 3.2). The 
! medium was then transferred to tk' cells which were incubated for 48 hr. Survival of tk' cells
i
! was measured after transfer to 96 well plates, as described in section 2.2.7. Figure 3.4.A.L
|
| shows there was no significant difference in survival, compared to controls treated with GCV,
j
| for the cell lines tested (L929, CarB and BHK).
!
The failure to transfer toxicity, via the medium, from CarB tk+ and BHK tk+ cell lines 
was not due to degradation of GCV or toxic metabolites. Medium containing 10pM GCV,
| which has been preincubated for 48 hr, was still toxic to tk+ cultures.
r
j  Separation of tk+ and tk' cells, by an Anopore filter, also prevented a bystander effect
I
| (figure 3.4.B.). The filter was permeable to GCV because adding prodrug to the medium of tk
ii
I cells, killed tk+ cells, which were on the opposite side of the membrane. Any toxicity produced
| by the tk+ cells should have passed rapidly to the tk‘ cells so degradation of potentially toxic
i
| metabolites was less likely to occur. This experiment used equal numbers of tk+ and tk' cells
i
| but there was no detectable bystander effect. In contrast, when tk+ and tk' cells were in
| contact, and formed gap junctions, the same concentration of GCV (lOpM) almost completely
j killed cultures containing only 20% tk+ cells (figure 3.2.).
These experiments have shown that a detectable level of toxicity is not transferred via 
the medium and, in culture, cell contact is a requirement for the tk / GCV bystander effect. 
This leaves gap junctions or some form of vesicular transfer as the likely the mechanism of the 
bystander effect and since differences in apoptosis may account for the lack of vesicle 
production in some cell lines, this is explored below.
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3.3.4. The role of apoptosis in the tk / GCV bystander effect
Apoptosis often occurs in response to toxic agents, for example, chemotherapeutic 
agents (Cece et al, 1995). Apoptosis also occurs when tk+ cells are treated with GCV and this 
| has led to the suggestion that phagocytosis of apoptotic vesicles is a mechanism of transfer of
i
| toxicity (Freeman et al, 1993). If L929 tk+ and MCF-7 tk+ cells do not undergo apoptosis and
|
| produce vesicles in the same way as the other cell lines examined, this could account for a lack
| of bystander effect.
! In the report by Freeman et al (1993) cell contact was shown to be required for a
I
| bystander effect. Since contact is necessary for transfer via gap junctions, and may be required
i-
[ for transfer by vesicles, this raises the problem of how to differentiate between these
[ mechanisms. Fortunately, shedding of vesicles occurs late during apoptosis, whereas other
f
j events in programmed cell death, such as DNA cleavage, occur much earlier. For example, in
| bovine epithelial cells treated with ricin, changes in DNA have been shown to occur at 7 hr
i
[ while release of vesicles was seen at times after 16 hr (Hughes et al, 1996; section 1.11.2.).
f
I Determining the time that DNA damage occurs should define the earliest time of vesicle[
! release. Transfer via gap junctions should, on the other hand, occur much faster. For example,
i
I extensive nucleotide transfer between coupled cells occurs in one hr (Sheridan et al, 1979) and
|
in section 3.2.2. Lucifer Yellow spreads to >20 cells in 2 minutes. Determining the time of 
transfer of toxicity should distinguish which mechanism is involved. Therefore, experiments 
were designed to answer the following questions
1) Do all the tk+ cell lines die by apoptosis after GCV treatment? If only cells that 
show a bystander effect die this way, this may account for the lack of bystander killing in L929 
and MCF-7 cultures.
2) When does apoptosis occur? If apoptosis occurs at a much later time in cells that do 
not show a bystander effect this could account for differences in bystander killing.
3) When does transfer of toxicity occur? Early transfer prior to the onset of apoptosis 
would favour GJIC as the basis of the bystander effect.
Some of the experiments below rely on colony formation. L929, CarB and BHK cells 
readily form colonies and these cells do (CarB and BHK) or do not (L929) show a bystander 
effect. Therefore these cell lines have been selected as representatives to study the tk /  GCV 
bystander effect further. (MCF-7 cells form colonies more slowly, while B9 cells can clump, 
making studies such as flow cytometry difficult, see below).
The time course of cell death of tk+ cells in response to GCV was determined using a 
terminal transferase assay. Free ends of DNA produced by nuclease activity during apoptosis 
and necrosis incorporate fluorescein labelled nucleotides, which allows cells with fragmented 
DNA to be seen under appropriate UV illumination. Cleavage of DNA occurs in apoptosis and 
necrosis (see below) therefore this method detects both events. While GCV treatment had no 
detectable effect on tk' cells at any of the time points examined, tk+ cells showed DNA damage 
at times after 8 hr and morphological evidence of cellular damage was first evident at 16 to 24 
hr (figures 3.5.a.b. and c. part A). The time course of cellular degeneration in L929 tk+ and 
CarB tk+ cells was similar but the events occurred earlier in BHK tk+ cells. In each cell line a 
marked reduction in cell number occurred with time. Closer examination of the 
photomicrographs in figures 3.5 (a, b and c. part A) reveals that cell shrinkage (see phase 
contrast photomicrograph) and condensation of DNA (see immunofluorescence 
photomicrograph), have occurred, which are indicative of apoptosis. However, some cells 
appear swollen and enlarged, which suggests necrosis (see section 1.11.2.).
Apoptosis is associated with the appearance of *180 bp DNA fragments which 
represent cleavage of linker regions between nucleosomes by a specific endonuclease. This
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Figure 3.5a. A population of L929 tk+ cells treated with GCV die by apoptosis. (A) In 
situ analysis of GCV induced cell death. L929 tk+ cells were seeded at 1 x 105 cells / 
ml in 2 well chamber slides. 24 hr later, cells were treated with 20pM GCV for 0, 8, 24 
or 48 hr. Cells were stained using an Apotag detection kit as described in section 2.6.1. 
Immunofluorescence and phase contrast photomicrographs are shown. Untreated 
cultures show only background staining and positive staining is seen after 8 hr. This 
demonstrates that apoptosis or necrosis occurred. (B) Presence of DNA fragmentation 
was determined by agarose gel electrophoresis of 32P end labelled samples. Cultures of 
L929 or L929 tk+ cells were incubated with 20pM GCV for the times indicated above. 
Genomic DNA was isolated from these cells and free ends of DNA were labelled with 
a [32P]-dCTP as described in section 2.6.2. b(i) UV illumination of ethidium bromide 
stained DNA shows equal loading between samples. b(ii) The gel was dried and 
exposed to autoradiographic film. L929 parental cells (tk ) and untreated tk+ cells show 
no evidence of specific DNA fragmentation, whereas cells treated for 24 and 48 hr do 
(arrows). This demonstrates that some cell death occurs by apoptosis.
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Figure 3.5b. A population of CarB tk+ cells treated with GCV die by apoptosis. (A) In 
situ analysis of GCV induced cell death. CarB tk+ cells were seeded at 1.5 x 105 cells / 
ml in 2 well chamber slides. 24 hr later, cells were treated with 20p,M GCV for 0, 8, 24 
or 48 hr. Cells were stained using an Apotag detection kit as described in section 2.6.1. 
Immunofluorescence and phase contrast photomicrographs are shown. Untreated 
cultures show only background staining and positive staining is seen after 8 hr. This 
demonstrates that apoptosis or necrosis occurred. (B) Presence of DNA fragmentation 
was determined by agarose gel electrophoresis of 32P end labelled samples. Cultures of 
CarB or CarB tk+ cells were incubated with 20p,M GCV for the times indicated above. 
Genomic DNA was isolated from these cells and free ends of DNA were labelled with 
ct[32P]-dCTP as described in section 2.6.2. b(i) UV illumination of the ethidium 
bromide stained DNA shows equal loading between samples. b(ii) The gel was dried 
and exposed to autoradiographic film. CarB parental cells (tk ) and untreated tk+ cells 
show no evidence of specific DNA fragmentation, whereas cells treated for 24 and 48 
hr do (arrows). This demonstrates that some cell death occurs by apoptosis.
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Figure 3.5c. A population of BHK tk+ cells treated with GCV die by apoptosis. (A) In 
situ analysis of GCV induced cell death. BHK tk+ cells were seeded at 5 x 104 cells /  ml 
in 2 well chamber slides. 24 hr later, cells were treated with 20p,M GCV for 0, 4, 8 or 
24 hr. Cells were stained using an Apotag detection kit as described in section 2.6.1. 
Immunofluorescence and phase contrast photomicrographs are shown. Untreated 
cultures show only background staining and positive staining is seen after 8 hr. This 
demonstrates that apoptosis or necrosis occurred. (B) Presence of DNA fragmentation 
was determined by agarose gel electrophoresis of 32P end labelled samples. Cultures of 
BHK or BHK tk+ cells were incubated with 20pM GCV for the times indicated above. 
Genomic DNA was isolated from these cells and free ends of DNA were labelled with 
a [32P]-dCTP as described in section 2.6.2. b(i) UV illumination of the ethidium 
bromide stained DNA shows equal loading between samples. b(ii) The gel was dried 
and exposed to autoradiographic film. BHK parental cells (tk') and untreated tk+ cells 
show no evidence of specific DNA fragmentation, whereas cells treated for 8 and 24 hr 
do (arrows). This demonstrates that some cell death occurs by apoptosis.
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contrasts to necrosis where non specific nucleases digest DNA generating a range of fragment 
sizes. Separation of DNA fragments by agarose gel electrophoresis, reveals laddering or 
smearing which indicate apoptosis or necrosis, respectively.
To determine which event (s) was predominant, genomic DNA was isolated from tk+ or 
tk' cells (L929, CarB and BHK) that had been treated with GCV for different times up to 48 
hr (figure 3.5. a, b. and c. part B). Free ends of DNA were labelled with a [32P]-dCTP and 
separated by electrophoresis (section 2.6.2.). Radiolabelling enhances the sensitivity of this 
assay. No change in DNA integrity was visible in the ethidium bromide stained gel, but did 
show equal loading between lanes (figures 3.5. a, b and c. part Bi). Exposure to 
autoradiographic film revealed laddering at times after 4 hr of GCV treatment in tk+ cells 
(figures 3.5. a, b and c. part Bii). Apoptosis occurred in each of the cell lines but appeared 
earliest in CarB tk+ and BHK tk+ cells, and latest in L929 tk+ cells. All the samples that 
showed laddering also showed smearing, which suggests that necrosis occurred in parallel.
Flow cytometric analysis of cells stained with propidium iodide (PI) allows changes in 
DNA content to be studied. When intercalated with double stranded DNA, PI fluoresces with 
exposure to 488nm excitation. The level of fluorescence is proportional to DNA content of 
individual cells. In addition, cell size increases during the cell cycle to a maximum prior to 
mitosis. Plotting fluorescence against cell size indicates the proportion of cells in each phase. 
Any change in the distribution of cells indicates a change in DNA content.
In earlier experiments, which used labelling of fragmented DNA to assess the time 
course of apoptosis, degeneration occurred more rapidly in BHK tk+ cells, therefore an 
additional time point was included for flow cytometric analysis of this cell line. The results in 
figure 3.6 show changes in DNA content (as changes in the flow cytometric profile) were 
detectable at times after 2 hr of GCV treatment of BHK tk+ cells or at times after 4 hr 
treatment of L929 tk+ and CarB tk+ cells. These data are consistent with those in figure 3.5
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Figure 3.6. The earliest changes in DNA content of GCV treated tk+ cells occurs at times after 2 
hr. tk+ cells were seeded (L929 tk+ and CarB tk+, 1 x 105; BHK tk+ 5 x 104 cells / ml) in 90mm 
tissue culture plates and allowed to settle for 24 hr. Cultures were treated with 20pM GCV for times 
indicated above, (the additional time point for BHK tk+ cells was due to the shorter division time of 
this cell line, see figure 3. lb.). Cells were harvested and prepared for flow cytometry as described in 
section 2.6.3. DNA content of untreated and treated cells was quantified by collecting the emissions 
from propidium iodide stained samples that had been excited by 488 nm light. The data from each 
figure have been collected from 10,000 cells / sample and are representative of three independent 
experiments.
and suggest the shorter doubling time (more S-phase entry) of BHK cells leads to a faster 
activation of cellular degeneration.
An apoptotic peak, which has been reported by others in response to toxic agents 
(Cece et al, 1995), was not seen in the histograms from GCV treated tk+ cells here. Previous 
studies have shown that some cells dying by apoptosis release DNA containing vesicles which, 
due to their small size, generate a peak to the left of the histogram (the larger the particle, the 
further to the right the signal). The absence of such an apoptotic peak in the histograms of the 
GCV treated tk+ cells, and the detection of laddering only by a sensitive radiolabelling assay, 
suggest that only a small proportion of the cells are undergoing apoptosis at the time points 
investigated.
Collectively these data demonstrate the mechanism of cell death in cells that do and do 
not show a bystander effect occurs, in part, by apoptosis. The time courses of these events are 
similar for L929 tk+ and CarB tk+ cells, and there are no obvious differences that can be 
related to the differences in bystander effect. Changes in BHK tk+ cells occur earlier. 
However, no changes in morphology or DNA content of any of the cells examined can be 
detected at 2 or 4 hr and it seems reasonable to conclude that apoptotic vesicles will not be 
released before these times. If transfer of toxicity occurs at these early times, it would provide 
evidence that apoptotic vesicles are not involved.
To examine the time at which toxicity is transferred, the effect of GCV treatment on 
colony formation in separate cultures, was investigated, for different times up to 4 hr,. 
Treatment of tk+ cells with GCV for 2 hr resulted in >90% to cell death and complete killing 
was seen after 4 hr treatment (figure 3.7a.). During these periods of treatment, only a fraction 
of the cells can be expected to be in S-phase, which is when toxicity from GCV-TP occurs.
The remaining cells, that were not synthesising DNA during treatment, can only be killed if, at 
a later time they enter S-phase in the presence of toxic metabolites and this could occur either by j
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Figure 3.7. Toxicity in the tk / GCV bystander effect is transferred within 2 hr of applying GCV. 
tk+ cells alone (A) or tk+ and tk' mixed (1:1) cultures (B) were seeded (L929, 1 x 106; CarB, 2 x 106; 
BHK, 5 x 105 cells / well) in 35 mm plates and allowed to settle for 4 hr. Cells were untreated (0 hr) 
or treated for 2 or 4 hr with 20pM GCV. Cells were released with trypsin and aliquots of the cell 
suspension were transferred to 90 mm plates containing full medium (no GCV) in order to test the 
ability of cells to form colonies. When visible colonies had formed they were stained with Giemsa. 
Colonies were counted and survival calculated as a percentage relative to untreated cultures. Data 
represent the mean +/- SEM of three independent experiments. In the cells lines tested >95% of tk+ 
cells are killed by 2 hr of GCV, whereas in mixed cultures tk' cells are killed only when cells 
communicate (CarB and BHK, not L929 cells).
the persistence of GCV-TP or by further production of GCV-TP from residual GCV. In the 
protocol described above, GCV treated tk+ cells were transferred to medium without prodrug, 
and cellular GCV might be expected to become diluted by equilibrium with the surrounding 
medium. Therefore, it is more likely that persistence of GCV-phosphates, which cannot cross 
that cell membrane, were the cause the death, and this suggests that these metabolites may 
have a relatively long half life.
To determine whether transfer of toxicity can occur during 2 or 4 hr of treatment, 
mixed cultures (1:1) of cells that do not (L929 and L929 tk+) or do (CarB and CarB tk+ or 
BHK and BHK tk+) show a bystander effect were seeded to give subconfluent cultures after 4 
hr. Cultures were treated with 20|uM GCV for 2 or 4 hr, trypsinised and colony formation 
measured (figure 3.7a.). At both times GCV killed only approximately half the L929 cells (the 
tk+) but most of the CarB and BHK cells, compared to untreated controls. The phenotype of 
the surviving L929 cells was shown to be tk' since in parallel experiments, treatment of mixed 
cultures of L929 tk'pgaT and L929 tk+(3gal' cells resulted only in survival of cells that stained 
positive with x-gal (section 2.2.13.).
It is also possible that the bystander effect seen in the CarB and BHK cells depends on 
some form of cytoplasmic budding and uptake that occurs in normal cultures. Like any form of 
vesicular transfer, such a mechanism could result in tk* cells gaining tk activity. To examine 
this possibility (transfer of tk enzyme or genetic information to make the enzyme), tk+ and tk' 
(L929, CarB or BHK) mixed cultures, at the same densities as before, were left for 8 hr, 
trypsinised, plated at low density (to prevent contact) and then treated with 20^iM GCV. Only 
half the cells (compared to untreated controls) were killed in each mixed culture (figure 3.7b.). 
These data show that after coculture, under conditions that generate a pronounced bystander 
effect, negligible tk activity was transferred from the tk+ to the tk' cells.
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Taken together, the above data show that transfer of toxicity in the tk / GCV system is 
not via the medium and is unlikely to involve uptake of apoptotic or other vesicles. Apoptosis 
did occur in all tk+ cell lines treated with GCV, but mixed cultures of tk+ and tk' cells were 
committed to death before apoptosis could be detected. The most likely explanation of the 
bystander effect in this system is transfer of toxic metabolites via gap junctions.
3.3.5. Modulation of GJIC and the tk / GCV bystander effect
The correlation between the tk / GCV bystander effect and GJIC would be enhanced if 
it were possible to selectively modulate communication with genetic manipulation or specific 
inhibitors. Expression of genes that enhance gap junction formation in poorly coupled cells can 
markedly increase the level of junctional communication. For example, expression of E- 
cadherin increased coupling of CarB cells up to >5-fold (figure 3.1.) while in Hela cells, 
expression of connexin 43 (Cx43) resulted in a 20- to 40-fold increase (Mesnil et al, 1996). In 
L929 and MCF-7 cells, which do not express E-cadherin and Cx43, respectively, there is no 
detectable coupling (figure 3.1.). Expression of the appropriate functional genes in these cells, 
however, fails to induce communication and it appears that the defects are more complex 
(Pitts, unpublished data). Some other factor(s), not yet identified, is required for proper 
formation of gap junctions in these cell types.
Decreasing the level of communication may provide an alternative way to study the 
correlation. However, currently available chemical modulators such as forskolin are not 
specific to gap junctions and also inhibit phagocytosis (Nambu et al, 1989) while others, such 
as TPA (12-O-tetradecanyol phorbol-13-acetate), which are also not specific, fail to 
completely inhibit coupling in many cell lines (Rivedal and Sanner, 1992). Another approach is 
the use of antisense constructs. This approach has proved effective, and specific, in reducing
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levels of several proteins, for example, the proto-oncogene bcl-2 (see section 1.6.). Goldberg 
j et al (1994) demonstrated a full length Cx43 antisense (Cx43-AS) construct can reduce
I
junctional communication in Rat 1 cells in culture. Lucifer Yellow dye spread was reduced 
from 49 cells in parental cultures to 1 cell in an antisense expressing clone, a reduction of 
98%. If communication of the cells in the present study could be reduced this effectively, 
coupling would be close to zero. This would allow further examination of the role of GJIC in 
1 the bystander effect. However, connexins are a family of proteins and it is possible there will
| be redundancy in function. It may be important to select a cell line with a limited number of
| connexins expressed. BHK cells express Cx43, but many connexins, such as Cx-26, -31, -31.1,
i
[ -32, -37, -40, -46 and -50, are not expressed (Davis et al, 1995). As the sequences of hamster
j
j (BHK cells) and rat (Rat-1 cells) Cx43 show 95% homology, and the Cx43 AS plasmid used
|
j by Goldberg (above) was successful in Rat-1 cells, the same construct was transfected into
)\
BHK cells. Cells with this plasmid can be selected for with G418. Resistant clones were 
| picked and complete lysates were resolved by SDS-PAGE. Western blot analysis revealed
i
! reduced levels of Cx43 protein in some of the clones (figure 3.8.A.). In parental cells, Cx43 is
I present in unphosphorylated and phosphorylated forms which migrate as separate bands with
i
I apparent molecular weights of 40-45 kDa, which is consistent with previous reports (Musil
ii
I and Goodenough, 1991). Parental cells and most clones also express a protein of higher
I
fj molecular weight (90 kDa) that reacts with the antibody. The appearance of a similar band has
i
j. been reported previously (Davis et al, 1995). Since there is no correlation with level of Cx43,
| the presence of this band is likely to represent non specific binding. For example, clones 1 to 6
I show similar levels of the 90kDa protein but Cx43 varies (figure 3.8.A). The level of coupling
of 4 clones that showed marked decreases in Cx43 expression (3 have no detectable
expression) was analysed by microinjection of Lucifer Yellow. However there was no
reduction in coupling in these clones (Figure 3.8.B.). Decreasing Cx43 expression did not
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reduce communication in BHK cells, and similar results were found with CarB and B9 cells 
(data not shown). The tk / GCV bystander effect cannot be investigated, in these cells, in this 
way.
3.3.6. Absence of a bystander effect in mixed cultures of cells that can form gap 
junctions and cells that cannot
The experiments in sections 3.3.1. to 3.3.4. provide evidence for a correlation between 
GJIC and the bystander effect in this system. However further support for gap junctions may 
be obtained by determining whether transfer of toxicity occurs in mixed cultures of cells that 
do or do not show a bystander effect. It has previously been demonstrated that coupling only 
occurs between different cell lines when both can form functional gap junctions, that is to say 
the inability to form gap junctions is dominant in mixed cultures (Pitts, 1971; Gilula et al, 
1972). The role of gap junctions in the bystander effect would be supported if transfer of 
toxicity is not seen in cultures where only one cell line is coupled. Transfer of toxicity by 
vesicles or the medium should be non specific. Therefore CarB and L929 cells were selected 
to address this issue. CarB tk+, but not L929 tk+ cells, show a strong bystander effect when 
cultured with parental cells (Table 3.1.). In addition, these cells have similar population 
doubling times (figure 3.1.).
Mixed cultures (1:1) of L929 and CarB tk+, CarB and L929 tk+, CarB and CarB tk+ or 
L929 and L929 tk+ cells were seeded to give subconfluent cultures after 4 hr. Cultures were 
treated with 20 pM GCV for 4 hr, trypsinised and colony formation examined (figure 3.9.). 
Colony formation, not an MTT assay, was used to assess survival of cultures as CarB and 
L929 cells metabolise MTT at different rates so comparing treated and untreated mixed 
cultures would give false levels of survival. The cultures of CarB and CarB tk+ (>95% killing)
CarB vs CarB tk CarB vs L929 tk
No GCV 20pM GCV No GCV 20|iM GCV
L929 vs CarB tkL929 vs L929 tk+
No GCV 20|aM GCV No GCV 20|iM GCV
Figure 3.9. GJIC is required in tk+ and tk* cell populations for the tk / GCV bystander effect. Mixed 
cultures (1:1) of tk+ and tk* cells indicated in each of the figures above were seeded (1 x 106 cells / well) 
in 35 mm plates. 24 hr later cells were treated with 20pM GCV for 4 hr. After this time cells were 
released with trypsin and aliquots of the cell suspension were transferred to 90mm plates containing full 
medium (no GCV) in order to test the ability of cells to form colonies. When visible colonies had formed 
they were stained with Giemsa. Colonies were counted and survival calculated as a percentage of 
untreated cultures. Data represent mean +/- SE of one experiment performed in triplicate. CarB cells have 
GJIC and L929 cells do not. A bystander effect is only seen in CarB with CarB tk cells.
or L929 and L929 tk+ (=50% killing) were controls with or without bystander effects, 
respectively (figure 3.9). The same experiments were performed previously in section 3.3.4 
and gave very similar results. In cultures of CarB tk+ with L929 and L929 tk+ with CarB cells 
killing was =50-60%. The surviving cells were identified as L929 or CarB, respectively, since 
L929 cells form diffuse colonies that stain light purple with giemsa, while CarB cells form 
dense colonies that stain deep purple. These cells were also distinguished on the basis of cell 
morphology.
These results support the role of gap junctions in the tk /  GCV bystander effect. If 
spread of toxicity was based on some form of vesicle transfer, donor (tk1) cells would have to 
release sufficient vesicles to transfer toxicity, while recipient (tk') cells would have to 
phagocytose the vesicles. If this was the mechanism, then CarB cells can act as donor and 
recipients, since they show a bystander effect, but these experiments have demonstrated that 
L929 cells cannot function in either role, and it might be expected that the chance of L929 
cells having defects in both vesicle formation and phagocytotic pathways, is remote.
3.3.7. The tk / GCV system and p53 status
The cell lines that have been used to examine the bystander effect have a functional 
p53 gene (Blagosklonny et al, 1995; Schulze-Lutum et al, 1994; Lee et al, 1996). This protein 
is important in the regulation of the cell cycle in response to DNA damage and may be 
required for apoptosis in some cell types (Kastan et al, 1991). It is possible that GCV- 
triphosphate activates cell death pathways which require p53. The anticipated use of the tk /  
GCV system is for cancer treatment, but many cancers, for example >50% of non small cell 
lung carcinomas, lack p53 (Ngugen et al, 1997) and it is important to determine whether tk+ 
cells without functional p53 are killed by GCV.
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B95 fibroblasts are derived from a p53 knockout mouse (Alan Balmain, CRC 
Beatson). The p53 gene has been disrupted by insertion of a neoR marker. The neo gene is 
expressed and the B95 p53' cells are resistant to G418. Therefore these cells were transfected 
with a plasmid carrying tk and hygromycinR genes. Clones resistant to 50p,g / ml of 
hygromycin B were picked and screened for sensitivity to 5pM GCV. A clone with a similar 
growth rate to that of the parental cells was expanded. Survival of separate cultures of tk+ and 
tk' cells was measured after treatment with increasing concentrations of GCV, as described in 
section 2.2.7. (figure 3.10.A). Wild type cells were unaffected by 10p,M GCV, while tk+ cells 
were completely inhibited. Calculating the IC50 from each survival curve showed a 
therapeutic index of approximately 500. This was less than the values achieved in previous 
experiments (table 3.1.) but killing of transfected cells was effective. This difference is most 
likely explained by a lower tk activity, but this was not measured.
B95 p53' tk+ cells were killed by low concentrations of GCV, but the mechanism of 
cell death may be important. For example, if cell death occurs only by apoptosis, then killing of 
p53' tumours may not be as effective as that of p53+ tumours, because apoptosis is an 
immunologically silent event. The importance of the immune system has been described 
previously (section 1.11.5.). Therefore, if death of p53' cells occurs in a different way to p53+ 
cells, studying p53* tumour models may be more suitable.
B95 p53‘ (tk+ and tk') cells were treated with GCV for times of up to 48 hr, then 
genomic DNA was isolated. Changes in the integrity of DNA were investigated by an a [32P]- 
dCTP end labelling method (section 2.6.2.). Untreated cells and tk' cells showed no evidence 
of DNA damage (figure 3.10.B.). However, laddering and smearing were seen in GCV treated 
tk+ cells which indicates that apoptosis and necrosis occurred in parallel (figure 3.10.B).
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GCV treatment of B95 p53" tk+, L929 tk+, CarB tk+ and BHK tk+ (section 3.3.4.) cells 
results in similar patterns of DNA degradation, suggesting that death involves the same 
mechanisms. It therefore seems likely that the p53 status will not affect the outcome of the tk / 
GCV strategy for cancer therapy.
3.3.8. Effective range of the tk / GCV bystander effect
It seems reasonable to conclude, from the experiments of the previous sections, that 
transfer of toxicity in the tk / GCV bystander effect occurs via gap junctions, by metabolic co­
operation. Both donor and recipient cells must be able to form functional gap junctions. In 
addition, even when junctional communication is relatively low, high levels of tk activity can 
result in extensive bystander killing. Results have also demonstrated that GCV treatment of tk' 
cultures mixed with 2.5% tk+ cells can kill up to 65% of the cell population. This is an 
important observation but does not provide information on the effective range, the number of 
cell diameters, that toxicity can travel. It is likely that local or systemic delivery of a vector 
carrying the tk gene will lead mostly to transduction of cells near the injection site or near 
capillaries of solid tumours. Determining the distance toxicity can spread may, in conjunction 
with mixed culture survival assays, allow predictions of how effective treatments might be in 
vivo. The experiments below were designed to determine the effective range of tk /  GCV 
bystander killing.
Colonies of tk' cells were grown to increasing sizes and the effect of adding tk4 cells, 
with GCV, on colony survival was measured. A full description of the assay is provided, step 
by step, in figure 3.11. It is important to note that tk' cells were transfected with the |3gal 
lineage marker (tk'pgal4) but are referred to as tk' cells. Conversely, tk4pgal' are referred to as
92
3r.
<’
r-
o
r.
r  —: 3
o'
75
£ o
o
r t“  C f C  ~  '  y -  —  —
— , z .
s
0
6 J 0X • 3
c r.0
0 Q
z C LZ
—
T 3
1 O
0 O O C
O 'O
" ~ *
r .
< ’ O
p O 3
— [ 3r . 3
3 O ;
“ r r o
O S £
2 c 3— >
z 3
s ' 3 —  ■
0 O 3
z ? r
3
O W3
~ n C LO3 < O
3
0
3
0;
O
HI
0
z C L
3 M  .
3 3
C L
O t o
< ’
0 W * E
n O '
3 O
r r o * O
0 S
z
3 *
O 3
? i O
3 3z — .
3'
0 C - -
0 H2
o ’ 03
* < —
3  1
r. 3
1 1
O  cr
^  r ' 
5  I
' HI
§  §: 
O  3o rro 
< —.
■3
O
£o
o
o3C rC
c l
a.
c l
75
o  a.
2 3
I  Q^ n
o' <
T3
CT _
3"
s
3
3
c l
3
_c
3  t O
o o
1 - 1
o r.
S  =
^ J
—  5
ST  c l
^  t o
g  €
£  2  
~ (—3 ‘ o o ~
CL 3
>—. 3 
G  3  
~  C l  
r.
rg 2.
+ “
r-  ^2. o
2“ ^  2  O O O *2
3O
c l
*8 a ' 
=
2n —
75 J
8  i
o -1
Cl. "G_ 
CL 3
££. <zc o O
—  • r .
2o
C L
o
C l
5-oo;
£o
3
75
B.3 'o
CL
C Lo
te ?  5
- . 2 1
G  5 «  c -
B 3» 
o3r.
3
3 *O
3
3 *
3
1
r. o
3
HIrro o
3_
ET _
3 .  —  O  3
£
=  2 3
^  3 o
-  t o  
3 *O ^_ o:
7:
CL O-  3
s j  o ;  
■CO g.
rS r/
3 ' >
s  r-  5
3 1 5 .  z .
Z L  3  3
u » r. 0
" 0 0 t o 3H  r r o  
O  ^ * 3
S
O
3
C L
3
O
+
n 3
— . ZL c r 3
O
3 5 * c r
E c * 5
—  •
3' C / l IO
3* 0 “ 0r r o 3
- G _ 0 0 +
3
Oz
r . " 3 _
3
< 0
T 3
r r o
3 _
t o c /^ « v r .■ ' L L - - 3 0
* 2 •
O .
L 3
^  H c r
On
<
3
c r
3
z " O
O
3O O C L
£ C L
pz C r c r
O
C L
3
C L
C L
3 ' E .
5 '
0
3
O
C L H £ - C L
3O
r .
£
C 3 O
o _ 3o c X1
v T
c r y r r o H T
H Tp f
s ’
0
£3 |
—> 3 © 0
0 C L
7;oo
CLo
CL
o
CL
o
CL
1 J
-  I
7T  cr
■CD 0TC 3
^■3+ t;
O £ 
2,
“  3
g i2 rrc 
O 3*
P H 2 “
0 1C l  “
^  fro 3- c
“  f5
1  c l
o
0  3  
g S
—  • y
1  3
3  o
-p 2
*  G  
2. £
H -51 
- .  to*S« C 
P 3y; f t
o; L*
r r o  r *  o 
3 o >75
75o
75
75
& o
3 3
3O
3O
3.  y >
cr
C L
r r o
£
3
3o
3
2L Cr 
Zi o 
CT *
X ?s
! l— 3
"3
3  ^
2 g
3 lL
2  r :
a 2
3 ‘  O
3
3 3
^  tg
3 o
3*O
r.
2. O
13
0 y: 
2 -
1  i -3" £2
£  s .
p. p- 
2! ^
cfu (% rel. to 0|lM cont) 
° o o o o o r o ^ c >
0 0 0 0
oc
©
2  5
I  ”o o =■
-  i.
P =as rt
3 5*O 3 
3 ©■ ^ CJ
t© sr
© ^ 
= S.
©■
^  X©0 cr©—5
1 P+/  ry
85 j?
f/C
3
■3
^  r r o  
C lo + = o
- •  2. 
“
3* 75oo
CLo
3 -  C L
2  =2 
§  J?
"G H£-
as o 3 -to i .  2
1 z
^  g.
■g O
2  £■
o c
75
n
^ &3' v:
3  2.
Of o
£. o
3  C L
M
t o
t o
to
U»
I I
11 B.
g  =
,-i iA o;
lZ —N*O
'Ol
02
74
7
7
tk+ cells. As described in figure 3.11, the presence of colony forming units in “20p,M test” 
indicates initial colony size (step 3) exceeded effective range of toxicity from tk+ cells.
Cultures of L929, CarB and BHK cells were investigated. Representative results for 
L929, which were controls since there is no bystander effect with this cell line, and BHK are 
shown (figure 3.12.). Initial average colony size was measured from 20 colonies and used to 
determine the effective range of the bystander effect (figure 3.12.A). Colony density was 
important since tk+ cells can settle and grow amongst a diffuse colony which would result in 
spread of toxicity from tk+ cells within a colony. Therefore the range of the bystander effect 
can only be determined when tk+ cells settle at the periphery and this occurred when colonies 
were compact (see below).
In L929 control cultures, all colonies, even those small and diffuse, were unaffected by 
GCV treatment (figure 3.12.B) and this shows that any reduction of survival in BHK tk' cells 
was not due to an artefact introduced by the experimental design.
BHK tk' colonies were an average of 0.8-, 0.9- and 1.2-mm in diameter at the time of 
treatment and represent intervals of 24 hr of growth (figure 3.12.A). Treatment of the smallest 
colony (0.8mm) resulted in complete killing which was not unexpected since 75% of the 
colonies appeared diffuse and tk+ cells will have settled with the tk' colonies (see above). 
However, when tk+ cells were added after a further day of growth, when the colony size was 
0.9mm, and 90% appeared compact, GCV treatment still killed all the tk' cells (figure 3.12.B). 
Colonies of 1.2mm in diameter were not completely inhibited and a minority of cells survived, 
indicating the effective range had been exceeded. Further increases in colony size, before 
addition of tk+ cells, resulted in more tk' survivors. Therefore the m ax im u m  distance that 
toxicity could be transferred was approximately 0.5mm (1mm diameter) and since BHK cells 
were estimated to be =20pm across, this suggested that passage through »25 cells was 
achieved.
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Figure 3.12. The effective range of the tk / GCV bystander effect in BHK cells is approximately 25 cell 
diameters. This experiment was performed as described in figure 3.11. Photomicrographs [L929 (A):
BHK (A)] show representative initial colony sizes (bar 0.2mm). Values represent mean diameter +/- SE 
of 20 colonies (measurements taken from extremities). Colonies were scored as compact or diffuse (given 
as % comp.) and is a qualitative assessment. L929 (1) and BHK (1) are scored diffuse. L929 (3) and BHK 
(2) / (3) are scored compact. (B) Following the addition of tk+bgak cells and GCV treatment, the ability 
of tk-bgal+ cells to form colonies was determined. Viability of L929 tk'bgarf is not reduced compared 
to control. This demonstrates that there is no bystander effect in these cells. BHK tkbgarf colonies which 
are compact but under 1.2mm in diameter are completely inhibited after treatment. This demonstrates that 
in BHK cells colonies of up to 0.5mm radius (-25 cells) can be inhibited by addition of excess tk+ cells 
combined with GCV treatment.
It is possible this result was distorted by tk+ cells settling on, or within, tk' colonies. If 
this did occur then toxicity would have been transferred to the colony from internal and 
external tk+ cells and survival of tk" cells would be reduced, even in large colonies. However, 
this did not occur and when colonies become sufficiently large, they survived (figure 3.12. 
BHK B-3).
In separate studies using the reverse strategy, CarB tk+ colonies were grown, then tk' 
cells were added. GCV treatment killed tk+ and some tk' cells leaving a section of the tissue 
culture plate without cells, showing that toxicity can spread effectively into the tk' cell 
population. However, this was not seen in BHK cultures where tk+ cells are killed, but residual 
tk' cells formed a complete monolayer. Presumably, due to the faster growth rate and possiMy 
migration rate of BHK cells, the area of tk+ and tk' cells that had been cleared, was rapidly 
repopulated. The limited data available from these experiments, are consistent with the 
estimate of 0.5mm as the effective range of the bystander effect, under these conditions.
3.4. Discussion
The nature of toxicity produced by tk+ cells treated with GCV dictates the mechanism 
of transfer to cells, without the suicide gene. The tk+ cells studied here do not release a soluble 
toxic factor, such as cyclic GCV-MP or a cytotoxic cytokine. GCV-phosphates cannot cross 
the cell membrane and a more specialised transfer mechanism is required. This could involve 
direct cytoplasmic continuity through gap junctions or transfer based on release and uptake of 
vesicles containing cytoplasmic components. Such vesicular transfer is not normally detectable 
but may become more significant as cells degenerate during apoptosis (Cece et al, 1995; 
Hughes et al, 1996). If vesicles were involved, it is likely that transfer would occur by ■ 
phagocytosis rather than fusion. This would result in vesicular contents ending up, not in the
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cytoplasm, but in the lysomal compartment, still leaving a membrane (s) to cross to reach the 
cytoplasm. Despite such uncertainties, some mechanism based on vesicular transfer is often 
invoked as a possible basis of the bystander effect in the tk /  GCV system (Freeman et al, 
1993; Samejima and Mercelo, 1995).
The results here argue in favour of transfer of GCV metabolites via gap junctions for 
the following reasons. Cells that did not form gap junctions did not show a bystander effect 
(section 3.3.1.). Transfer of toxicity occurred before there was evidence of apoptotic 
degeneration (section 3.3.4.). The progress and extent of apoptosis (and presumably any 
vesicle formation) were similar in all cells examined, including those that showed no bystander 
effect. There was no detectable transfer of tk enzymic activity and it seems unlikely that 
released vesicles could selectively capture only particular cytoplasmic components. The 
bystander effect was absent in mixed cultures of cells that can form gap junctions and cells that 
cannot
These data are consistent with a recent report (Hamel et al, 1996) that showed PA317 
(mouse fibroblasts) tk' cells can engulf cytoplasmic and nuclear material released from tk+ cells 
but toxicity is transferred before these events occur. In addition these authors demonstrated 
that tk+ cells preincubated with GCV for 2 hr had a diminished capacity to cause bystander 
killing of cells added subsequently, although phagocytosis still occurred.
The correlation between the tk /  GCV bystander effect and gap junctions would be 
enhanced if it were possible to selectively modulate communication. However, chemical 
inhibitors are non specific (Nambu et al, 1989; Samejima and Mercuelo, 1995) and down 
regulation of Cx43 protein levels with antisense sequence had no detectable effect on GJIC of 
BHK cells (section 3.5.5.). Previous efforts in the laboratory to introduce communication into 
L929 and MCF-7 cells by expression of genes involved in gap junction formation have failed. 
For example, expression of E-cadherin in L929 cells (which express connexin 43 but not E-
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cadherin) or connexin 43 in MCF-7 cells (which express E-cadherin but not connexin 43) had 
no effect on junctional communication. Gap junction formation in the cells studied here cannot 
be regulated by introducing or inhibiting one protein. Formation is more complex and a 
factor(s) that is presently unidentified may be involved.
It is possible to increase the level of communication in cells that are poorly coupled. 
However, increasing coupling in CarB cells by transfection with E-cadherin was not associated 
with an increase in bystander effect. This is in contrast to other reports that have shown a very 
strong correlation between level of communication and bystander effect (Fide et al, 1995; 
Elshami et al, 1996) and that increasing coupling of Hela cells by transfection with Cx43 can 
increase the bystander effect (Mesnil et al, 1996).
It is possible that the differences between the results presented here and these reports 
are due to differences in tk activity. In section 3.3.2. a strong correlation between level of tk 
activity and bystander effect was identified and this is consistent with data published by Chen 
et al (1995a). This suggests that in the cell lines studied here, high levels of tk activity prevent 
gap junctional communication from being a limiting factor in transfer of toxicity. This would 
be consistent with the high rates of transfer that can occur through gap junctions. For 
example, transmission of action potentials within excitable tissues, results in rapid changes 
(<msec) in ion concentrations through gap junctions while HPRT" cells, cultured with HPRT+ 
cells, are able to maintain normal growth rates in medium containing aminopterin and 
hypoxanthine by acquiring all the purine nucleotides required for RNA and DNA synthesis via 
the junctional pathway (review, Pitts and Finbow, 1986 and see Pitts, 1971). The limiting 
factor may now be uptake of GCV by tk+ cells or production of GCV-TP and incorporation 
into DNA in tk' cells.
The reports showing a correlation between bystander effect and communication did 
not investigate the level of tk activity. If levels of tk activity were low, then concentration
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gradients of GCV-phosphates will not be steep. In this case, an increased rate of exchange of 
small molecules between cells that are well coupled may facilitate bystander killing. 
Alternatively, if the number of gap junctions is sufficiently low it seems inevitable that transfer 
must become rate limiting, whether there is high or low tk activity. Increasing communication 
would then be an advantage. This may be the case for Hela cells where communication is 
increased by 40 fold (0.8 to 35 cell spread) with introduction of Cx43 (Mesnil et al, 1996).
Communication in tumorigenic cell lines is often reduced compared with normal cells 
taken from the same tissue (section 1.12.2.) and vectors that can achieve very high levels of tk 
expression will be required i n  v i v o . If high levels of tk activity cannot be achieved, then 
delivery of a combination of the tk gene and genes involved in gap junction formation may 
enhance the bystander effect. Recently it was shown that tumour cure occurred more often 
when mice" were inoculated with mixtures of C6tk+ and C6tk' glioma cells that also had 
enhanced communication through transfection with Cx43 (Dilber et al, 1997).
It is likely, however, that below a certain threshold of tk activity, the bystander effect 
will be ineffective since there is a correlation between tk activity and bystander killing. It is 
also possible that low levels of tk activity will fail to lead to any cell death in communicating 
cultures since tk" cells may protect tk+ cells (Wygoda et al, 1997). In this report, the authors 
suggested that cells may be tolerant to low levels of GCV-TP and if tk activity is low, toxic 
metabolites may become sufficiently dispersed and diluted within a communicating culture, to 
prevent killing.
An issue that should be considered if genes involved in gap junction formation are 
introduced to tumours is disruption of communication compartments. Use of the tk /  GCV 
system to treat experimental tumours in animals is accompanied by little damage to normal 
surrounding tissue (Culver et al, 1992; Mullen, 1994). This is consistent with transfer by a gap 
junctional pathway. The body is divided into communication compartments. This results in
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effective coupling of cells by gap junctions with in, but not between compartments. For 
example, cells in the dermal and epidermal communication compartments of new bom mice 
are coupled (5 min dye spread: >500 or 25 cells, respectively) but only rarely does dye pass 
from one compartment to the other (Kam et al, 1986). It now seems likely that for tumour 
formation, cells must also form separate communication compartments (section 1.12.2.) and 
spread of toxicity from tk transfected tumour to normal cells will be minimised. Introducing 
genes such as connexin 43 may reduce such a barrier which will lead to spread of toxicity to 
normal tissues. Whether this would result in more extensive normal tissue damage would need 
to be investigated.
98
Chapter 4. Results - Analysis of the tk '/ GCV system in vivo
4.1. Introduction
Studies by others, using the tk /  GCV system i n  v iv o , have demonstrated the presence 
of a bystander effect and when only 10% of cells express the tk gene, tumours can be cured 
(Culver et al, 1992). These experiments were performed in immune competent animals and the 
bystander effect is likely to have been attributable to a combination of the immune system, 
damage to tumour vasculature and to transfer of toxicity by gap junctions. The immune system 
has been shown to play an important role in tumour cure (Vile et al, 1994b) but how important 
is junctional communication? Do bystander effects in culture correlate with tumour regression 
in  v i v o ? If a correlation could be established then it might be possible to use cultured cells to 
evaluate the effectiveness of suicide gene delivery systems.
The results in chapter 3 showed that, in culture, L929 cells did not communicate and 
did not show a bystander effect, whereas CarB or BHK cells were coupled and bystander 
killing was seen. If a similar pattern arises in nude mice, where the role of the immune system 
is minimised, it would suggest a correlation between culture and i n  v iv o  bystander effect. This 
would reflect the importance of gap junctions in bystander killing and future efforts for the 
clinical application of this system should be focused on increasing tk expression or 
communication in tumours. However if a correlation is not seen, then ways of enhancing the 
immune response, or the use of other enzyme prodrug systems should be investigated.
99
4.2. Analysis of the tk / GCV bystander effect in vivo.
tk+-|3gal" and tk'-|3gal+ cells from L929, CarB and BHK lines were used to study the 
bystander effect in nude mice. The presence of the |3gal marker should allow tk'-|3gal+ cells to 
be located in tumours that fail GCV treatment. For simplicity tk+-|3gal" and tk'-|3gal+ cells will 
be referred to as tk+ and tk".
Initially the time course of tumour formation of tk+ and tk" cells was determined in 
pilot studies. CarB cells grew aggressively in  v i v o , requiring 4 days to form palpable tumours, 
while L929 and BHK cells required approximately 10 days. Based on tumour volume, tk+ and 
tk" cells, for each cell line, grew at a similar rate i n  v iv o . This could not be pre-judged from the 
earlier i n  v i t r o  studies, since cells with similar doubling times in culture may differ i n  v i v o  
(Iwadate et al, 1996). These pilot studies also showed that intraperitoneal GCV injections did 
not cause noticeable discomfort to the animals and total body weight remained approximately 
constant.
To investigate the bystander effect i n  v i v o , separate or mixed populations of tk+ and tk" 
cells were used to induce tumours in nude mice and the effect of GCV treatment on tumour 
volume was monitored.
From studies in culture (Chapter 3) and i n  v iv o  (Culver et al, 1992), it has been shown 
that a large proportion of cells can be destroyed when only 10% of the population are tk+. 
Based on these observations, mixtures of CarB tk+ and tk" cells containing 0%, 5%, 10%, 
50%, and 100% tk+ cells were chosen. Only one PBS treatment group was included (100% 
tk*). Pilot studies had already demonstrated that, in a limited number of animals, growth rates 
of tk+ and tk" tumours were similar, so it was unlikely that tumours derived from mixtures of 
these cells would have different growth rates. The results below show that the response of 5% 
tk+ and 10% tk+ groups was similar to GCV. In subsequent experiments with L929 and BHK
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cells, the 5% tk+ group was omitted. These omissions do not affect the interpretation of results 
but reduce the number of animals required. 8 to 10 animals were included in the groups for 
each cell mixture.
Nude mice were inoculated at two sites with suspensions containing 0% tk+, 5% tk+ 
(CarB only), 10% tk+, 50% tk+, or 100% tk+ cells. Two groups of the 100% tk+ animals were 
included, one for injection with GCV and one for injection with PBS. The animals were then 
left until tumours became palpable. Daily intraperitoneal injections of GCV (45mg /  kg) or 
PBS (100% tk+ group only) were initiated (termed day 1) and continued for 7 days. Tumours 
were measured during and after treatment, in two dimensions with callipers and the
A “3
approximate tumour volume, based on the volume of a sphere ( h  nr ), was calculated, then 
plotted against time (figure 4.1). The survival data were based on tumour volumes <500mm3 
and mice with tumours exceeding this limit were terminated.
L929, CarB and BHK tumours containing 0% tk+ (100%tk) cells, treated with GCV, 
or 100% tk+ (0% tk'), treated with PBS, showed similar growth rates (figure 4.1.), which is 
consistent with culture data where tk' cells are relatively insensitive to GCV. With L929 
tumour bearing animals, GCV treatment did not result in a significant difference in survival 
between 0% tk+, 10% tk+ and 50% tk+ groups where animals were terminated on days 10, 10 
and 11, respectively (figure 4.1). L929 100% tk+ (GCV) tumours regressed completely (no 
palpable lump) by day 5, but were not cured since all tumours recurred by day 22 and all 
animals were terminated at day 30 (figure 4.2.A.). These data, for L929 tumours, directly 
correlate with the culture data (section 3.3.1.) showing no bystander effect. The recurrence of 
100% tk+ tumours is investigated further in section 4.3.
Animals with tumours formed from CarB 5% tk+ or CarB 10% tk+ cell mixtures 
showed an increase in survival of 9 days (to day 14), compared to those with the 0% tk+ 
control tumours, which where were terminated on day 5. When half the inoculation consisted
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Figure 4.1. GJIC plays a role in the tk / GCV bystander effect in vivo. Tumours were induced in 
nude mice by injecting separate or mixed populations of tk+ and tk' cells subcutaneously into each 
flank (105 cells / site). The study invo lved ten animals per group for CarB and 8 animals per group for 
L929 and BHK tumours. After 4 to 10 days tumours had grown to approximately 3 to 5 mm in diameter.
At this time intraperitoneal injections of GCV (45mg / kg, once daily) were initiated and continued for 7 
days (bars). Approximate tumour volumes were calculated from the average of two measurements (4/3ITr3). 
Animals were removed from the study when the total tumour burden exceeded 500mm3. In the BHK study 
animals with tumours containing 50% tk+ or 100% tk+ cells (treated with GCV) regrew at different times. 
The arrows indicate when animals were removed from the study due to excessive burden and the values 
indicate the number of animals remaining in the group. These data demonstrate that no bystander effect 
was seen in tumours which lack GJIC (L929), whereas tumours which communicate (CarB and BHK) 
did show an effect.
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of CarB tk+ cells, animals survived until day 20 (figure 4.1). The tumour growth curves (figure
4.1.) indicate a bystander effect i n  v i v o , which correlates with that seen in culture. With CarB 
100% tk+ tumours, GCV caused regression, but not cure, and animals were terminated on day 
27 due to tumour burden. This growth pattern, of regression then regrowth in these CarB 
100% tk+ tumours, is similar to that seen with GCV treated 100% tk+ L929 or 100% tk+ BHK 
tumours (figure 4.1).
Animals with BHK 10% tk+ (GCV treated) tumours survived 4 days longer (to day 15) 
than controls (day 11), and the growth curves suggest a weaker bystander effect than that seen 
with CarB cell mixtures (compare 10% tk+ CarB and 10% tk+ BHK in figure 4.1.). Growth of 
BHK 50% tk+ tumours, treated with GCV, was more variable. For example, with BHK 50% 
tk+ (GCV treated), animal 1 was terminated on day 17, six days after the controls, but at this 
time animal 6 had no palpable tumours and survived for a further 26 days (figure 4.1.; figure
4.2.C). A similar variation was seen with BHK 100% tk+ (GCV treated) tumours, where most 
tumours regressed (no palpable tumours) completely by day 11, but animal 5 was terminated 
on day 38 whereas animal 1 survived until day 57 (figure 4.2.D). With L 929,100% tk+ (GCV 
treated) tumours, variation was less pronounced (figure 4.2.A), with tumour regrowth 
occurring from day 15 to 22 and by day 30 tumour volume varied from 14mm3 to 450mm3 (32 
fold). In contrast, GCV treatment of CarB 100% tk+ tumours resulted in regression until day 
20 but at the end point of the experiment (day 27), variation in volume was only 6 fold (figure
4.2.B).
The irregularity of growth in some groups did not correlate with initial size. For 
example, with L929 100% tk+ (GCV treated) tumours, the initial volume for animal 7 was 
28mm3 but at day 30 was 14mm3, while over the same period burden of animal 6 increased 
from 0.5mm3 to 449mm3 (figure 4.2.A). Variations in growth rate of tumours within the same
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Figure 4.2. Recurrence of GCV treated tk tumours occurs at varying times. Subcutaneous tumours 
were induced as described in Figure 4.1. Tumours containing 100% CarB tk+ cells regrew at very 
similar times (Day 20) whereas regrowth (increases in tumour volume after GCV treatment) within 
the other three groups varied (L929 100% tk+, day 15 to 22; BHK 50% tk+, day 7 to 22; BHK 100% 
tk+, day 17 to 39). Time of recurrence did not correlate with tumour volume at the initiation of GCV 
treatment.
animal were also noted. The tumours of one animal in the BHK 100% tk+ (GCV treated) 
group were initially of similar size, but at termination there was a 27 fold difference in volume.
These experiments have shown a correlation between the bystander effect seen in 
culture and i n  v i v o  for L929 and CarB cells. L929 cells did not show a detectable bystander 
effect in either setting, while CarB cells showed marked bystander killing. However, in culture 
BHK cells showed a bystander effect but the effect was less obvious i n  v i v o . In all experiments 
with 100% tk+ tumours, using this protocol (daily injections of GCV, for 7 days), there was 
regression, but the tumours were not cured. This is investigated below.
4.3. Analysis of tumours
GCV treatment of tumours containing increasing proportions of tk+ cells did not cure 
animals in the experiments described above. There are several possible explanations for these 
results. These include, inadequate concentration of GCV, inadequate length of exposure to 
GCV, exit of tumour cells from cell cycle during treatment or resistance to GCV through loss, 
mutation or methylation of tk gene or sequences required for expression (Christy et al, 1982; 
Moolten et al, 1990). To understand the tk /  GCV system more clearly, the reasons for tumour 
regrowth must be examined.
Results from experiments in culture (section 3.3.1.) have shown that to kill most tk+ 
cells, with low concentrations (lpM ) of GCV, continuous treatment with GCV was required 
for 5 days. This protocol also involved cell transfer and was based, in part, on colony 
formation. The i n  v iv o  treatment described above used 45mg /  kg GCV Lp., once daily, for 7 
days. In humans, the half life of GCV is 2-4 hr, and the peak plasma concentration, after Lv. 
infusion of lOmg /  kg GCV, daily, is «20pM (Markham and Faulds, 1994). Peak 
concentration in mice can be expected to be higher, due a 4.5 fold higher dose and a different
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method of delivery (i.p. injection produces higher peak plasma concentration of prodrug than 
Lv. injection; Huber et al, 1995), but the half life may be different. In addition, the 
concentration of GCV in the tumour might be expected to be lower than the plasma 
concentration. tk+ cells may be exposed to toxic doses of GCV for relatively short times and 
this suggests tumour recurrence may be due to an inadequate or an unsustained concentration 
of GCV in the tumour, with the consequent survival of the tk+ cells.
To examine the tk activity remaining in the tumours, the tk assay (section 2.4.3.) was 
calibrated and activity was shown to be proportional to the percentage of tk+ cells in mixed 
cultures of tk+ and tk' cells (figure 4.3.A). Lysates were prepared from tumour samples and tk 
activity measured (figure 4.3.B).
Activity (per mg protein) in BHK 100% tk+ tumours treated with GCV or PBS was 
close to that of tk+ cultured cells. This observed tk activity was consistent with the presence of 
the tk gene seen in Southern blot analysis (figure 4.4.Aii) and a similar GCV sensitivity, 
relative to BHK tk+ cells, when tumour cells were returned to culture (figure 4.4.B). This 
suggests that complete tumour cure failed because cells were not cycling, or the concentration 
of GCV was too low, and this suggestion was supported by subsequent experiments (section
6.4.) where GCV treatment using the same regime above for 14 (instead of 7) days can cure 
tumours expressing the tk gene.
The low levels of tk activity of tumours derived from the 10% tk+ or 50% tk+ L929, 
CarB and BHK cell mixtures suggests that more tk" cells survived than tk+ (figure 4.3.) and 
that bystander killing (in the CarB and BHK tumours) is less efficient than direct killing of the 
tk+ cells. It was hoped that these suggestions would be supported by x-gal staining of tumours, 
however, staining of replicate samples was not consistent, and it would be unwise to place 
much emphasis on these histological results.
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Figure 4.3. Analysis of tk enzyme activity in cells before and tumours after GCV treatment. (A) Separate 
or mixed cultures of tk+ and tk' cells were seeded (1 x 106 / cells) in 90mm plates at the ratios indicated 
above. 24 hr later cells were harvested and tk activity determined as described in section 2.4.3. Data 
represent mean +/- SEM of two independent experiments, each performed in duplicate.This demonstrates 
that percentage of cells with tk expression correlates to activity. (B) In all treatment groups tumours were 
not cured (see figure 4.1.). Tumours were removed, snap frozen and protein lysates prepared from 
tumours from each group, tk activity was analysed. Data represent mean +/- SEM activity from 3 
tumours, each analysed in duplicate experiments.
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Figure 4.4. The tk gene is lost from L929 cells in vivo. tk+ and / or tk' cells were used to induce tumours 
^described in figure 4.1. After treatment with GCV tumours regrew. Tumours were removed and 
presence of the tk gene analysed by (A) Southern blot analysis or (B) sensitivity to GCV in culture. (A) 15pg 
ofgenomic DNA was digested with SstI and Smal restriction enzymes, which releases a 700bp fragment of 
ik tk gene. DNA was separated by agarose gel electrophoresis (Ai) before transfer to Hybond N+ membrane. 
Aii) shows the autoradiograph after probing the membrane with full length 32P labelled tk cDNA (see 
Materials and Methods). (B) L929 or BHK cells were isolated from tumour samples and grown in culture.
Cells were seeded at 1 x 105 and 5 x 104 cells / ml, respectively, in 24 well plates. 24 hrs later cells were 
treated with GCV for 2 days. Survival was assayed using standard protocol (see Materials and Methods) and 
compared to untreated controls. Data represent mean of one experiment, performed in triplicate.
Analysis of CarB 100% tk+ tumours revealed that tk activity in GCV and PBS treated 
tumours was approximately 40% (8 pmoles l25I-IDC converted /  hr /  mg prot.) and 60% (12 
pmoles), respectively, of cultured tk+ cells (figure 4.3). Even though tk activity was lower, 
sensitivity of these tumour cells, after return to culture, to GCV was indistinguishable to CarB 
tk+ cells. This is, perhaps, not unexpected since previous results (section 3.3.2.) have 
demonstrated that BHK tk+ cells had a similar therapeutic index even when tk activity varies 5 
fold.
Due to the similar sensitivity of CarB 100% tk+ tumours and CarB tk+ cells or BHK 
100% tk+ tumours and BHK tk+ cells, the absence of tk activity in tumours produced from 
CarB 5% tk+, 10% tk+, and 50% tk+ cell mixtures can most likely be explained in a similar way 
to that for the BHK tumours.
These tk activity and GCV sensitivity data suggest that insufficient toxicity was the 
reason for the lack of BHK and CarB tumour cure.
From the L929 tumour groups, only 100% tk+ tumours, treated with PBS, had a 
detectable (<10% activity of cultured L929 tk+ cells) level of tk activity (figure 4.3.). These 
observations were consistent with analysis of the sensitivity of L929 tumour samples to GCV, 
after return to culture, where lOpM GCV, a concentration that kills all cultured L929 tk+ cells, 
killed 42% of L929 100% tk+ (PBS treated) cells and had no significant effect on the survival 
of GCV treated tumour groups (figure 4.4.B.).
Loss or reduced tk activity of L929 tumours may have occurred from disruption of the 
tk gene and /  or promoter, or from methylation of the promoter. The absence of the tk gene in 
all GCV treated L929 tumours and the presence of low levels of the tk gene in PBS treated 
L929 100% tk+ tumours suggests that gene loss caused resistance to GCV, hence caused 
recurrence in L929 100% tk+ (GCV treated) tumours (figure 4.4.A ii.).
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Together the results from these studies have shown that tumours expressing the tk 
gene were not cured with daily treatment of GCV for 7 days, and it is likely that this was due 
to insufficient exposure to GCV, and /  or resistance to GCV caused by loss of the tk gene. 
Stability of the tk gene varied between the cell lines studied, for example, loss occurred within 
20 days in L929 tumours but there was no significant reduction in expression after 60 days in 
BHK tumours.
4.4. Discussion
The intention of the experiments in this chapter was to determine whether a correlation 
exists between the levels of bystander effect seen in culture and that seen i n  v i v o . K there was 
such an association, the culture model would be a useful tool for evaluating important 
parameters for this form of cancer therapy, and the requirement for i n  v i v o  tests may be 
reduced.
The absence of a bystander effect in L929 cells, in culture, correlates with lack of 
killing L929 tk' cells in  v iv o . These cells do not communicate in 2 dimensions (in culture) and 
from the experiments in this chapter, it appears that cells do not become coupled in a 3 
dimensional setting ( in  v i v o ) . This observation supports recently published results (Ishii- 
Morita et al, 1997) which showed that some cell types can be killed a bystander effect i n  v iv o  
(bystander sensitive) while others cannot (resistant). Mixing sensitive and resistant cells in 
culture, or as tumours, i n  v i v o ,  also prevented a bystander effect. When these cells were 
investigated in culture, metabolic co-operation only occurred between bystander sensitive tk+ 
and tk' cells (Ishii-Morita et al, 1997). These culture data also support those in section 3.3.6.
Although it is anticipated that the majority of tumours will be coupled (Yamasaki, 
1990), albeit at lower levels than corresponding normal tissues, it would be undesirable to use
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the tk /  GCV system when cells do not form gap junctions, since there would be no bystander 
effect. For example, tumours derived from some nerve cells and lymphocytes would be poor 
choices for this therapy since they are known not to form gap junctions. Consistent with this 
expectation, the tk /  GCV combination does not lead to bystander killing in lymphocyte 
cultures (Tiberghien et al, 1993; Rogers et al, 1996). However, analysis of cells in culture that 
have been explanted from tumours may produce artefactual results. For example, MCF-7 
breast cancer cells are uncoupled as a monolayer but when grown in 3 dimensions, on a 
collagen based matrix, the cells communicate, albeit to a limited extent, as judged by Lucifer 
Yellow microinjection (Quarrie, personal communication). Low levels of transfer measured by 
dye transfer (2 minutes) can permit extensive nucleotide exchange over periods of several 
hours (Pitts and Kam, 1985). To evaluate patterns of communication in human tumours, it 
may be necessary to explant tumour segments and measure coupling in 3 dimensions by 
Lucifer Yellow microinjection into cells in the tissue. Levels of communication in the dermis 
and epidermis of newborn mice have been determined in this way (Kam et al, 1986). This is 
not to say that junctional communication will be the only consideration in determining whether 
the tk /  GCV system should be used on a particular tumour. The importance of the immune 
system has been stated several times before (see section 1.11.5.).
From the studies here it is clear that there are some variations between the bystander 
effects seen in culture and those seen in  v i v o . Comparing CarB with BHK cells, the extent of 
bystander killing in culture is similar but in  v iv o  the effect in BHK tumours is weaker. This 
might be accounted for by a difference in growth rates. For example, in culture CarB cells 
have a longer doubling time than BHK cells, but i n  v iv o  CarB cells grow aggressively which 
may make them more susceptible to killing by a system that relies on DNA damage. In support 
of this suggestion, Iwadate et al (1996) demonstrated that GCV treatment of animals with 
established, slow growing 9L tk+ tumours, increased survival by 7 days compared to controls,
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whereas in parallel experiments, with fast growing 9L tk+ tumours, survival was increased by 
>60 days. Therefore the tk /  GCV system is likely to be most effective for fast growing, 
aggressive tumours and in those with slower growth rates, the introduction of cytokine genes, 
to stimulate the immune system, or the use of different enzyme prodrug systems, should be 
considered.
In the experiments described here, all tumours recurred, but those derived from CarB 
tk+ or BHK tk+ cells, retained high levels of tk activity. This suggests that cells were out of cell 
cycle or were insufficiently exposed to GCV. Support for this suggestion comes from Osaki et 
al (1994) who showed extending or increasing the dose of GCV can lead to tumour cure.
In some cases prolonging the treatment regime does not result in tumour cure (Cool et 
al, 1996). In these situations resistance to GCV may be acquired. It is possible that this arises 
from hypermethylation of the promoter (Veelken et al, 1996) or by gene inactivation, by loss 
or mutation. I n  v i v o , L929 tk+ tumours become resistant to GCV within 15 to 20 days of 
implantation. This is unlikely to result in resistance when tumour cells are targeted by 
recombinant adenovirus since GCV treatment is likely to commence with 24 hr of infection 
(Chen et al, 1995b). However transduction of tumours by recombinant retroviral particles 
generated from vector producer cells (vpcs; see section 1.15.1.) is optimal after 7 days (Culver 
et al, 1994) and the stability of the tk gene in the producer cell line w ill need to be assessed.
More of a concern, are treatments that may require long term tk stability. For example, 
transduction of lymphocytes to avoid graft versus host disease (GVHD; section 1.4.1.) or 
combined expression of m d r l  and tk genes in protection of stem cells against 
chemotherapeutic agents (section 1.4.2.). If resistance to tk arises in these instances then 
GVHD or cancer cells expressing multiple drug resistance protein may result. A potential way 
to avoid cellular resistance to prodrugs is to incorporate multiple suicide genes, a strategy 
which has proved effective in culture, where introduction of multiple copies of the tk gene to
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murine sarcoma cells correlated with reduced frequency of GCV resistant clones (Moolten et 
al, 1992b). Methods of achieving expression of several genes within cells will be considered 
further in chapter 7.
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Chapter 5. Results - Analysis of tp / DFUR and cd / FC enzyme / prodrug systems.
5.1. Introduction
For enzyme /  prodrug systems to function in cancer gene therapy the characteristics of 
each strategy will have to be appropriate for the target tumours. For example, the tk /  GCV 
system requires cells to be cycling and, for a bystander effect, gap junctional communication. 
Enzyme /  prodrug systems that do not rely on gap junctions will be better suited to some 
tumours, such as lymphomas. The pathways of the tp /  DFUR and cd /  FC systems produce 
FU as a common toxic metabolite. This base analogue can cross the cell membrane and using 
the cd /  FC combination, bystander effects that are independent of cell-cell contact, have been 
demonstrated (Hirschowitz et al, 1995; Lan et al, 1996). FU is subsequently converted to 
phosphorylated products that are not be able to cross the cell membrane (section 1.10.2.;
1.10.3.; figure 1.2.). If this conversion operates at a high rate then the level of membrane 
permeable metabolites may be reduced. However, the presence of gap junctions may allow 
additional, and perhaps more rapid transfer of toxic compounds, which may enhance the 
bystander effect.
The effectiveness of the tk /  GCV and cd /  FC systems have been compared (Rogers et 
al, 1996; Hoganson et al, 1996; Trinh et al, 1995) and in each report the therapeutic index 
achieved was greater with the cd system than with the tk system. It is important to determine 
whether the cd /  FC system is always superior because it will be desirable to choose the most 
effective system for cancer therapy. The tp /  DFUR combination has not been compared to 
any other enzyme /  prodrug system.
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This chapter investigates the efficacy of the tp /  DFUR and cd /  FC systems in a way 
that enables them to be compared to the tk /  GCV strategy. The potential role of gap junctions 
in transfer of toxicity in the tp /  DFUR bystander effect is also examined.
5.2. Growth characteristics of cell lines transfected with the tp or cd genes.
Introduction and expression of the tp gene to L929, CarB and BHK cells was not 
achieved as easily as with the tk gene. Transfection of L929 cells with a plasmid carrying the 
tp gene and NeoR marker produced G418 resistant colonies, but only a fraction (~ 15%) were 
sensitive to lpM  DFUR, a concentration that had no effect on survival of parental cells. 
Transfection of CarB and BHK cells, by this approach, did not produce any colonies that were 
sensitive to lpM  DFUR. For comparison, after transfection of these cell lines with the tk gene, 
>50% of G418 resistant colonies were sensitive to GCV.
Due to the difficulty in achieving tp expression in CarB and BHK wild type cells, 
alternative approaches, including subcloning of the tp gene into different plasmids and the use 
of retroviral transduction, were used to produce double transfected CarB tk+-tp+ or BHK tk+- 
tp+ cells (from CarB tk+ or BHK tk+ cells, section 3.2.2.). These double transfected cells 
would allow the’ same cells to be used to study the tp /  DFUR and the tk /  GCV systems, and 
for analysis of the potential advantages of combining the tk and tp systems (section 6.3.). For 
simplicity, the CarB tk+-tp+ or BHK tk+-tp+ clones that were used are termed CarB tp+ or 
BHK tp+, in this chapter.
For analysis of the cd /  FC system, L929 and BHK wild type cells were transfected 
with the cd gene (section 2.2.3.) and G418 resistant clones that were sensitive to 1000pM FC, 
were expanded.
i l l
The population doubling time of a selected BHK tp+ clone was similar to that of the 
wild type cells, but the rate of proliferation of an L929 tp+ clone was decreased while that of a 
CarB tp+ clone was increased (Table 5.1.; figure 3.1.). The variations that were seen can most 
likely be explained by clonal differences and will be considered in the results of the analyses in 
section 5.4. The levels of GJIC of these tp+ clones were measured by Lucifer Yellow  
microinjection, and found to be not significantly different (t-test, p>0.05) from those of wild 
type cells (Table 5.1.; figure 3.1.).
The population doubling times of the L929 cd+ and BHK cd+ selected clones were not 
significantly different (t-test, p>0.05) to the respective wild type cells (Table 5.2.; figure 3.1.). 
GJIC was not measured in these clones since studies which were dependent on the level of 
coupling were not performed.
5.2.2. Analysis of the tp / DFUR and cd / FC bystander effect in culture.
In order to make a comparison between the tk /  GCV, tp /  DFUR and cd /  FC systems, 
analyses of the latter systems were performed in parallel experiments to those used to analyse 
the tk /  GCV strategy (section 3.3.1.; section 2.2.7.). Treatment of tp+ cell lines with DFUR, 
at concentrations that had no effect on the survival of parental cells, led to almost complete 
cell death (figure 5.1.A.). In mixed cultures of tp+ and tp" cells, bystander killing of tp' cells 
was seen in cell lines with (CarB or BHK) or without (L929) GJIC. For example, when the 
culture contained 10% tp+ cells, lpM  DFUR killed 30% of L929 cells or 80% of CarB cells, 
while 10pM DFUR killed >90% BHK cells (figure 5.I.A .). These concentrations caused 
<15% cell death in untransfected cultures (figure 5.I.A .). The bystander effects in this system 
did, however, appear weaker than those in the tk /  GCV system and this can be seen more 
clearly by calculating the IC50s from the survival curves of each mixed culture (figure 5.I.B .;
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Table 5.1.). For example, in cultures containing 10% BHK tp+ cells, there was a 12 fold 
decrease in the IC50 with respect to DFUR, while in those with 10% BHK tk+ cells there was 
a 290 fold reduction in the IC50 with respect to GCV (figure 5.1.; Table 5.1.; Table 5.3.). 
Similar differences were seen between the therapeutic indices of these systems and this will be 
considered further in section 5.5.
From the cell lines studied, the weakest bystander effect, in the tp /  DFUR system, was 
seen using mixed cultures of L929 tp+ cells, where 10% tp+ cells reduced the IC50 by 6 fold 
compared with untransfected cells (Table 5.1.; Table 5.3.). It is possible that the presence of 
gap junctions in the CarB and BHK cell lines enhances bystander killing by transfer of 
phosphorylated toxic metabolites to tp' cells and this suggestion is investigated further in 
section 3.4.
Using the cd /  FC system, L929 cd+ and BHK cd+ cells were almost completely killed 
by 1000p,M FC, a concentration of prodrug that did not affect the survival of parental cells. In 
mixed cultures of 10% cd+ and 90% cd" cells, lOOOpM FC killed -70%  of the L929 culture 
and ~50% of the BHK culture. These bystander effects are seen more clearly as reductions in 
IC50 compared with untransfected cultures (figure 5.2.; Table 5.2.). Cultures containing 10% 
L929 cd+ cells showed a 23-fold reduction in IC50, but in those with 10% BHK cd+ cells, the 
reduction was only 6-fold. These variations were most likely caused by the higher cd activity 
seen in L929 cd+ cells (Table 5.2.). Increasing the percentage of cd+ cells in the culture caused 
a progressive reduction of the IC50 and cultures containing only cd+ cells showed a 
therapeutic index of >100 (figure 5.2.; Table 5.2.).
The above analyses have demonstrated that expression of the tp gene or the cd gene 
can sensitise these cell lines to the appropriate prodrug and in both enzyme /  prodrug systems, 
toxicity can spread to untransfected cells, irrespective of whether or not there are functional 
gap junctions. However, bystander killing in these systems was <10% as effective when
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Figure 5.1. Survival and IC50 of mixed populations of tp+ and tp cells. (A) Varying mixtures of tp+ 
and tp cells were seeded in 24 well tissue culture plates (L929, 1 x 105; CarB 1.5 x 105; BHK, 5 x 104 
cells / well). 24 hr later, cells were treated with DFUR for 2 days. After this time cells from each well were 
released with trypsin. Aliquots of the suspension were transferred to 96 well plates containing media and 
DFUR, as described in section 2.2.7. Survival was determined using the MTT assay. By calculation from 
each of the survival curves in (A), the IC50, with respect to DFUR, for each of the cell mixtures was 
calculated (B). Each data point represents the mean +/. SEM (bars) of two independent experiments, each 
performed in triplicate. L929 cells lack GJIC whereas CarB and BHK cells communicate. All show a 
bystander effect.
Cell line L929tp+ CarB tp+ BHKtp+
Population doubling time (hr) 23.7 ± 0.4 16.210.4 10 .910
GJIC 0 ± 0 3.410.5 11.911.0
IC50 - 0% tp+cells 14 + 5 4.010.1 29.5 18.5
IC50 - 10% tp+ cells 2.2 1  0.4 0.3410.03 2.410 .5
IC50 - 100% tp+cells 0.25 ± 0.05 0.0710.01 0.25 10.04
Bystander effect(0% IC50/io% icso) 6 .211 .2 11.911.1 12.111.0
Therapeutic index(0% IC50/ioo%
IC50)
5 4 1 9 6 3 1 1 3 116116
Table 5.1. Summary o f population doubling time, GJIC, bystander effect and 
therapeutic index in cell lines used to study the tp / DFUR system. Population 
doubling time was determined as described in section 2.2.5. Data represent mean ± SE 
from 2 experiments. GJIC has been determined by Lucifer Yellow dye injections as 
described in section 2.2.12. Data are from a minimum o f 10 separate, 2 minute, 
injections and represent the mean ± SE. IC50s. Bystander effect and therapeutic index 
have been calculated from the survival curves in figure 5.1. as indicated in the table. 
Data represent mean ± SEM of two independent experiments each performed in 
triplicate.
B’©u>■**
120
100
3ow 80
"oJu 60
> 40
C
3 20
0
^929 / L929 cd+ survival
- • -0 %  cd+
■*- 5% cd+
10%  cd+ 
hi- 2 0 %  cd+ 
50% cd+ 
h -  1 0 0 %  cd-+
10 100 1000 10000 
Cone FC (pM)
L929 / L929 cd+ IC50100000
10000
1000
100
0 20 40 60 80 100
% cd+ cells
3(/!
&
120
100.
80
60
40
20
0
BHK / BHK cd+ survival BHK/BHK cd+ IC50
h-0%  cd+ 
h-2.5%  cd+ 
-t- 5% cd+
10% cd+ 
-t-20% cd+ 
h- 50% cd+ 
-1-100% cd+
-------- 1---------1-------- 1 ' ^
0 10 100 1000 10000 
Cone FC (|lIM )
23
u
CJcoU
10000
1000
100
1 0  — i— i— i— i t i— i i t
0 20 40 60 80 100
% cd+ cells
Figure 5.2. Survival and IC50 of mixed populations of cd+ and cd' cells. (A) Varying mixtures of cd+ 
and cd' cells were seeded in 24 well tissue culture plates (L929, 1 x 105; BHK, 5 x 104 cells / well). 24 hr 
later, cells were treated with FC for 2 days. After this time cells from each well were released with trypsin. 
Aliquots of the suspension were transferred to 96 well plates containing media and FC, as described in 
section 2.2.7. Survival was determined using the MTT assay. By calculation from each of the survival 
curves in (A), the IC50, with respect to FC, for each of the cell mixtures was calculated (B). Each data 
point represents the mean +/_ SEM (bars) of two independent experiments, each performed in triplicate.
L929 cells lack GJIC whereas BHK cells communicate. Both show a bystander effect.
Cell line L929 cd+ BHKcd+
Population doubling time (hr) 23.7 + 1.4 11.5 ±0.5
Specific enzyme activity 1133 ± 29  (4) 413 ± 15 (4)
IC50 - 0% cd+ cells 8400 + 2100 7050 ± 950
IC50 -10% cd+ cells 400 ± 200 1125 ±75
IC50 -100% cd+ cells 31.5 ±3.5 65 ± 3
Bystander effect(0% IC50/io% icso) 24.5 ± 7 6.3 ± 0.5
Therapeutic index(0% IC50/ioo%
ICSO)
263 ±38 109 ± 11
Table 5.2. Summary o f population doubling time, cd activity, bystander effect and 
therapeutic index in cell lines used to study the cd / FC system. Population doubling 
time was determined as described in section 2.2.5. Data represent mean ± SE from 2 
experiments. Specific enzyme activity has been determined by a cd specific assay 
(section 2.2.4.). Activity represents pmoles 3H cytosine converted / min / mg protein 
and is stated as mean ± SE of the number of experiments is shown in parentheses. 
Untransfected cells had undetectable cd activity. IC50s have been calculated from the 
survival curves in figure 5.2. Bystander effect and therapeutic index have been 
determined from these values, as indicated in the table. Data represent mean ± SEM of 
two independent experiments each performed in triplicate.
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compared to the tk /  GCV system, in coupled cells, and this is considered further in section
5.5.
5.3. Transfer o f toxicity via the medium in tp / DFUR and cd / FC system s.
Previous reports have demonstrated the release of FU to the medium when cd+ cells 
are treated with FC (Huber et al, 1995). Results in the last section showed that transfer of 
toxicity to untransfected cells in the tp /  DFUR and cd /  FC systems was independent of gap 
junctions, and although it is likely that this was via the medium, it is important to investigate 
this suggestion in order to compare these systems with the tk /  GCV combination.
In medium transfer experiments, cultures of tp+ and cd+ cells were treated, for 2 days, 
with DFUR or FC, respectively, at concentrations known to produce a bystander effect. The 
medium was then transferred to untransfected cells and survival was measured in the same 
way that has been described previously for the tk /  GCV system (section 2.2.9.; section
3.3.3.).
Medium transferred from DFUR treated tp+ cells reduced survival of tp' cells by >90% 
in all the cell lines tested when compared to controls, where tp+ cells were cultured without 
the prodrug, or where tp' cells were treated with the prodrug (figure 5.3.A .). Similar results 
were seen in parallel experiments with the cd /  FC system (figure 5.4.A.).
Support for the above results came from the observation that separation of tp+ and tp' 
cells (figure 5.3.B.) or of cd+ and cd' cells (figure 5.4.B.) with an Anopore filter membrane did 
not prevent spread of toxicity to untransfected cells.
It can be concluded that toxicity was transferred via the medium and that cell contact 
hence gap junctions, are not required for a bystander effect in the tp /  DFUR or cd /  FC
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Figure 5.3. Transfer of toxicity in the tp/DFUR bystander effect through the medium. (A) tp+ cells 
were seeded (L929 and CarB, 1 x 105; BHK, 5 x 104) cells / ml in 24 well plates and treated with DFUR 
for 48 hr. The media from drug treated cells was transferred to untransfected cells and incubated 
for 2 days. Survival was assayed using standard protocol (see section 2.2.7.) and compared to survival 
of controls. Treatments in each experiment are summarised below the graph. (B) Untransfected cells 
were seeded (L929, 5 x 104; CarB, 7 x 104;BHK, 2 x 104) in 0.5 ml in 24 well plates. 0.02|xm filter 
inserts were placed in each well and an equal number of tp+ cells added to the insert. DFUR was added 
to the media and cells were incubated for 3 days. Survival was assayed using standard protocol and 
compared to control groups. Each data point represents mean +/- SEM (bars) of two independent 
experiments, each performed in triplicate.
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Figure 5.4. Transfer of toxicity in the cd / FC bystander effect through the medium. (A) cd+ cells were 
seeded (L929, 1 x 105; BHK, 5 x 104) cells / ml in 24 well plates and treated with lOOOpM FC for 48 hr. 
The media from drug treated cells was transferred to untransfected cells and incubated for 2 days.
Survival was assayed using standard protocol (see section 2.2.7.) and compared to survival of controls. 
Treatments in each experiment are summarised below the graph. (B) Untransfected cells were seeded 
(L929, 5 x 104; BHK, 2 x 104) in 0.5 ml in 24 well plates. 0.02pm filter inserts were placed in each 
well and an equal number of cd+ cells added to the insert. 2000pM FC was added to the media and cells 
were incubated for 3 days. Survival was assayed using standard protocol and compared to control groups. 
Each data point represents mean +/- SEM (bars) of two independent experiments, each performed in 
triplicate.
\systems. However these observations did not exclude the possibility that gap junctions could 
enhance the bystander effect and this is investigated below.
5.4. Role o f gap junctions in the tp / DFUR bystander effect.
The tp /  DFUR bystander effect was stronger in CarB and BHK cells, which have gap 
junctions, than L929 cells, which lack them (Table 5.1.). This difference may have been due to 
differences in level of tp expression or to the levels of junctional communication, tp is required 
for conversion of DFUR to FU, but also for the subsequent conversion of FU to 5- 
fluorouridine (FUR) and 5-fluoro-2’-deoxyuridine (FUdR), see figure 1.2. Cellular enzymes 
phosphorylate these compounds and the toxic products interfere with RNA and DNA 
synthesis (section 1.10.2). Elevating levels of tp activity by transfection is  likely to increase the 
rate of formation of FUR and FUdR, and if further reactions (which result in phosphorylation) 
are fast, then the level of metabolites that can leave the cell, across the membrane, may be 
lowered which could reduce the bystander effect seen. In this situation, the presence of gap 
junctions may enhance transfer of phosphorylated toxic compounds to neighbouring cells, 
hence enhance the bystander effect.
To test this hypothesis, L929 and BHK cells-were used to compare the tk /  GCV and 
tp /  DFUR systems. The tk /  GCV system acted as a control since gap junctions are required 
for transfer of toxicity. Mixed cultures of 10% tk+ or 10% tp+ cells and 90% wild type cells 
were seeded at high or low density (50 fold difference) and survival of cultures in response to 
increasing concentrations of GCV or DFUR, respectively, was measured (see section 2.2.7.; 
figure 5.5).
At high or low density, the survival of mixed cultures containing L929 tk+ cells, was 
not significantly different, which was expected since these cells are not coupled (figure 5.5.A.).
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Figure 5.5. Gap junctions do not improve the tp / DFUR bystander effect. 10% tk+ (A) or 10% tp+
(B) cells were mixed with 90% wild type cells to a high (L929, I x 105; BHK 5 x 104 cells / well) or low 
(L929, 2 x 103; BHK 1 x 103 cells / well) density in 24 well tissue culture plates. 24 hr later cells were 
treated with GCV or DFUR, as indicated, for 2 days. After this time cells from each well were released 
with trypsin. Aliquots of the suspension were transferred to 96 well plates containing media with GCV 
or DFUR, as described in section 2.2.7. Survival was determined using the MTT assay and compared 
to untreated controls. Each data point represents the mean +/_ SEM (bars) of two independent 
experiments, each performed in triplicate. L929 cells lack GJIC, whereas BHK cells communicate.
This contrasted to mixed cultures containing BHK tk+ cells, where the bystander effect seen 
when cultures were at low density was greatly reduced compared to that seen at high density 
(figure 5.5.A.). The bystander killing that was seen in cultures at low density is likely to reflect 
the cell-cell contact that occurs even in sparse cultures.
In mixed cultures of tp+ and tp' cells, the presence of junctional communication did not 
alter the bystander effect since survival of mixed cultures, at high or low density, was similar 
with increasing DFUR (figure 5.5.B.).
These results demonstrate that GJIC did not enhance the tp /  DFUR bystander effect, 
and it is possible that the differences in bystander killing observed initially, between the 
different cell types, were due to variations in levels of tp expression. Alternatively, the slower 
rate of proliferation of L929 tp+ cells may mean that in mixed culture with tp* cells, the 
proportion of tp+ cells becomes reduced as the assay progresses, which may result in release of 
lower levels of toxic metabolites to the medium, therefore reducing bystander killing.
5.5. Discussion
The results in this chapter have shown that toxicity in the tp /  DFUR and cd /  FC 
systems is transferred via the medium and is independent of gap junctions. These observations 
are consistent with previous reports using the cd /  FC system (Hirschowitz et al, 1995; 
Haberkom et al, 1996b) and with a recent report, investigating the tp /  DFUR system (Kato et 
al, 1997).
The data here have shown that in cultures containing 10% tp+ cells the IC50 is reduced 
by 5- to 10-fold compared with wild type cells, while in those with 100% tp+ cells, the IC50 is 
reduced by 50- to 100-fold. Similar reductions have been observed in other cell lines 
transfected with the tp gene (Patterson et al, 1995; Kato et al, 1997). The authors of these
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reports demonstrated that transfection with the tp gene increased activity by up to 100-fold 
compared to parental cells, however, the data presented here show that similar increases in tk 
enzyme activity lead to substantially larger increases in sensitivity to GCV. For example, BHK 
tk clones, with activities of >40 fold higher than parental cells, have a bystander effect of >100 
and therapeutic index of >1000 (section 3.3.2.).
The apparently consistent, limited enhancement of sensitivity seen in the tp /  DFUR 
system is disappointing because all of the studies, including those here, have achieved tp 
expression from a strong (CMV) promoter. The use of a tissue specific promoter is likely to 
produce lower levels of tp expression, which can be expected to reduce the bystander effect. 
There also appears to be a large variation in sensitivity of untransfected cells to DFUR. For 
example, the IC50 of CarB cells is 4|iM  while that of human epidermal carcinoma cells is 
250pM (Haraguchi et al, 1993). Even if transfection of the tp gene sensitised the latter cells by 
100-fold, the IC50 would only be similar to that of CarB cells. Such a marked variation in the 
sensitivity of parental cells to GCV and FC appears not to occur, for example, in the cell lines 
studied here, there is <3-fold variation and a survey of the literature suggests this may be true 
for other cell lines of different origins.
These observations suggest that the use of the tp /  DFUR system for cancer gene 
therapy may be restricted to tumours which have high levels of endogenous tp activity, for 
example, those of the breast, cervix and stomach (Yamamoto et al, 1996), where further 
increasing the level of tp expression may be beneficial.
The studies here, using the cd /  FC system, have demonstrated a relatively weak 
bystander effect and a therapeutic index of <300, which contrasts to numerous previous 
reports where stronger bystander effects and higher therapeutic indices were seen (Huber et al, 
1995; Trinh et al, 1995; Hoganson et al, 1996; Li et al, 1997; Kanai et al, 1997). In some 
cases, these differences may be accounted for by variations in the level of cd activity. For
117
example, expression of cd was 50- to 100-fold higher in hepatocellular carcinoma or breast 
cancer cell lines, after adenoviral delivery of the cd gene (Li et al, 1997; Kanai et al, 1997), 
compared with the cell lines studied here. However, the level of enzyme activity does not 
always explain differences in sensitivity, since transfection of a lung adenocarcinoma cell line 
with the cd gene (Hoganson et al, 1996) produced a similar level of expression, but a stronger 
bystander effect, compared to those seen in L929 cd+ and BHK cd+. It is possible that FU 
sensitivities of these cell lines are different
These observations highlight the importance of selecting an appropriate regime for 
treatment of different tumours. In the cell lines studied here, the tk /  GCV system is more 
effective than the cd /  FC system, while the latter strategy is more effective in other cell lines. 
In some tumours, the use of the tp /  DFUR combination may be more effective.
118
Chapter 6. Results - Combination of enzyme / prodrug systems
6.1. Introduction.
Clinical trials involving the intratumoural implantation of retroviral vector producer 
cells, in patients with glioblastoma multiforme, have demonstrated low transduction 
efficiencies (<0.2% of tumour cells) with the tk gene, and subsequent GCV treatment resulted 
in a reduction in tumour size in only a fraction of patients (Culver et al, 1996; Izquierdo et al, 
1996). For gene therapy to play a role in the treatment of cancer, it will be important to 
increase the transduction efficiency of tumour cells and to enhance the bystander effect.
Bystander killing in tk /  GCV system depends on gap junctions and the toxic 
metabolite that is transferred inhibits DNA synthesis, while in tp /  DFUR or cd /  FC strategies, 
toxicity passes through the medium and interferes with both DNA and RNA synthesis. It is 
possible that combining these systems, that have bystander effects operating by different 
pathways or that kill cells by different mechanisms, may enhance untransfected cell killing. The 
experiments in this chapter investigate the effect of combining the tk /  GCV system with either 
the tp /  DFUR system or the cd / FC system.
6.2. Combining the tk / GCV and tp / DFUR systems.
L929 cells do not form gap junctions and were excluded from these studies, since both 
suicide gene systems must have a bystander effect. Double transfection of CarB or BHK cells 
with the tk gene, and subsequently the tp gene, has been described previously in sections 3.2.2. 
and 5.2.
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Mixed cultures of 10% tk+-tp+ (CarB or BHK) with 90% wild type cells were treated 
with GCV and /  or DFUR for two days and survival was measured in the same way that has 
been described previously (section 3.3.1.; section 5.2.2.; section 2.2.7.). At high or low  
concentrations of prodrug there was no significant difference in survival between single or 
combined treatments, but at intermediate doses, an increased bystander effect was seen with 
the combined treatment (figure 6.1.). For example, lpM  GCV reduced survival of CarB mixed 
cultures (10% tk+-tp+: 90% wild type) to 28% and lpM  DFUR reduced survival to 33% but 
when combined, survival was reduced to 13%, compared to untreated controls (figure 6.1.).
There was a similar trend in 10% BHK tk+-tp+ : 90% BHK mixed cultures. No 
significant difference in survival was seen between treatment groups at high or low prodrug 
concentrations, but while separately, O.lpM GCV or lpM  DFUR did not cause a significant 
level of cell death in the mixed cultures, the combined treatment killed 50% of cells (figure 
6.1.).
The data from these cell lines show that combining the tk /  GCV and tp /  DFUR 
strategies can, in the right circumstances, lead to an enhanced bystander effect compared to 
treatment with only one prodrug.
Transfer of toxicity is via gap junctions in the tk /  GCV system and via the medium in 
the tp /  DFUR system. It is possible that high, local concentrations of GCV-phosphates are 
transferred to neighbouring cells, but FU in the medium may spread more uniformly to both 
near and distant cells. GCV may therefore kill the nearby cells more effectively, while the 
distant cells may be killed by DFUR. Alternatively, when one system is used alone, the 
concentration of toxic metabolites in a proportion of the cells may be too low to cause cell 
death but, by combining treatments, the level of toxicity may be raised above a threshold, 
killing additional cells. If this latter hypothesis is correct, it would be important to co-ordinate 
prodrug delivery so the peaks of toxic metabolite production coincide.
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Figure 6.1. Combining the tk / GCV and tp / DFUR enzyme / prodrug systems results in an improved 
bystander effect at intermediate prodrug concentrations. 10% CarB tk+-tp+ or 10% BHK tk+-tp+ double 
transfected cells were mixed with 90% parental cells in 24 well plates (CarB 1.5 x 105; BHK 5 x 104 
cells / ml). 24 hr later increasing concentrations of either GCV, DFUR or both were added to the 
media, as indicated in the graphs above. Survival was assayed using standard protocol (see section 
2.2.7.) and expressed as percentage growth inhibition of untreated cells. All data represent mean +/- 
SEM (bars) of two independent experiments, each performed in triplicate with the exception of CarB 
tk+-tp+ cultures treated with lpM GCV and / or lpM DFUR where data are mean +/- SEM of three 
independent experiments, each performed in triplicate.
\To test whether timing of prodrug treatment is important, survival of mixed cultures of 
10% CarB tk+-tp+ and 90% CarB cells, treated with GCV and DFUR, was determined in the 
same way as before (section 2.2.7.), but treatment was staggered. In some experiments, lpM  
GCV was added to cultures immediately (time Ohr) and lpM  DFUR was added 4, 8 or 24 hr 
later, while in others, the treatment regime was reversed (figure 6.2.). However, in both cases, 
addition of the second prodrug at times after the first failed to enhance the synergistic effect 
further. This may suggest production of toxic metabolites coincides most effectively when 
prodrugs are added simultaneously.
6.3. Combining the tk / GCV and cd / FC systems.
Combining the tk /  GCV and tp /  DFUR systems demonstrated that it was possible to 
modestly enhance the bystander effect. However, as discussed in chapter 5, application of the 
tp /  DFUR system is likely to be limited to a small proportion of tumour types and combining 
the cd /  FC and tk /  GCV strategies may be more useful.
To combine these systems in  v iv o  will either require two vectors, each expressing one 
gene, or one vector with both genes. At present, the most popular method of delivery i n  v i v o  
uses retroviruses but there is a limit to the number or particles that can be used before 
unacceptable toxicity arises. Therefore, two separate vectors, each at half the maximum dose 
will, theoretically, only deliver half as many therapeutic genes to die tumour compared to the 
one vector system. There are also other issues to be considered before designing a suitable 
strategy for combined gene delivery.
Separate expression of two foreign genes from their own promoters in retroviral 
vectors has been associated with interference. For example, in a recombinant retrovirus 
carrying neo and tk genes, expression of the tk gene was repressed when the neo gene was
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Figure 6.2. Varying time of prodrug application in the tk / GCV and tp / DFUR combined bystander 
effect does not result in improved cell killing. 10% CarB tk+-tp+ double transfected cells were mixed 
with 90% CarB cells in 24 well plates (1.5 x 105 cells / well). After 24 hr lpM GCV or lpM DFUR 
was added to the medium and at the times specified above (parentheses, hr) the second prodrug (lpM  
DFUR or lpM GCV) was added. 48 hr from the first prodrug treatment cells were transferred to 96 
well plates. Survival was assayed as described in section 2.2.7. and compared to untreated controls. 
The dotted line indicates the extent of cell death when both prodrugs are added simultaneously at time 
0 hr. Data represent the mean +/- SE (bars) of one experiment performed in triplicate.
expressed, and visa versa (Emerman and Temin, 1984). Ideally one promoter should drive 
expression of two genes.
cDNAs could be separated by an internal ribosome entry site (IRES) from 
encephalomyocarditis virus (a picomavirus). Transcription produces a bi-cistronic message 
and translation of the 5’-message is CAP dependent while peptide synthesis from the 3’- 
message is initiated from sequences in the IRES. This approach has been used successfully to 
co-express m d r l  and tk genes in culture but efficient expression of both genes is not 
guaranteed (Sugimoto et al, 1994). Potential use of the IRES will be discussed further in 
chapter 7.
The second approach joins the sequences of two cDNAs, in frame, and expression 
produces a fusion protein, which if successful, has the activity of both enzymes. However, the 
enzyme activities of the chimera may be reduced, compared to the native proteins, due to 
incorrect folding of the fusion protein, or by stearic hindrance of the active sites, which could 
decrease the value of such an approach. Currently the folding patterns of peptides cannot be 
predicted, and until tested, the feasibility of fusion proteins cannot be judged.
Another consideration is whether a longer transcript can be delivered efficiently by 
vectors. Retroviral delivery of a GCSF-ERES-tk/neo construct resulted in production of the 
cytokine, granulocyte colony stimulating factor, and also a tk-neo fusion protein (Veelken et 
al, 1996). This fusion chimera caused cellular sensitivity to GCV and resistance to G418, but 
the number of G418 resistant colonies was reduced by 50% compared to a GCSF-IRES-neo 
construct. This may have been due to incorrect folding of the fusion protein or an excessive 
transcript length.
Despite the potential problems, expression of some fusion proteins has been successful 
For example, fibrosarcoma cells expressing a tk-neo construct (see above) had both enzyme 
activities (Veelken et al, 1996) and when hygromycin phosphotransferase was fused to the N-
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terminus of tk (hyg-tk), NIH3T3 cells showed resistance to hygromycin and sensitivity to 
GCV (Lupton et al, 1991). Alternatively, when the cd gene was fused to the cDNA of the 
cellular marker, CD44, (CD44-cd) and used to transform E. coli cd" mutants, deamination of 
cytosine was as efficient as that of wild type E. coli strains (Asman et al, 1995). This suggests 
that fusion of proteins to the N- or C-terminus of tk, and the N-terminus of cd, did not cause 
stearic hindrance, at least in some cases. However, the pattern of folding of each fusion 
protein will be different and, as this cannot be predicted, tk-cd or cd-tk fusion chimeras were 
constructed. The strategy used for the cd-tk fusion is shown in figure 6.3. and by the same 
process, but using different primers, the tk-cd fusion was generated (section 2.5.5.).
The suicide genes in both constructs were separated by an Xbal restriction site, which 
is 6 base pairs in length, hence fuses the cDNAs in frame. The Xbal sequence translates to 
serine and lysine residues. Transcription of the chimeras was driven by the CMV promoter and 
the Kozak sequence was added to enhance translation (Kozak, 1986). The pCDNA3.1" 
expression plasmid also has a neo selection marker.
Transient transfections (calcium phosphate; see section 2.2.3.) with both constructs 
were performed to determine whether expression of these fusion proteins produced sensitivity 
to either, or both, prodrugs. Initial screening showed that killing of cells was achieved with 
10pM GCV or lOOOpM FC, but less cell death was seen with FC treatment in cells transfected 
with tkcd than with those transfected with cdtk.
Subsequent stable transfections with the tkcd construct failed to produce clones that 
were sensitive to either prodrug. It is possible that if only a small proportion of the tkcd fusion 
proteins were correctly folded, or if the activity of each molecule was low, then killing may be 
seen in transient, but not in stable, transfections. Transient transfection of genes results in 
more cells expressing higher levels of the construct than in stable transfections.
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Figure 6.3. Cloning strategy for producing the cytosine deaminase-thymidne kinase fusion chimera. 
The cd gene was amplified by PCR using primers with the sequence GCC GCC ACC ATG TCG AAT 
AAC GCT TTA CAA and GTG GTG TCT AGA ACG TTT GTA ATC GAT GGC TTC. The PCR 
product was cloned into the Invitrogen cloning vector (pCR II) and then subcloned to the expression 
vector pCDNA3.1\ The tk gene was amplified by PCR using primers with the sequence GAG GAG 
TCT AGA ATG GCT TCG TAC CCC and GTG GTG TCT AGA TCA GTT AGC CTC CCC CAT.
The product was cloned into the Stratagene pCR Script vector. Subcloning tk into pCDNA3.1 - cd 
generated a cdtk chimera, linked by an Xbal sequence and driven by a CMV promoter.
Stable transfections with the cdtk construct produced G418 resistant colonies and from 
30 cdtk clones that were picked, 27 were sensitive to lOpM GCV, but only 6 of these were 
sensitive to lOOOpM FC. The clones that were sensitive to FC were always sensitive to GCV. 
It is likely that tk is folded correctly but cd is partially impaired and only clones with high 
levels of expression of the chimera will be sensitive to FC. Alternatively, this could relate to 
the relative ease of achieving tk expression, compared to cd (section 3.2.2; section 5.2.), in 
this cell line.
From the cdtk+ clones sensitive to both prodrugs, one clone was selected. GJIC 
(Lucifer Yellow dye injection) and population doubling time (over 48hrs) were measured and 
were not significantly different to those of the parental cells (Table 6.1.). To determine how 
effective the cdtk construct was in sensitising cultures to the prodrugs, survival of separate 
and mixed cultures was measured in response to GCV or FC treatment. The protocol that was 
used has been described in previous chapters (section 3.3.1; section 5.2.).
A bystander effect was seen with either prodrug (figure 6.4.A.), but the increases in 
sensitivity of the cultures were more clearly seen from the IC50 curves (figure 6.4.B.). For 
example, the presence of 10% BHK cdtk+ ceils reduced the IC50-FC by ~23 fold and IC50- 
GCV >300 fold, while the therapeutic index with FC was >400 and with GCV was >2000 
(figure 6.4.B.; Table 6.1.). The bystander effect and therapeutic index in this selected BHK 
cdtk+ clone were greater than that seen in the BHK clone expressing only cd, but similar to the 
BHK tk+ clone (Table 6.2.). These data were supported by analysis of enzyme activities (Table
6.1.) where BHK cdtk+ cells showed ~3-fold higher cd activity than BHK cd+ cells (see below; 
section 5.2.) but similar tk activity to BHK tk+ cells (section 3.3.1.).
To test if the bystander effects observed with cells expressing the chimeric protein 
were similar to those seen with cells expressing the enzymes separately, BHK cd+ cells were 
transfected with a plasmid carrying the tk and hyg genes. Hygromycin resistant clones were
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Figure 6.4. BHK cells transfected with a cdtk chimera are sensitive to FC and GCV and show 
bystander effects. (A) Varying mixtures of BHK cdtk+ and BHK cells were seeded (5 x 104 cells 
/ ml) in 24 well tissue culture plates. 24 hr later cells were treated with FC (Ai) or GCV (Aii) for 
2 days. After this time cells from each well were released with trypsin. Aliquots of the suspension 
were transferred to 96 well plates containing media and FC or GCV, as described in section 2.2.7. 
Survival was determined using the MTT assay. By calculation from each of the survival curves in 
(A), the IC50, with respect to FC (Bi) or GCV (Bii), was calculated. Each data point represents the 
mean +/_ SEM (bars) of two independent experiments, each performed in triplicate.
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picked and one of the clones that showed sensitivity to both FC and GCV was selected for 
further use.
GJIC and doubling times of this selected BHK cd+-tk+ clone were similar to the BHK 
cdtk+ clone, but cd and tk activity were lower (compare Table 6.1.A. and B.). These 
differences in enzyme activities highlight the difficulty of obtaining clones with similar 
expression levels and such variations may be accounted for the number of integrated genes or 
whether the genes are inserted into silenced regions of the genome. The lower levels of 
expression generated weaker bystander effects and therapeutic indices in cultures containing 
BHK cd+-tk+ cells, in response to FC or GCV, compared to those with BHK cdtk+ cells. 
However, comparison of the synergistic effects of BHK cd+-tk+ double transfectants with 
BHK cdtk+ cells should not be affected by the proportional differences, since synergy should 
rely on increased concentrations of toxic metabolites produced by two, relative to one, enzyme 
prodrug systems. A lower expression of each enzyme will require higher concentrations of 
prodrug to generate a bystander effect, but combining the systems should still lead to an 
increased spread of toxicity.
To compare the above systems, survival of mixed cultures of 10% BHK cdtk+ or 10% 
BHK cd+-tk+ cells and 90% BHK cells was measured after treatment with FC and GCV, as 
described previously (section 6.2.; section 2.2.7.). As before (section 6.2.), high or low 
concentrations of prodrug, separately or combined, did not result in significant differences in 
survival, but at intermediate concentrations of FC and GCV, combined treatment killed 15- 
20% more cells. This increase was similar in cultures with BHK cd+-tk+ or BHK cdtk+ cells 
(figure 6.5.).
This demonstrates that a cdtk fusion protein can be used to combine these enzyme / 
prodrug systems and, in some cases, an enhanced bystander effect can be produced. The 
synergistic effect, seen in these experiments, occurred at intermediate prodrug concentrations
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(A) BHK cdtk+ fusion chim era
cdtk+ chimera cdtk+ chimera cdtk+ chimera 
O.lpM GCV + +  - +
lOOpM FC + - + +
(B) BHK cd+-tk+ double transfectants
BHK 10% 10% 10%
cd+-tk+ double cd+-tk+ double cd+-tk+ double
0.5pM GCV + +  - +
500pM FC + + +
Figure 6.5. Combining the tk / GCV and cd / FC enzyme / prodrug systems results in an improved 
bystander effect at intermediate prodrug concentrations. 10% BHK cdtk+-chimera (A) or 10% BHK 
cd+-tk+ double transfected (B) cells were mixed with 90% parental cells in 24 well plates (5 x 104 
cells / ml). 24 hr later either GCV, FC or both were added to the media at the concentrations 
indicated in the graphs above. Survival was assayed using standard protocol (see section 2.2.7.) and 
expressed as percentage growth inhibition of untreated cells. All data represent mean +/- SEM (bars) 
of two independent experiments, each performed in triplicate.
and the level of synergy was similar when enzymes were expressed as a fusion protein or 
individually in the same cell.
6.4. Efficacy of the cdtk fusion protein in vivo.
An enhanced bystander effect was seen with combined FC and GCV treatment of 
cultures containing 10% BHK cdtk+ cells and it is important to determine whether this 
improved killing leads to increased tumour regression in vivo.
Tumours were generated in nude mice using BHK (0% BHK cdtk+), BHK cdtk+ 
(100% BHK cdtk+) or mixtures of the two cell types (10% BHK cdtk+) in the same way as 
described previously (section 4.2.; section 2.3.). There were 4 animals in each of the 10 
treatment groups, which are described in Table 6.3. When tumours were approximately 4 mm 
in diameter, prodrug treatment was initiated. FC (250mg / kg) and / or GCV (45mg / kg) were 
administered Lp., daily, for 14 days. Survival was scored as tumour volume of <500mm and 
animals exceeding this burden were terminated.
Animals with 0% BHK cdtk+ tumours survived for a similar time with (FC / GCV) or 
without (PBS) treatment and this showed that combined prodrug had no effect on 
untransduced cells (figure 6.6.).. Comparing the growth rates of BHK and BHK cdtk+ cells 
showed that, although similar in culture, BHK cdtk+ tumours grew more slowly in vivo. 
Survival of animals with 0% BHK cdtk+ (PBS treated) tumours was only 15 days, but animals 
with 100% BHK cdtk+ (PBS treated) tumours, survived for 20 days (see section 6.5. for 
further discussion).
With 10% BHK cdtk+ tumours, survival was similar between PBS and FC treatment 
groups but was marginally extended in the GCV and in most of the FC / GCV treated animals 
(figure 6.6.). There was one exception, where an animal in the FC / GCV treatment group,
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Group Ratio
BHK cdtk+ : BHK cells
Treatment
1 0% : 100% PBS
2 0%: 100% FC + GCV
3 10%: 90% PBS
4 10%: 90% FC
5 10%: 90% GCV
6 10%: 90% FC + GCV
7 100%: 0% PBS
8 100%: 0% FC
9 100%: 0% GCV
10 100%: 0% FC + GCV
Table 6.3. Determination of the relative efficacy of single or combined prodrug 
treatment on tumours containing different percentages of BHK cdtk+ cells. 
Monolayers of BHK cdtk+ or parental cells were trypsinised and viability assessed by 
trypan blue dye exclusion. Cell suspensions (106 / ml), at the ratios described above, 
were prepared. Nude mice (4 per group) were injected subcutaneously to each flank 
with lOOpl of the suspension. Tumours were allowed to form for ~10 days before 
treating with FC (250mg / kg) and / or GCV (45mg / kg) intraperitoneally, once daily 
for 14 days, as described above. Results are shown in figure 6.6.
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Figure 6.6. In vivo analysis of tumours containing different percentages of BHK cdtk+ cells. Nude 
mice were injected s.c. with BHK and BHK cdtk+ cell mixtures as described in figure 6.3. and section 
6.4. The bar indicates the 14 day period of intraperitoneal injections of prodrug. Approximate tumour 
volumes were calculated from an average of two measurements (4/ 3Trr3) . The different graphs are plotted 
against the same time scale. Animals were removed from the study if the total tumour burden exceeded 
500mm3. * In the 10% BHK cdtk+ group treated with FC and GCV, the tumours in one animal 
regressed and this animal was tumour free for >50 days (71 days total survival).
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| that did have tumours (each 35mm3 in volume) on day 3, became completely tumour free by
!
day 13 and showed no recurrence in >50 days (71 days total; figure 6.6.). Day 71 was the end 
point of the experiment, due to the time constraint. For comparison, the other animals in this 
| group had tumours of 14mm3 (average volume) on day 3, which grew to 80mm3 by day 13,
j
\ which was similar to the PBS group.
i
! FC treatment of 100% BHK cdtk+ tumours resulted in regression, but not cure, and
I
survival of animals was increased by 18 days, from day 20, in controls treated with PBS, to
[
j
; day 38. However, treatment with GCV or FC / GCV resulted in cure of all animals with 100%
| BHK cdtk+ tumours (survival of 71 days). It is therefore not possible to determine whether
| combined treatment was more effective than GCV alone in these 100% BHK cdtk+ tumours.
[
| These data suggest that the use of a cdtk fusion protein should be investigated further
as combined treatment may lead to more tumour regressions. With the FC / GCV treated 10% 
BHK cdtk+ group, one animal was cured while the others were not. However, these studies
| were performed on small groups of animals and should be repeated on larger groups. Since all
I
I animals survived in the GCV or FC / GCV treated 100% BHK cdtk+ groups and only limited
f
f
| conclusions can be drawn.
i
i 6.5. Discussion
The results in this chapter have demonstrated that combining the tk /  GCV and tp / 
DFUR or cd / FC enzyme / prodrug systems can lead to a modest enhancement of the 
bystander effect, in model systems in culture. Importantly, combined prodrug treatment led to 
cell death at concentrations where either prodrug alone was ineffective, and if a similar effect 
is seen in tumours, then cells will be in exposed to toxic levels of prodrug for longer periods of 
time.
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Studies in nude mice have shown that a single daily intraperitoneal injection of 500mg / 
kg of FC produces a maximum plasma concentration of 4000pM and that the half life of FC is 
40 minutes (Huber et al, 1995). Therefore the plasma concentration should be =100pM at 3 hr 
and undetectable at 6 hr. Culture studies in the previous sections have shown that in a 
population containing 10% BHK cdtk+ cells, the IC50 for FC was 250p,M. If this value applies 
to tumours in nude mice, then cells will have been exposed to prodrug at or above the IC50 
dose for <3 hr each day. It is possible that this could explain the lack of tumour regression in 
the 10% BHK cdtk+ group treated with FC.
Treatments with other prodrugs, such as GCV, are also likely to suffer from the 
problem of short term toxic levels (Markham and Faulds, 1994) and enhancing sensitivity to 
prodrug may be an important factor in achieving tumour cure. Furthermore, the prodrug 
concentrations that can be used in humans are often lower than those used in animal models 
and sensitivity to reduced levels of prodrug may be all the more important.
The tk / GCV system has also been combined with the nitroreductase (ntr) / 5-arizidin- 
l-yl-2,4 dinitrobenzamide (CB1954) system (Bridgewater et al, 1995). CB1954 is converted, 
by ntr, to a toxic compound (5-arizidin-l-yl-4-hydroxyamino-2-nitrobenzamide) that cross­
links DNA and toxicity is not dependent on cell cycling (Bridgewater et al, 1995). In NIH3T3 
cells, combined expression of the tk and ntr genes enhanced the therapeutic index and 
bystander effect when prodrug treatment was given in combination. Enhancement of cell 
killing was optimal when cells were exposed to GCV for 72 hr and to CB1954 for 24 hr. In 
the studies here, the combined effect of the tk / GCV and tp / DFUR systems was most 
effective when prodrugs were added simultaneously. For treatment of tumours with different 
combined enzyme / prodrug strategies, the optimal timing and application of prodrug will need 
to be established.
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The results here show that the arrangement of enzymes within a fusion protein is 
important but the consequences cannot be predicted. For example, colonies that were sensitive 
to FC and GCV could be selected from transfections with the cdtk construct, but not from 
those with the tkcd construct. The lack of prodrug sensitivity in tkcd transfectants was not 
expected, on the basis of earlier work with fusion proteins containing tk or cd. In tk-neo 
(Veelken et al, 1996) or CD44-cd (Asman et al, 1995) fusion chimeras, the suicide enzymes 
were functional even though folding of the C-terminus of tk or the N-terminus of cd was 
restricted by the presence of another peptide domain. In the tkcd fusion protein described 
here, the folding of the same termini were restricted, but there was no detectable sensitivity, of 
G418 selected colonies, to GCV or FC.
Most BHK cdtk+ clones isolated were sensitive to GCV but only 20% were sensitive 
to FC and for a more detailed study, the clone selected had a high level of cd activity. If, 
however, the clones had been pooled, cd activity would have been reduced since a large 
percentage were not sensitive to FC. Under these conditions, the results appear consistent 
with another report that was published during the course of this work. Rogulski et al (1997) 
constructed a cdtk fusion protein where the two enzymes were separated by 11 residues (10 
glycines and one phenylalanine), which to distinguish it, will be termed cd-gly-tk. Retroviral 
transduction with the cd-gly-tk fusion construct (and neo) of 9L cells resulted in pooled clones 
having 40% cd- and 200%-tk activity compared to transduction of the same cells, with genes 
in separate vectors. The predicted and actual lower activity of cd in the cdtk and cd-gly-tk 
chimeric proteins, respectively, may be accounted for by incorrect folding of cd, which could 
be disturbed if the N-terminus of tk forms a more stable structure, or by stearic hindrance, 
which could arise as a result of the position of the tk domain in relation to the active site of cd. 
Both these suggestions could be correct, but until the positions of the active sites are 
determined, this can only be speculation.
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Although the study by Rogulski did not analyse the bystander effect, it demonstrated 
that pooled 9L cd-gly-tk clones were more sensitive to GCV than FC, and combining 
intermediate concentrations of each prodrug enhanced cell killing, in culture. These 
observations support the data in this thesis.
Treatment of animals with 100% BHK cdtk+ tumours with GCV for 14 days led to 
tumour cure in all mice (this chapter), whereas the same regime, for only 7 days, did not cure 
animals with 100% BHK tk+ tumours (chapter 4). It is possible that increasing the length of 
prodrug treatment led to the increased rate of tumour cure and such a suggestion is supported
I
I by the observations of others (Osaki et al, 1994). There may, however, be alternative
j explanations for the cures seen, for example, the slower in vivo growth rates of BHK cdtk+
i
[ cells compared to BHK tk+ cells, or the presence of the cdtk fusion protein.
I!
| Slower growth of cells in vivo may mean that at the start of prodrug treatment the
|
| volume of 100% BHK cdtk+ tumours was less than that of the 100% BHK tk+ tumours, which
I could account for the cures seen in the former group. However, the volumes of tumours|
I
| within these different groups were similar at the time of treatment, and a slower growth rate, if
| anything, would be expected to reduce animal survival since GCV mediated killing requires
| cells to be cycling. Support for this suggestion comes from a study where groups of animals
E
j were inoculated with 9L tk+ cells, with high or low rates of proliferation in vivo, then treated
with GCV (Iwadate et al, 1996). Survival was inversely proportional to tumour growth rate, 
i.e. the animals with the fastest growing tumours survived the longest, 
j Enhanced eradication of tumours may have been due to the presence of the cdtk fusion
protein, rather than tk alone. This possibility cannot be excluded since the fusion protein may
I lead to greater activation of, for example, macrophages or granulocytes (T-cells are absent
[
| from nude mice). Previously it has been suggested that the antigenicity of the cd suicide
protein may be an important factor in the clearance of tumours in syngeneic mice (Mullen et 
al, 1996).
The cure of one 10% BHK cdtk+ tumour bearing animal, but not the other three, 
suggests that this fusion chimera should be investigated further to establish whether combining 
the cd /  FC and tk / GCV enzyme / prodrug systems could be used as a potential treatment in 
cancer therapy. Combining other systems may be warranted and possible candidate genes are 
discussed in the next chapter.
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Chapter 7. Discussion and future directions.
Enzyme / prodrug systems represent a novel approach for the treatment of cancer. The 
use of the tk / GCV strategy has led to decreases in tumour size in some patients with 
glioblastoma multiforme, but although this is encouraging, treatment had no effect in the 
majority of patients (Culver et al, 1996; Izquierdo et al, 1996). The lack of therapeutic effect 
was most likely due to the low level of transduction (<0.2%) and the limited number of cells in 
S-phase (Ram et al, 1995). Clearly, if suicide gene therapy is to be considered for use in cancer 
treatment, cell killing needs to be improved. The primary aim for improvement must be the 
enhancement of gene transfer, since gene expression in the target cells is a fundamental 
requirement for enzyme / prodrug systems. Enhancing gene delivery is an area that is currently 
being addressed (e.g. Kruse et al, 1997). However, a better understanding of the mechanism of 
bystander effects of enzyme / prodrug systems may also lead to improved treatment by 
facilitating the choice of the most appropriate regime for each cancer.
In this thesis the mechanisms of the bystander effects in the tk / GCV, tp / DFUR and 
cd / FC strategies have been investigated. Results from analysis of the tk / GCV system have 
shown that gap junctions are required for the spread of toxicity from tk+ to tk' cells, and when 
coupled, even at a low level, high levels of tk activity result in extensive bystander killing. 
However, if the level of tk activity, or the level of communication is sufficiently low, then 
increasing coupling, by introduction of genes involved in gap junction formation, may enhance 
spread of toxicity.
There are now several reports that document an increase in tk / GCV bystander effect, 
in culture, when communication of poorly coupled cells is increased by transfection of 
connexin genes (Mesnil et al, 1996; Elshami et al, 1996; Mesnil et al, 1997; Dilber et al, 1997; 
Shinora et al, 1996; Vrionis et al, 1997). These reports did not examine the levels of tk
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activity, and it is possible that tk expression was low. This would contrast to the high levels of 
tk activity in the cell lines described in this thesis, which may account for the failure to enhance 
the bystander effect in poorly coupled CarB cells, by increasing the level of coupling by 
transfection with E-cadherin (Chapter 3; Holden et al, 1997)
Experiments in vivo have demonstrated that tumours formed from tk+ and tk' C6 
glioma cells are cured more often when Cx43 expression had been increased by transfection 
(Dilber et al, 1997). These observations suggest that introduction of genes involved in gap 
junction formation may enhance the tk / GCV bystander effect in some human tumours. To 
employ this approach, tumours will have to be characterised, and those with low levels of 
coupling and connexin expression, may be suitable for treatment.
On the basis of the data obtained in this thesis, another way to enhance the tk /  GCV 
bystander effect may be to increase levels of tk expression. Results in chapter 3 demonstrated 
a correlation between bystander killing and level of tk activity, but it seems likely that the use 
of tissue specific promoters, to prevent ubiquitous expression of the therapeutic gene, will 
reduce the level of enzyme activity (Kanai et al, 1997). Methods of increasing tk activity, not 
involving promoters, are likely to be required.
One possibility may be to modify the structure of the tk protein so that activity is 
enhanced. Such an approach, based on analysis and subsequent modification of the 3 
dimensional structure, has proved successful in enhancing the activity of glucoamylase, from 
Aspergillus awamori (Fierobe et al, 1996). However, nuclear magnetic resonance or x-ray 
crystallograpy data are not yet available for the tk enzyme, and the 3 dimensional structure of 
tk is not known. Furthermore, computer modelling predictions of the residues involved in 
substrate binding have not been consistent with mutational analyses (Folkers et al, 1991; 
Michael et al, 1994).
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An approach that has had some success is the generation of mutant forms of the tk 
enzyme. Munir et al (1994) produced 190 tk mutants, by modifying a portion of the nucleotide 
sequence that encodes a putative thymidine binding site, and showed that one mutant had a 
five fold higher activity towards phosphorylation of thymidine. Although this study did not
i[
j investigate phosphorylation of GCV, it shows that this is a potentially feasible, even if labour
i
intensive, way to enhance activity. However, activity may not be the only factor that should be 
taken into consideration. If mutants with increased activity are used, the strength of substrate
i
i l  /I binding ( /Km) versus the rate of the reaction (Kcat) should be considered. It has been
i
suggested that enzymes with the lowest Km (strongest binding) and the highest Kcat (highest
| rate of activity) may not be ideal choices, since cells closest to the blood vessels would convert
| all prodrug to drug, without allowing prodrug to penetrate to cells positioned deeper within
the tumour (Connors and Knox, 1995). Penetration of the prodrug to the tumour is likely to 
be a requirement in the therapies that are discussed later.
| Enzyme / prodrug systems that involve tk, tp or cd suicide genes are most effective at
i
1
j  killing when cells are in S-phase of the cell cycle, which means that their use may be limited to
i
| fast growing tumours, such as some pituitary tumours (Anniko et al, 1983). A large
percentage of the cells of many tumours, for example, malignant glioma (Nishiyama et al, 
1985), are cycling slowly, or out or cycle, and treatment is likely to be more effective if the 
therapy does not require cells to be in cycle.
The ntr / CB1954 system converts the prodrug to a bifunctional alkylating agent that 
kills cycling and non-cycling cells by introducing DNA interstrand cross links (Sunters et al, 
1991). A potential advantage of this system is that ntr is the only enzyme required for the 
formation of the toxic metabolite and further reactions catalysed by cellular enzymes, which 
could be rate limiting, are not involved. This contrasts to the systems described above, where a
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minimum of two other reactions are required for toxicity, and in some instances, these may be 
rate limiting (see discussion of Chapter 3). The ntr / CB1954 system appears promising from 
culture studies, where a therapeutic index of nearly 1000 has been demonstrated (Bailey et al,
1996). However, experiments in transgenic mice, where expression of ntr is restricted to T- 
cells (Drabek et al, 1997) or to the luminal cells of the mammary gland (Clark et al, 1997), 
suggest that the difference in sensitivity between toxic doses of prodrug administered 
systemically and doses required to kill the ntr+ cells may be less than 5-fold. Another possible 
draw-back is the apparent lack of bystander effect in some (Clark et al, 1997), but not other 
(Bridgewater et al, 1997) experimental models. It is possible that a more effective prodrug will 
be synthesised from on-going studies (Anlezark et al, 1995).
An alternative to the ntr / CB1954 system is the use of the E.coli DeoD gene, which 
codes for purine nucleoside phosphorylase (PNP). This enzyme converts the prodrug 6 
methylpurine-2,-deoxyribonucleoside (MP-d) to the toxic adenine analogue, 6 methylpurine 
(MP) which inhibits protein and RNA synthesis (Sorscher et al, 1994). Killing is not dependent 
on the cells being in cycle, and the bystander effect seen is transferable via the medium 
(Hughes et al, 1995). This PNP / MP-d system appears promising and inclusion in a proposed 
treatment regime is discussed later.
The results in chapter 6 demonstrated that combining cd and tk systems can lead to an 
enhanced bystander effect and the improvement can be achieved with a fusion protein. 
However, Rogulski et al (1997) showed that cd activity of 9L cells expressing a cd-gly-tk 
fusion chimera was reduced when compared to 9L cells that expressed cd alone and this 
appears to be consistent with the data in chapter 6 (see section 6.5.). If cd activity is reduced 
due to incorrect folding of cd in the chimeric protein, then it is possible that a linker region 
that is longer, or comprised of different amino acids, may increase cd activity. However, with 
the exception of the cdtk and cd-gly-tk fusion proteins described here and by Rogulski et al
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(1997), there are no available reports that document the fusion of a peptide domain to the C- 
terminus of cd, therefore modification of the linker region cannot be based on previous 
experience using fusion chimeras involving this enzyme.
If cd activity is reduced by stearic hindrance of the active site by the tk domain, again, 
modifying the linker region may be an advantage (figure 7.1.). In the fusion protein described 
in this thesis, the cd and tk enzymes were separated by two amino acids and the close 
proximity of the enzymes may lead to direct hindrance (figure 7.1.A.). In the report by 
Rogulski, separation was achieved with 11 residues, most of which were glycine so the linker 
region is likely to be flexible. If amino acids on the surface of each enzyme cause repulsion (or 
attraction), this may lead to stearic hindrance (figure 7.2.B.) which might be increased with a 
flexible linker region. If these hypotheses are correct, then introducing a structured linker 
region, such as an a-helix, may be of benefit (figure 7.I.C.). Whether such a structure would 
be stable and lead to enhanced enzyme activities, would need to be tested. If changes in the 
linker region were successful in raising the level of activity, similar techniques could be applied 
to the fusion proteins discussed later.
Combining treatments can, under the correct conditions, lead to an enhanced 
therapeutic effect. For example, 9L cells expressing a cd-gly-tk fusion are more effectively 
killed when FC, GCV and y-irradiation (137Cs source) treatments are given together, compared 
to any other separate or combined (dual) treatment using these components (Rogulski et al,
1997). However, careful consideration is required when different treatments are combined, 
since killing could be reduced if antagonistic therapies are used. For example, tk expression 
from an AFP-tk construct was increased in the presence of dexamethasome, leading to 
enhanced cell killing (Ido et al, 1995), but in vivo, this steroid suppresses the immune response 
(Barba et al, 1994; Ram et al, 1994). Dexamethasome might be expected to reduce an immune 
mediated bystander effect but, never the less, has been used to reverse GCV induced
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Figure 7.1. Hypothetical role of the linker region between fusion proteins.
neutropenia in clinical trials using the tk / GCV system (Culver, 1996). This observation 
suggests that alternative therapies such as systemic treatment with the cytokine, granulocyte 
colony stimulating factor (GCSF), might be used to alleviate symptoms (Markham and Faulds, 
1994).
In a different example, combined use of FU and verapamil together can be beneficial 
(Shchepotin et al, 1994) but verapamil inhibits the tk / GCV bystander effect (Marini et al, 
1996). The reduction in bystander killing may occur through reduced levels of GJIC. 
Verapamil inhibits calcium efflux from the cell (Taylor and Simpson, 1992) which could result 
in increased concentrations of intracellular calcium ions, a factor that may be associated with a 
reduction in junctional communication (review, Loewenstein, 1979). Combining verapamil 
with FC and GCV treatment in cdtk transduced cells would, therefore, not be desirable.
Most tumours consist of dividing and non dividing cells. Therefore, combining suicide 
gene systems that have proved to be effective at killing cells that are in S-phase (e.g. the tk / 
GCV and cd / FC systems) with those that provide the opportunity to also kill non dividing 
cells (e.g. the PNP / MP-d and ntr / CB1954 systems), may be beneficial However, due to the 
importance of the immune system, any therapy that does not enhance immune infiltration is 
unlikely to succeed on a regular basis. There are now several reports that suggest combining 
suicide gene systems and cytokine gene delivery can lead to an increase in tumour cures in 
experimental animals (Chen et al, 1995b; Chen et al, 1996b; Mullen et al, 1996; Santodonato 
et al, 1996). It may therefore be advantageous to combine the introduction of several suicide 
and cytokine genes. The final pages of this thesis are included as a suggestion for the 
development of a theoretical strategy to try to accomplish such a combination. A summary is 
provided in figure 7.2. and the logic behind the suggested strategy is provided below.
Cytokines are secreted into the extracellular space, where they bind to and activate the 
proliferation of particular cell lineages of the immune system. For example, IL-2 is required for
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proliferation of TILs (Rosenberg et al, 1990; Rosenberg et al, 1993) and GMSCF is required 
for stimulation of granulocyte and macrophage lineages (Gough et al, 1985; Al-Shammary et 
al, 1995). These cells can be found in many experimental tumours after enzyme /  prodrug 
therapy (see section 1.11.5.; Perez-Cruet et al, 1994) and may contribute to any 
immunological response that occurs.
If tumour cells were transfected with an IL2-cd fusion construct, then the signal 
sequence of the cytokine should lead to the release of the fusion protein from the celL This 
chimeric protein may bind to TILs, by virtue of the IL-2 domain, and some of these stimulated 
cells may migrate further into the tumour. This would be of benefit since the majority of cells 
transduced by local or systemic vector delivery will be near blood vessels or near the periphery 
of the tumour. With IL2-cd molecules now deeper in the tumour, FC treatment may lead to 
additional cell killing. TILs bound by IL2-cd should remain preferentially located within 
tumour deposits due to their ability to locate to tumours and to recognise unique tumour 
markers (Rosenberg, 1992; Rosenberg et al, 1993).
The use of a cytokine to direct cd to tumours is an extension of previous work where 
an antibody, raised against a tumour specific marker, was used to target suicide enzymes to 
the extracellular side of tumour cells, in a system termed antibody directed enzyme prodrug 
therapy (ADEPT). FC treatment of animals with experimental tumours targeted with an 
antibody directed to a tumour epitope demonstrated a 17-fold increase in the concentration of 
FU in the tumour, compared to subtoxic, systemic FU treatment (Wallace et al, 1994). In a 
different example, decreases in tumour size were seen when patients with metastatic colon 
cancer were injected with a conjugate of an antibody to CEA conjugated with 
carboxypeptidase G2 (CpG2), which converts a subsequently added prodrug, CMDA (4-[N- 
(2-chloroethyl)-N-(2-mesyloethyl)amino]-benzoyl-L-glutamic acid) to phenol mustards 
(review, Connors and Knox, 1995).
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The disadvantage of the ADEPT approach is that active conjugate remains in the 
blood, which can lead to conversion of prodrug to drug and hence general toxicity. Adverse 
effects can be reduced, but not prevented, by introducing a clearing antibody which binds to 
the active site of the enzyme and decreases the level of active circulating conjugate (review, 
Connors and Knox, 1995). Targeting the cDNA for CpG2 to tumour cells, for use as an 
intracellular enzyme / prodrug system, is now being investigated in culture (Marais et al, 
1996).
The use of extracellular targeting will place limitations on the enzyme / prodrug 
systems that can be used, because strategies that require, for example, ATP or a reducing 
environment for prodrug activation, will not be effective. The toxic metabolites produced must 
also be able to cross the membrane to enter cells. Therefore, fusions between a cytokine and tk 
(requires ATP to produce GCV-MP) or ntr (requires NAD[P]H as a cofactor) cannot be used. 
It is possible that the characteristics of the cd / FC and PNP / MP-d systems, such as a 
bystander effect mediated by membrane permeable toxic metabolites, may make them suitable 
for this strategy.
Based on previous results (Chapter 6), it is likely that the proposed system would be
enhanced if two cytokine-enzyme fusions were introduced to the tumour, and suitable choices
may be IL2-cd and GMCSF-PNP (figure 7.2.). However, there will be a limit to the number of
viral particles that can be introduced to patients before toxicity arises and fusion constructs
should, preferably, be contained within the same vector but separated by an IRES site to avoid
problems of promoter interference (Chapter 6; Emmerman and Temin, 1984). Previous studies
on translation of peptides from bi- and tri-cistronic vectors, containing single or fused
constructs, has shown this approach to be successful, in culture (Tahara et al, 1995; Okada et
al, 1996; Veelken et al, 1996; Lotze et al, 1997; Rogulski et al, 1997), which suggests that
expression of two fusion proteins, by a similar approach, may be feasible (figure 7.2.).
»
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The level of immune activity in spontaneously arising tumours is low (Sacco et al, 
1996) and transfer of fusion constructs by TILs or granulocytes into deeper regions of the 
cancer is unlikely to occur. In addition, the few cells of the immune system that are present 
may be destroyed by prodrug treatment, which could suppress the immune mediated bystander 
effect. Immune infiltration may be enhanced if a second vector, carrying only suicide genes, 
was introduced (figure 7.2.).
Previous reports have demonstrated that the tk / GCV system can lead to activation of 
an immune response in tumours (Perez-Cruet et al, 1994). Again, including two suicide genes 
may produce a greater effect and these could be expressed as two peptides from a bicistronic 
message or as a single fusion protein. The enzymes used in this second vector should activate 
different prodrugs to the cytokine-enzyme fusion proteins, so that immune stimulation and the 
effect of further prodrug treatment are not attenuated (figure 7.2.). Potential choices may be 
the tk and ntr genes.
To apply this strategy, the timing of administration of vectors 1 and 2 (figure 7.2.) 
would need to be optimised, as would that of each of the prodrugs. Simultaneous vector 
delivery may lead to transduction of the same or separate tumour cells, and it might be 
anticipated that transduction of the same cells would reduce the therapeutic effect (see above). 
If intratumoural or local vector delivery is used, such as implantation of retroviral vector 
producer cells (Oldfield, 1993), then different sites of implantation may reduce transduction of 
the same cells by vectors 1 and 2. Following tumour transduction, it may be possible to apply 
a protocol, along the lines of that outlined below.
Administration of GCV or CB1954 should kill some of the tk or ntr expressing cells 
and this should lead to immune infiltration, which may be enhanced by the presence of 
cytokine activity in IL2-cd and GMCSF-PNP fusion proteins (figure 7.2.). Some of the 
immune cells bound by the fusion chimeras may migrate deeper into the tumour and, it is
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hoped that prodrug treatment, using FC and MP-d, would lead to additional killing of cycling 
and non cycling tumour cells (figure 7.2.).
The timing of FC and MP-d treatment will have to provide a compromise between the 
level of production of the fusion protein versus inactivation of the fusion chimera by host 
antibodies. It may be of benefit to combine treatment further with radio- or chemo-therapy, 
but due to the potential antogonistic effects of combinations, the choice will have to be 
considered carefully.
To employ a strategy based on these ideas and suggestions, the feasibility of several 
aspects will need to be evaluated. Many current efforts are aimed at increasing the titre of viral 
vectors to increase the transduction efficiency (Kaptein et al, 1997; Kruse et al, 1997), but 
introduction of larger amounts of foreign genetic sequence may reduce viral titres (review, 
Chong and Vile, 1996) and this would be expected to reduce the level of transduction. The 
strategy proposed here would require introduction of up to 4kb of gene sequence to vectors, 
not including 5’- or 3’- untranslated regions (such as promoter sequences).
There are no available reports that have documented the use of the PNP / MP-d 
strategy in an ADEPT approach and the extracellular activation of this prodrug would need to 
be established.
Previously in this thesis it was pointed out that the folding of fusion proteins, 
containing cd and tk suicide enzymes, could not be predicted, so it is not known whether the 
cytokine-suicide enzyme fusions suggested here would be functional Furthermore, it may be 
difficult to determine how these fusion proteins will behave in the tumour environment, where 
pH and ion concentrations may differ to more normal physiological conditions (Denny, 1996). 
Another consideration is whether the immune cells will carry the cytokine-enzyme fusion 
chimeras deeper into the tumour bed, and even if this does occur, whether prodrug
141
concentrations, in these regions, will be sufficient to kill cells. It is possible that only a detailed 
investigation will resolve these issues.
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